Document_and_Entity_Informatio
Document and Entity Information Document (USD $) | 12 Months Ended | ||
Dec. 28, 2013 | Feb. 16, 2014 | Jun. 29, 2013 | |
Entity Information [Line Items] | ' | ' | ' |
Entity Registrant Name | 'CHARLES RIVER LABORATORIES INTERNATIONAL INC | ' | ' |
Entity Central Index Key | '0001100682 | ' | ' |
Current Fiscal Year End Date | '--12-28 | ' | ' |
Entity Filer Category | 'Large Accelerated Filer | ' | ' |
Document Type | '10-K | ' | ' |
Document Period End Date | 28-Dec-13 | ' | ' |
Document Fiscal Year Focus | '2013 | ' | ' |
Document Fiscal Period Focus | 'Q4 | ' | ' |
Amendment Flag | 'false | ' | ' |
Entity Common Stock, Shares Outstanding | ' | 47,659,400 | ' |
Entity Well-known Seasoned Issuer | 'Yes | ' | ' |
Entity Voluntary Filers | 'No | ' | ' |
Entity Current Reporting Status | 'Yes | ' | ' |
Entity Public Float | ' | ' | $2,012,149,235 |
CONSOLIDATED_STATEMENTS_OF_INC
CONSOLIDATED STATEMENTS OF INCOME (USD $) | 12 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Net sales related to products | $476,362 | $467,944 | $483,309 |
Net sales related to services | 689,166 | 661,586 | 659,338 |
Net sales | 1,165,528 | 1,129,530 | 1,142,647 |
Costs and expenses | ' | ' | ' |
Cost of products sold | 272,302 | 255,409 | 267,966 |
Cost of services provided | 494,122 | 478,492 | 472,439 |
Selling, general and administrative | 225,695 | 208,248 | 198,648 |
Asset impairments | 4,202 | 3,548 | 7,492 |
Amortization of other intangibles | 17,806 | 18,068 | 21,796 |
Operating income (loss) | 151,401 | 165,765 | 174,306 |
Other income (expense) | ' | ' | ' |
Interest income | 730 | 589 | 1,353 |
Interest expense | -20,969 | -33,342 | -42,586 |
Other, net | 7,165 | -3,266 | -411 |
Income from continuing operations, before income taxes | 138,327 | 129,746 | 132,662 |
Provision for income taxes | 32,911 | 27,628 | 17,140 |
Income (loss) from continuing operations, net of income taxes | 105,416 | 102,118 | 115,522 |
Income (loss) from discontinued operations, net of taxes | -1,265 | -4,252 | -5,545 |
Net income (loss) | 104,151 | 97,866 | 109,977 |
Less: Net loss (income) attributable to noncontrolling interests | -1,323 | -571 | -411 |
Net income (loss) attributable to common shareowners | $102,828 | $97,295 | $109,566 |
Basic: | ' | ' | ' |
Continuing operations attributable to common shareowners (in dollars per share) | $2.18 | $2.12 | $2.26 |
Discontinued operations (in dollars per share) | ($0.03) | ($0.09) | ($0.11) |
Net income (loss) attributable to common shareowners (in dollars per share) | $2.15 | $2.03 | $2.16 |
Diluted: | ' | ' | ' |
Continuing operations attributable to common shareowners (in dollars per share) | $2.15 | $2.10 | $2.24 |
Discontinued operations (in dollars per share) | ($0.03) | ($0.09) | ($0.11) |
Net income (loss) attributable to common shareowners (in dollars per share) | $2.12 | $2.01 | $2.14 |
CONSOLIDATED_STATEMENTS_OF_COM
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Net income (loss) | $104,151 | $97,866 | $109,977 |
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment Realized upon Sale or Liquidation, before Tax | 0 | 636 | 0 |
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax | -15,322 | 4,682 | -12,264 |
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, before Tax | 0 | 209 | -325 |
Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, before Tax | 0 | 712 | 0 |
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, before Tax | 19,293 | -8,634 | -23,728 |
Other Comprehensive Income (Loss), Reclassification, Pension and Other Postretirement Benefit Plans, Net Gain (Loss) Recognized in Net Periodic Benefit Cost, before Tax | 3,017 | 2,772 | 1,068 |
Other Comprehensive Income (Loss), before Tax | 111,139 | 98,243 | 74,728 |
Other Comprehensive Income (Loss), Tax | 7,805 | -1,677 | -6,272 |
Total comprehensive income | 103,334 | 99,920 | 81,000 |
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | 1,752 | 615 | 476 |
Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $101,582 | $99,305 | $80,524 |
CONSOLIDATED_BALANCE_SHEETS
CONSOLIDATED BALANCE SHEETS (USD $) | Dec. 28, 2013 | Dec. 29, 2012 |
In Thousands, unless otherwise specified | ||
Current assets | ' | ' |
Cash and cash equivalents | $155,927 | $109,685 |
Trade receivables, net | 220,630 | 203,001 |
Inventories | 89,396 | 88,470 |
Other current assets | 85,847 | 83,601 |
Current assets of discontinued businesses | 750 | 495 |
Total current assets | 552,550 | 485,252 |
Property, plant and equipment, net | 676,182 | 717,020 |
Goodwill | 230,701 | 208,609 |
Other intangible assets, net | 84,537 | 84,922 |
Deferred tax asset | 35,536 | 38,554 |
Other assets, noncurrent | 61,964 | 48,659 |
Long-term assets of discontinued businesses | 3,151 | 3,328 |
Total assets | 1,644,621 | 1,586,344 |
Current liabilities | ' | ' |
Current portion of long-term debt and capital leases | 21,437 | 139,384 |
Accounts payable | 31,770 | 31,218 |
Accrued compensation | 58,461 | 46,951 |
Deferred revenue | 54,177 | 56,422 |
Accrued liabilities | 56,712 | 45,208 |
Other current liabilities | 22,546 | 21,262 |
Current liabilities of discontinued businesses | 1,931 | 1,802 |
Total current liabilities | 247,034 | 342,247 |
Long-term debt and capital leases | 642,352 | 527,136 |
Other long-term liabilities | 82,497 | 104,966 |
Long-term liabilities of discontinued businesses | 8,080 | 8,795 |
Total liabilities | 979,963 | 983,144 |
Commitments and contingencies | ' | ' |
Redeemable noncontrolling interest | 20,581 | 0 |
Shareholders' equity | ' | ' |
Preferred stock, $0.01 par value; 20,000,000 shares authorized; no shares issued and outstanding | 0 | 0 |
Common stock, $0.01 par value; 120,000,000 shares authorized; 82,522,905 issued and 47,553,841 shares outstanding at December 28, 2013 and 79,607,981 issued and 48,220,037 shares outstanding at December 29, 2012 | 825 | 796 |
Capital in excess of par value | 2,206,155 | 2,097,316 |
Accumulated deficit | -265,473 | -368,301 |
Treasury stock, at cost, 34,969,064 shares and 31,387,944 shares at December 28, 2013 and December 29, 2012, respectively | -1,305,880 | -1,135,609 |
Accumulated other comprehensive income | 5,357 | 6,603 |
Total shareowners' equity | 640,984 | 600,805 |
Noncontrolling interests | 3,093 | 2,395 |
Total equity | 664,658 | 603,200 |
Total liabilities and equity | $1,644,621 | $1,586,344 |
CONSOLIDATED_STATEMENTS_OF_CAS
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Cash flows relating to operating activities | ' | ' | ' |
Net income (loss) | $104,151 | $97,866 | $109,977 |
Less: Income (loss) from discontinued operations | -1,265 | -4,252 | -5,545 |
Income (loss) from continuing operations | 105,416 | 102,118 | 115,522 |
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities: | ' | ' | ' |
Depreciation and amortization | 96,636 | 81,275 | 85,230 |
Amortization of debt issuance costs and discounts | 9,561 | 17,622 | 20,010 |
Impairment charges | 4,202 | 3,548 | 7,492 |
Non-cash compensation | 24,542 | 21,855 | 21,706 |
Deferred income taxes | -846 | 1,311 | -8,668 |
(Gain) loss on investments in limited partnerships | -5,864 | 618 | -869 |
Other, net | -755 | -5,519 | 5,797 |
Changes in assets and liabilities: | ' | ' | ' |
Trade receivables | -19,492 | -16,266 | 7,669 |
Inventories | -1,571 | 785 | 3,766 |
Other assets | 2,421 | -117 | -265 |
Accounts payable | -7,080 | -3,257 | 2,208 |
Accrued compensation | 11,926 | 4,612 | -7,412 |
Deferred revenue | -3,297 | -915 | -9,515 |
Accrued liabilities | 759 | -7,050 | -1,355 |
Taxes payable and prepaid taxes | -3,054 | 2,331 | -13,782 |
Other liabilities | -5,969 | -5,983 | -9,098 |
Net cash provided by operating activities | 209,045 | 208,006 | 206,842 |
Cash flows relating to investing activities | ' | ' | ' |
Acquisition of businesses and assets, net of cash acquired | 29,218 | 16,861 | 0 |
Capital expenditures | 39,154 | 47,534 | 49,143 |
Purchases of investments | 17,566 | 18,537 | 24,556 |
Proceeds from sale of investments | 11,584 | 25,156 | 31,607 |
Other, net | -307 | -2,786 | -5,447 |
Net cash provided by (used in) investing activities | -74,047 | -54,990 | -36,645 |
Cash flows relating to financing activities | ' | ' | ' |
Proceeds from long-term debt and revolving credit agreement | 511,804 | 74,116 | 250,708 |
Proceeds from exercises of stock options and warrants | 93,789 | 18,359 | 20,625 |
Payments on long-term debt, capital lease obligation and revolving credit agreement | 523,304 | 140,347 | 252,965 |
Purchase of treasury stock and Accelerated Stock Repurchase Program | 165,932 | 64,189 | 283,795 |
Other, net | -594 | 940 | -6,359 |
Net cash used in financing activities | -84,237 | -111,121 | -271,786 |
Discontinued operations | ' | ' | ' |
Net cash provided by (used in) operating activities | -1,906 | -106 | -1,559 |
Net cash provided by (used in) discontinued operations | -1,906 | -106 | -1,559 |
Effect of exchange rate changes on cash and cash equivalents | -2,613 | -1,009 | -7,107 |
Net change in cash and cash equivalents | 46,242 | 40,780 | -110,255 |
Cash and cash equivalents, beginning of period | 109,685 | 68,905 | 179,160 |
Cash and cash equivalents, end of period | 155,927 | 109,685 | 68,905 |
Supplemental cash flow information | ' | ' | ' |
Cash paid for interest | 12,029 | 15,145 | 22,321 |
Cash paid for taxes | 19,139 | 17,032 | 29,124 |
Capitalized interest | 243 | 467 | 298 |
Capital Expenditures Incurred but Not yet Paid | 6,960 | 2,778 | 5,302 |
Capital Lease Obligations Incurred | $0 | $69 | $0 |
CONSOLIDATED_STATEMENT_OF_CHAN
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (USD $) | Total | Accumulated Deficit (Earnings) | Accumulated Other Comprehensive Income | Common Stock | Capital in Excess of Par | Treasury Stock | Non-controlling Interest |
In Thousands, unless otherwise specified | |||||||
Balance at Dec. 25, 2010 | $527,363 | ($465,596) | $4,593 | $785 | $2,056,921 | ($1,071,120) | $1,780 |
Components of comprehensive income, net of tax: | ' | ' | ' | ' | ' | ' | ' |
Net income (loss) | 109,977 | ' | ' | ' | ' | ' | ' |
Net Income (Loss) Attributable to Noncontrolling Interest | 411 | ' | ' | ' | ' | ' | 411 |
Other Comprehensive Income (Loss), Net of Tax | -28,977 | ' | ' | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | ' | ' | -29,042 | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest | ' | ' | ' | ' | ' | ' | 65 |
Total comprehensive income | 81,000 | ' | ' | ' | ' | ' | ' |
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | 476 | ' | ' | ' | ' | ' | 476 |
Tax detriment associated with stock issued under employee compensation plans | -802 | ' | ' | ' | -802 | ' | ' |
Issuance of stock under employee compensation plans | 20,527 | ' | ' | 10 | 20,517 | ' | ' |
Acquisition of treasury shares | 269,655 | ' | ' | ' | 32,766 | -302,421 | ' |
Accelerated Stock Repurchase equity instrument | -14,140 | ' | ' | ' | -14,140 | ' | ' |
Stock-based compensation | 21,706 | ' | ' | ' | 21,706 | ' | ' |
Balance at Dec. 31, 2011 | ' | ' | ' | ' | ' | ' | ' |
Components of comprehensive income, net of tax: | ' | ' | ' | ' | ' | ' | ' |
Net income (loss) | 97,866 | ' | ' | ' | ' | ' | ' |
Net Income (Loss) Attributable to Parent | ' | 97,295 | ' | ' | ' | ' | ' |
Net Income (Loss) Attributable to Noncontrolling Interest | 571 | ' | ' | ' | ' | ' | 571 |
Other Comprehensive Income (Loss), Net of Tax | 2,054 | ' | ' | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | ' | ' | 2,010 | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest | ' | ' | ' | ' | ' | ' | 44 |
Total comprehensive income | 99,920 | ' | ' | ' | ' | ' | ' |
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | 615 | ' | ' | ' | ' | ' | 615 |
Tax detriment associated with stock issued under employee compensation plans | 125 | ' | ' | ' | 125 | ' | ' |
Issuance of stock under employee compensation plans | 18,426 | ' | ' | 11 | 18,415 | ' | ' |
Acquisition of treasury shares | 64,489 | ' | ' | ' | ' | -64,489 | ' |
Stock-based compensation | 21,855 | ' | ' | ' | 21,855 | ' | ' |
Balance at Dec. 29, 2012 | 603,200 | -368,301 | 6,603 | 796 | 2,097,316 | -1,135,609 | 2,395 |
Components of comprehensive income, net of tax: | ' | ' | ' | ' | ' | ' | ' |
Net income (loss) | 104,151 | ' | ' | ' | ' | ' | ' |
Net Income (Loss) Attributable to Parent | ' | 102,828 | ' | ' | ' | ' | ' |
Net Income (Loss) Attributable to Noncontrolling Interest | 1,323 | ' | ' | ' | ' | ' | 1,323 |
Other Comprehensive Income (Loss), Net of Tax | -817 | ' | ' | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | ' | ' | -1,246 | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest | ' | ' | ' | ' | ' | ' | 429 |
Total comprehensive income | 103,334 | ' | ' | ' | ' | ' | ' |
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | 1,752 | ' | ' | ' | ' | ' | 1,752 |
Tax detriment associated with stock issued under employee compensation plans | 1,069 | ' | ' | ' | 1,069 | ' | ' |
Issuance of stock under employee compensation plans | 93,821 | ' | ' | 29 | 93,792 | ' | ' |
Acquisition of treasury shares | 170,271 | ' | ' | ' | ' | -170,271 | ' |
Accelerated Stock Repurchase equity instrument | 8,963 | ' | ' | ' | ' | ' | ' |
Stock-based compensation | 24,542 | ' | ' | ' | 24,542 | ' | ' |
Balance at Dec. 28, 2013 | $664,658 | ($265,473) | $5,357 | $825 | $2,206,155 | ($1,305,880) | $23,674 |
Description_of_Business_and_Su
Description of Business and Summary of Significant Accounting Policies | 12 Months Ended | |||||||||||||||
Dec. 28, 2013 | ||||||||||||||||
Description of Business and Summary of Significant Accounting Policies [Abstract] | ' | |||||||||||||||
Description of Business and Summary of Significant Accounting Policies | ' | |||||||||||||||
Description of Business | ||||||||||||||||
Charles River Laboratories International, Inc. (the "Company") together with its subsidiaries is a leading global provider of solutions that accelerate the drug discovery and development process including research models and associated services and outsourced preclinical services. Our fiscal year is the twelve-month period ending the last Saturday in December. | ||||||||||||||||
Principles of Consolidation | ||||||||||||||||
The consolidated financial statements include all majority-owned subsidiaries. Intercompany accounts, transactions and profits are eliminated. | ||||||||||||||||
Reclassifications | ||||||||||||||||
Certain reclassifications have been made to prior year statements to conform to the current year presentation. These reclassifications have no impact on period reported net income or cash flow. | ||||||||||||||||
Use of Estimates | ||||||||||||||||
The financial statements have been prepared in conformity with generally accepted accounting principles and, as such, include amounts based on informed estimates and judgments of management with consideration given to materiality. Estimates and assumptions are reviewed on an ongoing basis and the effect of revisions to the estimates and assumptions is reflected in the consolidated statements prospectively in the period in which they are revised. | ||||||||||||||||
Cash and Cash Equivalents | ||||||||||||||||
Cash equivalents include time deposits and highly liquid investments with original maturities at the purchase date of three months or less. | ||||||||||||||||
Trade Receivables | ||||||||||||||||
We record trade receivables net of an allowance for doubtful accounts. We establish an allowance for doubtful accounts based on historical collection information, a review of major client accounts receivable balances and current economic conditions in the geographies in which we operate. Provisions to the allowance for doubtful accounts were $1,332 in 2013, $947 in 2012 and $426 in 2011. Write offs against the allowance for doubtful accounts were $373 in 2013, $697 in 2012 and $1,228 in 2011. | ||||||||||||||||
The composition of net trade receivables is as follows: | ||||||||||||||||
28-Dec-13 | 29-Dec-12 | |||||||||||||||
Client receivables | $ | 190,423 | $ | 174,774 | ||||||||||||
Unbilled revenue | 35,184 | 32,494 | ||||||||||||||
Total | 225,607 | 207,268 | ||||||||||||||
Less allowance for doubtful accounts | (4,977 | ) | (4,267 | ) | ||||||||||||
Net trade receivables | $ | 220,630 | $ | 203,001 | ||||||||||||
Concentrations of Credit Risk | ||||||||||||||||
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and trade receivables. We place our cash and cash equivalents in various financial institutions with high credit rating and limit the amount of credit exposure to any one financial institution. Our trade receivables are from clients in the pharmaceutical and biotechnology industries. No single client accounted for more than 5% of our net sales or trade receivables for any period presented. | ||||||||||||||||
Marketable Securities | ||||||||||||||||
Investments in marketable securities are reported at fair value and consist of time deposits with original maturities of greater than three months. Realized gains and losses on these securities are included in other income (expense) and are determined using the specific identification method. We currently hold no trading or held-to-maturity securities. | ||||||||||||||||
The amortized cost, gross unrealized gains, gross unrealized losses and fair value for marketable securities by major security type were as follows: | ||||||||||||||||
December 28, 2013 | ||||||||||||||||
Amortized | Gross | Gross | Fair | |||||||||||||
Cost | Unrealized | Unrealized | Value | |||||||||||||
Gains | Losses | |||||||||||||||
Time deposits | $ | 11,158 | $ | — | $ | — | $ | 11,158 | ||||||||
$ | 11,158 | $ | — | $ | — | $ | 11,158 | |||||||||
December 29, 2012 | ||||||||||||||||
Amortized | Gross | Gross | Fair | |||||||||||||
Cost | Unrealized | Unrealized | Value | |||||||||||||
Gains | Losses | |||||||||||||||
Time deposits | $ | 6,781 | $ | — | $ | — | $ | 6,781 | ||||||||
$ | 6,781 | $ | — | $ | — | $ | 6,781 | |||||||||
Maturities of debt securities were as follows: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Amortized | Fair | Amortized | Fair | |||||||||||||
Cost | Value | Cost | Value | |||||||||||||
Due less than one year | $ | 11,158 | $ | 11,158 | $ | 6,781 | $ | 6,781 | ||||||||
Due after one year through five years | — | — | — | — | ||||||||||||
Due after ten years | — | — | — | — | ||||||||||||
$ | 11,158 | $ | 11,158 | $ | 6,781 | $ | 6,781 | |||||||||
Inventories | ||||||||||||||||
Inventories are stated at the lower of cost or market. Cost is determined on the average cost method for our small model business and first-in-first-out (FIFO) for our large model and EMD businesses. For our small model business, cost includes direct materials such as feed and bedding, costs of personnel directly involved in the care of the models, and an allocation of facility overhead. For our large model business, cost is primarily the external cost we pay to acquire the model. Certain of our businesses value inventory based on standard costs, which are periodically compared to and adjusted to actual costs. We determine market value based on either replacement cost or estimated selling price less cost to sell and a normal profit margin. Inventory costs are charged to cost of sales in the period the products are sold to an external party. Inventory reserves are recorded to reduce the carrying value for inventory determined to be damaged, obsolete or otherwise unable to be sold. | ||||||||||||||||
The composition of inventories is as follows: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Raw materials and supplies | $ | 15,028 | $ | 14,525 | ||||||||||||
Work in process | 11,715 | 11,082 | ||||||||||||||
Finished products | 62,653 | 62,863 | ||||||||||||||
Inventories | $ | 89,396 | $ | 88,470 | ||||||||||||
Other Current Assets | ||||||||||||||||
Other current assets consist of assets we expect to settle within the next twelve months. | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Prepaid assets | $ | 20,058 | $ | 20,404 | ||||||||||||
Deferred tax asset | 29,139 | 30,018 | ||||||||||||||
Marketable securities | 11,158 | 6,781 | ||||||||||||||
Prepaid income tax | 25,247 | 26,169 | ||||||||||||||
Restricted cash | 245 | 229 | ||||||||||||||
Other current assets | $ | 85,847 | $ | 83,601 | ||||||||||||
Property, Plant and Equipment | ||||||||||||||||
Property, plant and equipment, including improvements that significantly add to productive capacity or extend useful life, are recorded at cost, while maintenance and repairs are expensed as incurred. We capitalize interest on certain capital projects which amounted to $243 in 2013, $467 in 2012 and $298 in 2011, respectively. We also capitalize internal and external costs incurred during the application development stage of internal use software. Depreciation is calculated for financial reporting purposes using the straight-line method based on the estimated useful lives of the assets as follows: buildings, 20 to 40 years; machinery and equipment, 3 to 20 years; furniture and fixtures, 5 to 10 years; vehicles, 3 to 5 years; computer hardware and software, 3 to 8 years and leasehold improvements, the shorter of estimated useful life or the lease periods. We begin to depreciate capital projects in the first full month the asset is placed in service. | ||||||||||||||||
The composition of net property, plant and equipment is as follows: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Land | $ | 40,157 | $ | 40,812 | ||||||||||||
Buildings | 694,074 | 697,547 | ||||||||||||||
Machinery and equipment | 367,244 | 356,960 | ||||||||||||||
Leasehold improvements | 37,959 | 34,916 | ||||||||||||||
Furniture and fixtures | 24,013 | 25,681 | ||||||||||||||
Vehicles | 3,859 | 3,736 | ||||||||||||||
Computer hardware and software | 112,328 | 107,171 | ||||||||||||||
Construction in progress | 42,075 | 46,186 | ||||||||||||||
Total | 1,321,709 | 1,313,009 | ||||||||||||||
Less accumulated depreciation | (645,527 | ) | (595,989 | ) | ||||||||||||
Net property, plant and equipment | $ | 676,182 | $ | 717,020 | ||||||||||||
Depreciation expense for 2013, 2012 and 2011 was $78,830, $63,207 and $63,435, respectively. | ||||||||||||||||
Valuation and Impairment of Goodwill and Indefinite-Lived Intangible Assets | ||||||||||||||||
Goodwill and other indefinite-lived intangibles are not amortized and are reviewed for impairment at least annually. Valuation of goodwill requires significant judgment. Assumptions and estimates are used in determining the fair value of assets acquired and liabilities assumed in a business acquisition. A significant portion of the purchase price in our acquisitions is assigned to intangible assets and goodwill. Assigning value to intangible assets requires that we use significant judgment in determining (i) the fair value and (ii) whether such intangibles are amortizable or non-amortizable and, if the former, the period and the method by which the intangible assets will be amortized. We utilize commonly accepted valuation techniques, such as the income approach and the cost approach, as appropriate, in establishing the fair value of intangible assets. Typically, key assumptions include: projected revenues and expenses that will be generated or expended from the use of the intangible asset, costs that would be avoided due to our ownership of the asset, client turn-over in the case of client relationships intangible assets, and the discount rate reflecting the risk associated with achieving these key assumptions. | ||||||||||||||||
We test goodwill for impairment annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. We have elected not apply the guidance available in ASU 2011-08, Testing Goodwill for Impairment, to assess purely qualitative factors as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. We perform the first step of the two-step goodwill impairment test for each of our reporting units as of the first day of fiscal November. The first step, identifying a potential impairment, compares the fair value of the reporting unit with its carrying amount. If the carrying amount exceeds fair value, the second step would need to be performed; otherwise, no further step is required. The second step, measuring the impairment loss, compares the implied fair value of the reporting unit's goodwill with its carrying amount. Any excess of the goodwill carrying amount over the implied fair value is recognized as an impairment loss, and the carrying value of goodwill is written down to fair value. Please refer to Note 3 for the results of our 2013 goodwill impairment test. | ||||||||||||||||
Valuation and Impairment of Long-Lived Assets | ||||||||||||||||
We assess the carrying value of property, plant and equipment and definite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not limited to the following: | ||||||||||||||||
• | significant financial underperformance relative to expected future operating results; | |||||||||||||||
• | significant negative industry, market or economic trends; or | |||||||||||||||
• | significant changes in our operating strategy that negatively affect the utilization of our long-lived assets. | |||||||||||||||
We assign long-lived assets to groups based on the lowest level at which cash flows are largely independent from other cash flows. Should we determine that a trigger has been met, we determine the recoverability of the long-lived asset group based on an estimate of undiscounted future cash flows resulting from the use of the asset group, including its eventual disposition. Should we determine that the carrying value of held-for-use long-lived assets may not be recoverable, we then measure any resulting impairment based on the fair value of the long-lived asset group. In some cases, fair value is based on the income approach using projected discounted cash flows and using a discount rate commensurate with the risk inherent in our current business model. We may also estimate fair value based on market prices for similar assets, as appropriate. Significant judgments are required to estimate future cash flows, including the selection of appropriate discount rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value for these assets. | ||||||||||||||||
Long-lived asset groups are classified as held-for-sale when the following conditions are met: we have committed to a plan to sell the asset group and it is unlikely that significant changes will be made to the plan; the asset group is available for immediate sale in its present condition and it is probable that the sale will be completed within one year; and an active program to locate a buyer has been initiated and the asset group is being marketed at a sale price that is reasonable in relation to its current fair value. Should we determine that the carrying value of held-for-sale long-lived assets exceeds its fair value, we will measure any impairment based on this difference. Subsequent adjustments to the carrying amount of held-for-sale assets based on changes in fair value are recorded but only to the extent of the carrying amount of the asset group when it entered the held-for-sale category. | ||||||||||||||||
Other Assets | ||||||||||||||||
Other assets consist of assets that we do not expect to settle within the next twelve months. The composition of other assets is as follows: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Deferred financing costs | $ | 7,126 | $ | 6,424 | ||||||||||||
Cash surrender value of life insurance policies | 26,507 | 25,240 | ||||||||||||||
Investments in limited partnerships | 17,911 | 8,492 | ||||||||||||||
Other assets | 10,420 | 8,503 | ||||||||||||||
Other assets | $ | 61,964 | $ | 48,659 | ||||||||||||
Accounting for Investments in Limited Partnerships | ||||||||||||||||
We have invested in a series of limited partnerships that invest in start-up companies primarily in the life sciences industry. Our total commitment to these entities as of December 28, 2013 is $35,000, of which we have funded $12,375 to date. Our ownership interest in these limited partnerships ranges from 3.8% to 12.1%. We account for these investments under the Equity-Method, whereby we record our portion of investment gains and losses of the limited partnerships each reporting period. Accordingly, we recognized equity income/(loss) of $5,864, $(618) and $869 for the years ended December 28, 2013, December 29, 2012 and December 31, 2011 respectively, reported in Other Income (Expense), net on our consolidated statements of income. As of December 28, 2013, these investments had a carrying value of $17,911, which is reported in Other Assets on the consolidated balance sheets. | ||||||||||||||||
Accounting for Investment in Life Insurance Contracts | ||||||||||||||||
Our investments in life insurance contracts are recorded at cash surrender value. Accordingly, we recognize the initial investment at the transaction price and remeasure the investment at cash surrender value based on fair value of underlying investments or contractual value each reporting period. Investments in and redemptions of these life insurance contracts are reported as cash flows from investing activities in the consolidated statement of cash flows. At December 28, 2013, we held 30 contracts with a carrying value of $26,507 and a face value of $67,482. | ||||||||||||||||
Restructuring and Contract Termination Costs | ||||||||||||||||
We recognize obligations associated with restructuring activities and contract termination costs by recording a liability at fair value for the costs associated with an exit or disposal activity as well as costs to terminate a contract or an operating lease. The overall purpose of our restructuring actions is to lower operating costs and improve profitability by reducing excess capacities. Restructuring charges are typically recorded in the period in which the plan is approved by our senior management and, where material, our Board of Directors, and when the liability is incurred. A liability for costs that will continue to be incurred under a contract for its remaining term without economic benefit to us is recognized and measured at its fair value when we cease using the right conveyed by the contract. | ||||||||||||||||
During 2013, 2012 and 2011, we implemented staffing reductions to improve operating efficiency and profitability at various sites. As a result of these actions, for the years ended December 28, 2013, December 29, 2012 and December 31, 2011, we recorded severance and retention charges as shown below. As of December 28, 2013, $1,475 was included in accrued compensation and $1,307 in other long-term liabilities on our consolidated balance sheet. As of December 29, 2012, $1,885 was included in accrued compensation and $1,751 in other long-term liabilities on our consolidated balance sheet. | ||||||||||||||||
The following table rolls forward our severance and retention cost liability: | ||||||||||||||||
Severance and Retention Costs | ||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||
Balance, beginning of period | $ | 3,636 | $ | 3,374 | $ | 10,658 | ||||||||||
Expense | 3,223 | 2,576 | 5,462 | |||||||||||||
Payments/utilization | (4,077 | ) | (2,314 | ) | (12,746 | ) | ||||||||||
Balance, end of period | $ | 2,782 | $ | 3,636 | $ | 3,374 | ||||||||||
The following table presents severance and retention costs by classification on the income statement: | ||||||||||||||||
Fiscal Year Ended | ||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||
Severance charges included in cost of sales | $ | 1,477 | $ | 1,203 | $ | 1,012 | ||||||||||
Severance charges included in selling, general and administrative expense | 1,746 | 1,373 | 4,450 | |||||||||||||
Total expense | $ | 3,223 | $ | 2,576 | $ | 5,462 | ||||||||||
The following table presents severance and retention cost by segment: | ||||||||||||||||
Fiscal Year Ended | ||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||
Research models and services | $ | 2,055 | $ | 1,068 | $ | 1,196 | ||||||||||
Preclinical services | 1,164 | 1,508 | 4,372 | |||||||||||||
Corporate | 4 | — | (106 | ) | ||||||||||||
Total expense | $ | 3,223 | $ | 2,576 | $ | 5,462 | ||||||||||
Other Current Liabilities | ||||||||||||||||
Other current liabilities consist of liabilities we intend to settle within the next twelve months. | ||||||||||||||||
The composition of other current liabilities is as follows: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Accrued income taxes | $ | 18,773 | $ | 18,216 | ||||||||||||
Current deferred tax liability | 1,960 | 410 | ||||||||||||||
Accrued interest and other | 1,813 | 2,636 | ||||||||||||||
Other current liabilities | $ | 22,546 | $ | 21,262 | ||||||||||||
Other Long-Term Liabilities | ||||||||||||||||
Other long-term liabilities consist of liabilities we do not intend to settle within the next twelve months. | ||||||||||||||||
The composition of other long-term liabilities is as follows: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Deferred tax liability | $ | 14,988 | $ | 13,147 | ||||||||||||
Long-term pension liability | 16,219 | 44,316 | ||||||||||||||
Accrued Executive Supplemental Life Insurance Retirement Plan and Deferred Compensation Plan | 28,708 | 26,663 | ||||||||||||||
Other long-term liabilities | 22,582 | 20,840 | ||||||||||||||
Other long-term liabilities | $ | 82,497 | $ | 104,966 | ||||||||||||
Stock-Based Compensation Plans | ||||||||||||||||
We grant stock options and restricted stock to employees and non-employee directors under our stock-based compensation plans. Stock-based compensation cost is measured at grant date, based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period. We estimate the fair value of stock options using the Black-Scholes valuation model. Key inputs and assumptions used to estimate the fair value of stock options include the exercise price of the award, the expected option term, the risk-free interest rate over the option's expected term, the expected annual dividend yield and the expected stock price volatility. The expected stock price volatility assumption is determined using the historical volatility of our common stock over the expected life of the option. The risk-free interest rate is based on the market yield for the five year U.S. Treasury security. The expected life of options is determined using historical option exercise activity. | ||||||||||||||||
We record deferred tax assets for stock-based awards based on the amount of stock-based compensation recognized in our consolidated statements of income at the statutory tax rate for the jurisdiction in which we will receive a tax deduction. Differences between the deferred tax assets and the actual tax deduction reported on our income tax returns are recorded in additional paid-in capital. If the tax deduction is less than the deferred tax asset, the calculated shortfall reduces our pool of excess tax benefits. If the pool of excess tax benefits is reduced to zero, then subsequent shortfalls would increase our income tax expense. Our pool of excess tax benefits is computed in accordance with the long-form method. | ||||||||||||||||
Revenue Recognition | ||||||||||||||||
We recognize revenue related to our products, which include research models, endotoxin and microbial detection (EMD) technology and avian vaccine support products, when persuasive evidence of an arrangement exists, generally in the form of client purchase orders, title and risk of loss have transferred, which generally occurs upon delivery of the products, the sales price is fixed or determinable and collectability is reasonably assured. For large models, in some cases clients pay in advance of delivery of the product. These advances are deferred and recognized as revenue upon delivery of the product. | ||||||||||||||||
Our service revenue is generally evidenced by client contracts and is recognized upon the completion of the agreed upon performance criteria. These performance criteria are generally in the form of either study protocols or specified activities or procedures that we are engaged to perform. These performance criteria are established by our clients and do not contain acceptance provisions based upon the achievement of certain study or laboratory testing results. Revenue of agreed upon rate per unit contracts is recognized as services are performed, based upon rates specified in the contract. Revenue of fixed fee contracts is recognized as services are performed in relation to total estimated costs to complete procedures specified by clients in the form of study protocols. In general, such amounts become billable in accordance with predetermined payment schedules, but are recognized as revenue as services are performed. Revisions in estimated effort to complete the contract are reflected in the period in which the change became known. | ||||||||||||||||
Deferred and unbilled revenue are recognized in our consolidated balance sheets. In some cases, a portion of the contract fee is paid at the time the services are initiated. These advances are recorded as deferred revenue and recognized as revenue as services are performed. Conversely, in some cases, revenue is recorded based on the level of service performed in advance of billing the client and recognized as unbilled receivable. | ||||||||||||||||
Guarantees | ||||||||||||||||
We include standard indemnification provisions in client contracts, which include standard provisions limiting our liability under such contracts, including our indemnification obligations, with certain exceptions. In addition, we are the guarantor of certain facility leases for businesses that have been sold to other parties. When we sell the business, we recognize the retained lease guarantee as a liability on our books at fair value and we amortize the liability ratably as our obligation decreases. In addition, we record contingent losses on the guarantee when it is probable that we will be required to make lease payments in excess of the remaining carrying amount of the guarantee liability and the additional payments are reasonably estimable. See Note 12 for discussion of guarantees related to our Phase I clinical business that we discontinued in 2011. | ||||||||||||||||
Derivatives and Hedging Activities | ||||||||||||||||
During the three years ended December 28, 2013, we entered into forward foreign currency contracts in order to hedge the foreign exchange impact of cash collections at our Canadian facility related to accounts receivable denominated in U.S. dollars and an intercompany loan between two of our subsidiaries with different functional currencies. As of December 28, 2013, there were no outstanding forward contracts. We recorded losses associated with these forward foreign currency contracts of $853 in 2013, $1,260 in 2012 and $6,287 in 2011. | ||||||||||||||||
Fair Value | ||||||||||||||||
We hold cash equivalents, investments and certain other assets and liabilities that are carried at fair value. We generally determine fair value using a market approach based on quoted prices of identical instruments when available. When market quotes of identical instruments are not readily accessible or available, we determine fair value based on quoted market prices of similar instruments. As of December 28, 2013, we do not have any significant non-recurring measurements of non-financial assets and non-financial liabilities other than the adjustment of our PCS Massachusetts facility to fair value in the fourth quarter of 2013 based on an impairment charge recorded in the period. | ||||||||||||||||
The valuation hierarchy for disclosure of the inputs used to measure fair value prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from or corroborated by observable market data through correlation. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. | ||||||||||||||||
The valuation methodologies used for assets and liabilities measured at fair value are as follows: | ||||||||||||||||
• | Time deposits—Valued at their ending balances as reported by the financial institutions that hold our securities, which approximates fair value. | |||||||||||||||
• | Investments in life insurance policies—Valued at cash surrender value based on fair value of underlying investments. | |||||||||||||||
• | Long-lived assets impaired during the period—Valued at fair value at the date of the impairment based upon the income or market approach. | |||||||||||||||
• | Hedge contracts (such as forward currency contracts)—Valued at fair value by management based on our foreign exchange rates and forward points provided by banks. | |||||||||||||||
• | Redeemable noncontrolling interest—Valued using a weighted combination of a market-based approach, utilizing information about our company as well as publicly available industry information to determine revenue and earnings multiples, and an income approach based on estimated future cash flows based on projected financial data discounted by a weighted average cost of capital. Significant assumptions include a discount rate of 18.5% and a long-term pretax operating margin of approximately 31.7%. | |||||||||||||||
Assets and liabilities measured at fair value on a recurring basis are summarized below: | ||||||||||||||||
Fair Value Measurements at December 28, 2013 | ||||||||||||||||
Quoted Prices in Active Markets for Identical Assets Level 1 | Significant Other Observable Inputs Level 2 | Significant Unobservable Inputs Level 3 | Assets and Liabilities at Fair Value | |||||||||||||
Time deposits | $ | — | $ | 11,158 | $ | — | $ | 11,158 | ||||||||
Life insurance policies | — | 19,534 | — | 19,534 | ||||||||||||
Total assets measured at fair value | — | 30,692 | — | 30,692 | ||||||||||||
Redeemable noncontrolling interest | — | — | 20,581 | 20,581 | ||||||||||||
Total liabilities measured at fair value | $ | — | $ | — | $ | 20,581 | $ | 20,581 | ||||||||
Fair Value Measurements at December 29, 2012 | ||||||||||||||||
Quoted Prices in Active Markets for Identical Assets Level 1 | Significant Other Observable Inputs Level 2 | Significant Unobservable Inputs Level 3 | Assets and Liabilities at Fair Value | |||||||||||||
Time deposits | $ | — | $ | 6,781 | $ | — | $ | 6,781 | ||||||||
Life insurance policies | — | 19,555 | — | 19,555 | ||||||||||||
Hedge contract | — | 16 | — | 16 | ||||||||||||
Total assets measured at fair value | $ | — | $ | 26,352 | $ | — | $ | 26,352 | ||||||||
The book value of our term and revolving loans, which are variable rate loans carried at amortized cost, approximates fair value based current market pricing of similar debt. We classify the fair value of our debt as Level 2 on the valuation hierarchy. | ||||||||||||||||
The following table presents a reconciliation for all liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the years ended December 28, 2013 and December 29, 2012. | ||||||||||||||||
Fair Value Measurements | ||||||||||||||||
Using Significant | ||||||||||||||||
Unobservable Inputs | ||||||||||||||||
(Level 3) | ||||||||||||||||
Year ended | ||||||||||||||||
Redeemable Noncontrolling Interest (Liability) | December 28, 2013 | |||||||||||||||
Beginning balance | $ | — | ||||||||||||||
Transfers in and/or out of Level 3 | — | |||||||||||||||
Purchases, issuances and settlements | 8,963 | |||||||||||||||
Total gains or losses (realized/unrealized): | ||||||||||||||||
Included in other income (expense) | 687 | |||||||||||||||
Included in other comprehensive income (CTA) | 367 | |||||||||||||||
Included in additional paid-in capital | 10,564 | |||||||||||||||
Ending balance | $ | 20,581 | ||||||||||||||
During the quarter ended December 28, 2013, we recorded an impairment charge for long-lived assets held and used related to our PCS Massachusetts facility (see Note 4). As a result, we adjusted the carrying amount of this asset group, which consists of land, building and fixtures, to fair value. Fair value was determined based on a weighted average of the replacement cost, market and income valuation approaches. In applying the income approach, we estimated the future net cash flows associated with leasing the asset group in the current market. In applying the replacement cost approach, we estimated the current estimated cost to reconstruct the facility and deducted the loss in value due to depreciation and obsolesce considerations. In applying the market approach, we performed a market sales comparison and adjusted for certain criteria, such as location, age and square footage, to make for a meaningful comparison. We determined the average of the three valuation approaches and adjusted the carrying value of the asset group to its fair value of $39,500, which we classified as Level 3, whereby the inputs are based on management's internal estimates and not corroborated with observable market data. | ||||||||||||||||
Income Taxes | ||||||||||||||||
We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and tax basis of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence both positive and negative, it is more likely than not that we will not realize some or all of the deferred tax assets. | ||||||||||||||||
As of December 28, 2013, earnings of non-U.S. subsidiaries considered to be indefinitely reinvested totaled $210,328. No provision for U.S. income taxes has been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, we would be subject to additional U.S. Federal and state income taxes and foreign income and withholding taxes, which could be material. It is our policy to indefinitely reinvest the earnings of our non-U.S. subsidiaries unless they can be repatriated in a manner that generates a tax benefit or an unforeseen cash need arises in the United States and the earnings can be repatriated in a manner that is substantially tax free. Determination of the amount of unrecognized deferred income tax liabilities on these earnings is not practicable due to the complexities with the hypothetical calculation. Additionally, the amount of the liability is dependent upon the circumstances existing if and when the remittance occurs. | ||||||||||||||||
We are a worldwide business and operate in various tax jurisdictions where tax laws and tax rates are subject to change given the political and economic climate in these countries. We report and pay income taxes based upon operational results and applicable law. Our current and deferred tax provision is based upon enacted tax rates in effect for the current and future periods. Any significant fluctuation in tax rates or changes in tax laws and regulations or changes to interpretation of existing tax laws and regulations could cause our estimate of taxes to change resulting in either increases or decreases in our effective tax rate. | ||||||||||||||||
We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, based on the technical merits of the tax position. The tax benefits recognized in our financial statements from such positions are measured based upon the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. | ||||||||||||||||
Foreign Currency Translation | ||||||||||||||||
The functional currency of each of our operating foreign subsidiaries is local currency. The financial statements of these subsidiaries are translated into U.S. dollars as follows: assets and liabilities at year-end exchange rates; income, expenses and cash flows at average exchange rates; and equity at historical exchange rates. The resulting translation adjustment is recorded as a component of accumulated other comprehensive income in the accompanying balance sheet. Exchange gains and losses on foreign currency transactions are recorded as other income or expense. We recorded an exchange gain (loss) of $136 in 2013, $(892) in 2012 and $6,237 in 2011. | ||||||||||||||||
Other Comprehensive Income | ||||||||||||||||
Our other comprehensive income (OCI) consists of unrealized gains (losses) on available-for-sale marketable securities, foreign currency translation adjustments and unrecognized pension gains and losses and prior service costs and credits. These items are presented, before tax effects, in the consolidated statements of other comprehensive income. We disclose the tax effects on each item included in Note 6. | ||||||||||||||||
Pension Plans | ||||||||||||||||
Our defined benefit pension plans' assets, liabilities and expenses are calculated using various assumptions. These assumptions are reviewed annually, or whenever otherwise required, based on reviews of current plan information and consultations with independent investment advisers and actuaries. The selection of assumptions requires a high degree of judgment and may materially change from period to period. | ||||||||||||||||
We recognize the funded status of our benefit plans on our consolidated balance sheets. We recognize gains, losses and prior service costs or credits that arise during the period that are not recognized as components of net periodic benefit cost as a component of accumulated other comprehensive income, net of tax. We measure plan assets and obligations as of the date of our fiscal year-end balance sheet. Additional information about certain effects on net periodic benefit cost for the next fiscal year that arise from delayed recognition of the gains or losses, prior service costs or credits, and transition asset or obligation are disclosed in the Note 8 of these financial statements. | ||||||||||||||||
Our defined benefit pension plans' assets, liabilities and expenses are calculated by accredited independent actuaries using various assumptions, which are approved by management. The actuarial computations require the use of assumptions to estimate the total benefits ultimately payable to employees and to allocate this cost to the service periods. The key assumptions used to calculate pension costs are determined and reviewed annually by management after consulting with outside investment advisers and actuaries. The key assumptions include the discount rate, the expected return on plan assets and expected future rate of salary increases. In addition, our actuaries utilize other assumptions such as withdrawal and mortality rate. The assumed discount rate, which is intended to be the rate at which benefits could effectively be settled, is adjusted based on the change in the long-term bond yield as of the measurement date. | ||||||||||||||||
We estimate the future return on invested pension assets annually based on information prepared by our outside actuaries and investment advisers, our targeted asset allocations and our own assumptions about that market. Our forward-looking pension assumptions, such as the rate of return on invested assets, are approved annually by our pension committee in the first quarter of the year and are updated as needed as of year-end. The rate of return on invested plan assets is primarily based on capital market models prepared by our advisers. These models use asset-class specific expected returns, standard deviations and correlation coefficients to derive a distribution of expected average portfolio return over the future duration of the pension plan's liabilities. | ||||||||||||||||
Differences between actual investment returns and estimated investment returns are recorded in accumulated other comprehensive income (loss) (AOCI) and are amortized over the remaining duration of the pension plans. As of December 28, 2013, the Company's AOCI includes $39,788 of net actuarial losses, which will be amortized over approximately 22 years. | ||||||||||||||||
Earnings Per Share | ||||||||||||||||
Basic earnings per share are calculated by dividing net income attributable to common shareholders by the weighted average number of common shares outstanding. Diluted earnings per common share are calculated by adjusting the weighted average number of common shares outstanding to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued, to the extent these additional shares are not anti-dilutive. | ||||||||||||||||
Discontinued Operations | ||||||||||||||||
The results of discontinued operations, less applicable income taxes (benefit) and assets and liabilities, are reported as a separate component in the accompanying statement of income and consolidated balance sheets for the current and prior periods. The statement of cash flows also reflects separate disclosure of cash flows pertaining to discontinued operations consistently for all periods presented. |
Business_Acquisitions
Business Acquisitions | 12 Months Ended | ||||
Dec. 28, 2013 | |||||
Business Combinations [Abstract] | ' | ||||
Business Combination Disclosure [Text Block] | ' | ||||
2. BUSINESS ACQUISITIONS | |||||
We completed two business acquisitions during the year ended December 28, 2013 and one business acquisition for the year end December 29, 2012. The results of operations of the acquired businesses are included in the accompanying consolidated financial statements from the dates of acquisition. During the year ended December 31, 2011 no significant business acquisitions were completed. | |||||
EMD Singapore | |||||
On October 4, 2013, we acquired an EMD products and service provider located in Singapore for approximately $4,934 in cash, subject to certain closing adjustments. The financial results of the acquired entity will be included in our RMS reportable business segment. | |||||
The preliminary purchase price allocation is as follows: | |||||
Current assets | $ | 300 | |||
Property, plant and equipment | 154 | ||||
Definite-lived intangible assets | 1,885 | ||||
Goodwill | 2,659 | ||||
Current liabilities | (64 | ) | |||
Total purchase price allocation | $ | 4,934 | |||
The breakout of definite-lived intangible assets acquired is as follows: | |||||
Weighted average amortization life (in years) | |||||
Client relationships | $ | 1,870 | 8 | ||
Other intangible assets | 15 | 2 | |||
Total definite-lived intangible assets | $ | 1,885 | 8 | ||
The definite-lived intangibles are largely attributed to the expected cash flows related to client relationships existing at the acquisition closing date. The goodwill resulting from the transaction is primarily attributed to the potential growth of the business in Southeast Asia. The goodwill is not deductible for tax purposes. The accounting for this acquisition is not yet complete due to our ongoing assessment of the fair value of assets acquired and associated income tax accounting thereon. We expect to complete the acquisition accounting in 2014. | |||||
Vital River | |||||
In October 2012, we entered into an agreement to acquire a 75% ownership interest of Vital River, a commercial provider of research models and related services in China, for $26,890 in cash, subject to certain closing adjustments. The acquisition closed in January 2013. Vital River's financial results are included in our RMS reportable business segment. | |||||
The purchase price allocation, net of $2,671 of cash acquired, is as follows: | |||||
Current assets (excluding cash) | $ | 3,092 | |||
Property, plant and equipment | 10,468 | ||||
Other long-term assets | 2,242 | ||||
Definite-lived intangible assets | 16,954 | ||||
Goodwill | 16,989 | ||||
Current liabilities | (11,303 | ) | |||
Long term liabilities | (5,260 | ) | |||
Redeemable noncontrolling interest | (8,963 | ) | |||
Total purchase price allocation | $ | 24,219 | |||
The breakout of definite-lived intangible assets acquired is as follows: | |||||
Weighted average amortization life (in years) | |||||
Client relationships | $ | 14,741 | 11.7 | ||
Reacquired rights | 2,053 | 1.3 | |||
Other intangible assets | 160 | 2.8 | |||
Total definite-lived intangible assets | $ | 16,954 | 10.4 | ||
The definite-lived intangibles are largely attributed to the expected cash flows related to client relationships existing at the acquisition closing date. In addition, the Company reacquired a right previously granted to the entity related to a royalty agreement for the distribution of products in China. The value assigned to the reacquired right is being amortized over the remaining life of the existing royalty agreement. The goodwill resulting from the transaction is primarily attributed to the potential growth of the business in China. The goodwill is not deductible for tax purposes. | |||||
Concurrent with the acquisition, the Company entered into a joint venture agreement with the noncontrolling interest holders that provide the Company with the right to purchase the remaining 25% of the entity for cash at its then appraised value beginning in January 2016. Additionally, the noncontrolling interest holders were granted the right to require the Company to purchase the remaining 25% of the entity at its then appraised value beginning in January 2016 for cash. These rights are accelerated in certain events. As the noncontrolling interest holders can require the Company to purchase for cash the remaining 25% interest, we classify the carrying amount of the noncontrolling interest above the equity section and below liabilities on the consolidated balance sheet. The acquisition-date fair value of the noncontrolling interest was determined based on the fair value of the consideration exchanged for the 75% of Vital River. Subsequent to the acquisition, each quarter we adjust the carrying amount of the noncontrolling interest to fair value using a weighted combination of a market-based approach and an income approach. The income approach uses estimated future cash flows based on projected financial data discounted by a rate which considers the Company's weighted average cost of capital and the specific risks of achieving these cash flows. Adjustments to fair value are recorded through additional paid-in capital. | |||||
Accugenix | |||||
In August 2012, we acquired 100% of Accugenix Inc. (Accugenix), for $18,408 in cash, subject to adjustments. Accugenix is a global provider of cGMP-compliant contract microbial identification testing. The acquisition strengthens our EMD portfolio of products and services by providing state-of-the-art microbial detection services for the biotechnology, pharmaceutical, and medical device manufacturing industries. Accugenix is based in the U.S. and is included in our RMS reportable business segment. | |||||
The purchase price allocation, net of $1,547 of cash acquired is as follows: | |||||
Current assets (excluding cash) | $ | 2,162 | |||
Property, plant and equipment | 549 | ||||
Current liabilities | (911 | ) | |||
Long term liabilities | (3,700 | ) | |||
Definite-lived intangible assets | 8,400 | ||||
Goodwill | 10,361 | ||||
Total purchase price allocation | $ | 16,861 | |||
The definite-lived intangible assets acquired are as follows: | |||||
Weighted average amortization life (in years) | |||||
Client relationships | $ | 1,500 | 13 | ||
Proprietary database | 4,100 | 11 | |||
Standard operating procedures | 2,500 | 4 | |||
Trademarks | 300 | 12 | |||
Total definite-lived intangible assets | $ | 8,400 | 9.3 | ||
The definite-lived intangibles are largely attributed to a proprietary database of thousands of species of organisms and the methods and technology to provide accurate, timely and cost-effective microbial identification services. The goodwill resulting from the transaction of $10,361 is primarily attributed to the potential for growth of the Company's global EMD products and services business through the increased competitive advantage and market penetration provided by the services offered by Accugenix. The goodwill is not deductible for tax purposes. | |||||
Accugenix [Member] | ' | ||||
Business Combinations [Abstract] | ' | ||||
Business Acquisitions | ' | ||||
The purchase price allocation, net of $1,547 of cash acquired is as follows: | |||||
Current assets (excluding cash) | $ | 2,162 | |||
Property, plant and equipment | 549 | ||||
Current liabilities | (911 | ) | |||
Long term liabilities | (3,700 | ) | |||
Definite-lived intangible assets | 8,400 | ||||
Goodwill | 10,361 | ||||
Total purchase price allocation | $ | 16,861 | |||
The definite-lived intangible assets acquired are as follows: | |||||
Weighted average amortization life (in years) | |||||
Client relationships | $ | 1,500 | 13 | ||
Proprietary database | 4,100 | 11 | |||
Standard operating procedures | 2,500 | 4 | |||
Trademarks | 300 | 12 | |||
Total definite-lived intangible assets | $ | 8,400 | 9.3 | ||
Goodwill_and_Other_Intangible_
Goodwill and Other Intangible Assets | 12 Months Ended | |||||||||||||||||||||||||||
Dec. 28, 2013 | ||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | |||||||||||||||||||||||||||
Goodwill and Other Intangible Assets | ' | |||||||||||||||||||||||||||
GOODWILL AND OTHER INTANGIBLE ASSETS | ||||||||||||||||||||||||||||
The following table displays the gross carrying amount and accumulated amortization of definite-lived intangible assets by major class: | ||||||||||||||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||||||||||||||
Gross carrying amount | Accumulated amortization | Gross carrying amount | Accumulated amortization | |||||||||||||||||||||||||
Backlog | $ | 2,916 | $ | (2,507 | ) | $ | 2,875 | $ | (2,375 | ) | ||||||||||||||||||
Client relationships | 311,507 | (238,002 | ) | 305,178 | (231,902 | ) | ||||||||||||||||||||||
Client contracts | 15,633 | (15,633 | ) | 15,366 | (15,366 | ) | ||||||||||||||||||||||
Trademarks and trade names | 5,399 | (4,997 | ) | 5,326 | (4,821 | ) | ||||||||||||||||||||||
Standard operating procedures | 2,754 | (1,498 | ) | 2,751 | (863 | ) | ||||||||||||||||||||||
Other identifiable intangible assets | 10,432 | (4,905 | ) | 10,033 | (4,718 | ) | ||||||||||||||||||||||
Total definite-lived intangible assets | $ | 348,641 | $ | (267,542 | ) | $ | 341,529 | $ | (260,045 | ) | ||||||||||||||||||
Additionally, as of December 28, 2013 and December 29, 2012, other intangible assets, net, consisted of $3,438 of indefinite-lived intangible assets. | ||||||||||||||||||||||||||||
The following is a schedule of goodwill by reportable segment and changes in the gross carrying amount and accumulated amortization of goodwill: | ||||||||||||||||||||||||||||
Adjustments to Goodwill | Adjustments to Goodwill | |||||||||||||||||||||||||||
Balance at December 31, 2011 | Acquisitions | Foreign Exchange/ Impairment | Balance at December 29, 2012 | Acquisitions | Foreign Exchange/ Impairment | Balance at December 28, 2013 | ||||||||||||||||||||||
Research Models and Services | ||||||||||||||||||||||||||||
Gross carrying amount | $ | 52,681 | $ | 10,361 | $ | 97 | $ | 63,139 | $ | 19,647 | $ | 765 | $ | 83,551 | ||||||||||||||
Preclinical Services | ||||||||||||||||||||||||||||
Gross carrying amount | 1,149,880 | — | 590 | 1,150,470 | — | 1,680 | 1,152,150 | |||||||||||||||||||||
Accumulated impairment loss | (1,005,000 | ) | — | — | (1,005,000 | ) | — | — | (1,005,000 | ) | ||||||||||||||||||
Total | ||||||||||||||||||||||||||||
Gross carrying amount | $ | 1,202,561 | $ | 10,361 | $ | 687 | $ | 1,213,609 | $ | 19,647 | $ | 2,445 | $ | 1,235,701 | ||||||||||||||
Accumulated impairment loss | (1,005,000 | ) | — | (1,005,000 | ) | (1,005,000 | ) | |||||||||||||||||||||
Goodwill, net | $ | 197,561 | $ | 208,609 | $ | 230,701 | ||||||||||||||||||||||
Our annual goodwill impairment assessment has historically been completed at the beginning of the fourth quarter. Based on our step one assessment for 2013, 2012 and 2011, the fair value of each reporting unit exceeded the reporting unit's book value (including allocated goodwill) and, therefore, our goodwill was not impaired. | ||||||||||||||||||||||||||||
Amortization expense of intangible assets for 2013, 2012 and 2011 was $17,806, $18,068 and $21,796, respectively. Amortization of revenue-producing intangible assets is excluded from cost of services. | ||||||||||||||||||||||||||||
Estimated amortization expense for intangible assets for each of the next five fiscal years is expected to be as follows: | ||||||||||||||||||||||||||||
2014 | $ | 16,396 | ||||||||||||||||||||||||||
2015 | 13,281 | |||||||||||||||||||||||||||
2016 | 11,351 | |||||||||||||||||||||||||||
2017 | 10,057 | |||||||||||||||||||||||||||
2018 | 9,181 | |||||||||||||||||||||||||||
Restructuring_and_Asset_Impair
Restructuring and Asset Impairments | 12 Months Ended |
Dec. 28, 2013 | |
Impairment of Long Lived Assets Disclosure [Abstract] | ' |
Impairment of Long Lived Assets | ' |
For the years ended 2013, 2012 and 2011, based on our most recent market outlook, we assessed our long-lived assets for impairment. The assessment included an evaluation of the ongoing cash flows associated with the use of the long lived assets. | |
In the fourth quarter of 2013, we recorded an asset impairment charge of $3,753, which was included in cost of sales, related to an adjustment to fair value of long-lived assets associated with our PCS Massachusetts facility. The long-lived assets, which include land, building and associated building improvements and equipment, were adjusted to an estimated fair market value of $39,500. In 2010, due to a decrease in demand for preclinical services and excess capacity in the industry, we consolidated our global preclinical facilities and temporarily ceased operations at this facility. As a result, we conducted an impairment test of the facility and adjusted the long-lived asset group to fair market value. We intend to maintain the space in the event additional capacity is needed in the future. Given the change in real estate values for similar properties in the surrounding area, we performed an updated asset impairment test in 2013. We calculated the fair value of the long-lived assets based upon a valuation completed by an independent third party valuation firm specializing in real estate. We utilized a weighted combination of the market value approach, cost replacement approach, and income capitalization approach. The resulting fair value of the asset group was below its book value. Accordingly, we recorded an impairment charge representing the excess of the carrying value of those assets over their respective fair market values. The decrease in fair market value was driven by a general trend in the regional real estate market, which currently favors real estate in Boston metropolitan area and is experiencing a decline in suburban markets. The long-lived assets of the facility are classified as held-for-use and we continue to depreciate these assets over their useful economic life. | |
During 2013, we implemented a plan to consolidate production in our U.S. research model facilities, which to date has resulted in the abandonment of certain long-lived assets, including a building at one of our facilities in California. As a result of these actions, we recorded $13,531 of accelerated depreciation to cost of sales related to the building based on its revised useful life. Also during 2013 we implemented a plan to consolidate operations within our U.S. Biologics facility, which is a leased facility, resulting in the abandonment of leasehold improvements and associated accelerated depreciation of $1,864, recorded in cost of sales, related to those leasehold improvements. We also recorded in 2013 asset impairments of $449 to cost of sales related to the consolidation of European operations noted in the following paragraph. | |
In 2012, we commenced a consolidation of certain research model operations in Europe. As a result, we recorded an impairment charge of $3,548 to cost of sales for the disposition of facilities that we own. Following the impairment, the long-lived asset group was classified as held-for-use as we ceased operations over the following several months. We have commenced a search for a buyer of the facility. We continue to utilize the facility in a limited capacity and, accordingly, we have not yet met the criteria for classifying the facility as held-for-sale. Once these conditions are met, we will classify the long-lived assets as held-for-sale, cease depreciation and adjust the assets to fair value quarterly. | |
In 2011, certain long-lived assets related to facilities in our RMS segment were no longer in use and not expected to be fully recoverable and as a result we recorded an impairment charge of $692 included in cost of sales. In addition, we sold the assets of our PCS-China facility for $4,593 and recognized a gain on the sale of $3,776. Also in 2011, we determined that the carrying value of our in process research and development acquired in the acquisition of SPC exceeded its fair value and as a result we recorded an impairment charge of $6,800 included in selling, general and administrative expenses. |
LongTerm_Debt_and_Capital_Leas
Long-Term Debt and Capital Lease Obligations | 12 Months Ended | |||||||
Dec. 28, 2013 | ||||||||
Debt Disclosure [Abstract] | ' | |||||||
Long-Term Debt and Capital Lease Obligations | ' | |||||||
AND CAPITAL LEASE OBLIGATIONS | ||||||||
Long-Term Debt | ||||||||
Long-term debt consists of the following: | ||||||||
December 28, 2013 | December 29, 2012 | |||||||
2.25% Senior convertible debentures: | ||||||||
Principal | $ | — | $ | 349,995 | ||||
Unamortized debt discount | — | (6,726 | ) | |||||
Net carrying amount of senior convertible debentures | — | 343,269 | ||||||
Term loan facility | 409,500 | 290,947 | ||||||
Revolving credit facility | 253,308 | 32,000 | ||||||
Other long-term debt | 241 | 232 | ||||||
Total debt | 663,049 | 666,448 | ||||||
Less: current portion of long-term debt | (21,241 | ) | (139,373 | ) | ||||
Long-term debt | $ | 641,808 | $ | 527,075 | ||||
Minimum future principal payments of long-term debt at December 28, 2013 are as follows: | ||||||||
Fiscal Year | ||||||||
2014 | $ | 21,241 | ||||||
2015 | 42,000 | |||||||
2016 | 47,250 | |||||||
2017 | 68,250 | |||||||
2018 | 484,308 | |||||||
Total | $ | 663,049 | ||||||
On May 29, 2013, we amended and restated our credit agreement dated September 23, 2011 to repay loans outstanding under the previous agreement, to retire our 2.25% Senior Convertible Debentures (the "2013 Notes") and to extend the maturity date of our credit agreement under a new $970,000 agreement (the "$970M Credit Facility"). The $970M Credit Facility provides a $420,000 U.S. term loan facility (the "Term Loan") and a $550,000 multi-currency revolving credit facility (the "Credit Facility"). The revolving credit facility may be drawn in U.S. Dollars, Euros, Pound Sterling, or Japanese Yen, subject to sub-limits by currency. Under specified circumstances, we have the ability to expand the term loan and/or revolving credit facility by up to $350,000 in the aggregate. | ||||||||
The $420,000 U.S. term loan matures in quarterly installments through maturity on May 29, 2018. The revolving credit facility also matures on May 29, 2018 and requires no scheduled payment before this date. The interest rates applicable to our term loans and revolving loans under the credit agreement are variable and based on an applicable rate plus a spread determined by our leverage ratio. As of December 28, 2013, the interest rate spread for adjusted LIBOR loans was 1.25%. | ||||||||
The $970M Credit Facility includes certain customary representations and warranties, events of default, notices of material adverse changes to our business and negative and affirmative covenants. As of December 28, 2013, we were compliant with all financial covenants. These covenants include (1) maintenance of a ratio of consolidated earnings before interest, taxes, depreciation and amortization less capital expenditures to consolidated cash interest expense, for any period of four consecutive fiscal quarters, of no less than 3.5 to 1.0 as well as (2) maintenance of a ratio of consolidated indebtedness to consolidated earnings before interest, taxes, depreciation and amortization for any period of four consecutive fiscal quarters, of no more than 3.75 to 1.0. In addition, we must maintain a ratio of consolidated indebtedness to quarterly consolidated earnings before interest, taxes, depreciation and amortization of 3.5 to 1.0 for our first and second fiscal quarters of 2014 and of 3.25 to 1.0 for each fiscal quarter thereafter. Our obligations under the credit agreement are guaranteed by our material domestic subsidiaries and are secured by substantially all of our assets, including a pledge of 100% of the capital stock of our domestic subsidiaries (other than the capital stock of any domestic subsidiary that is treated as a disregarded entity for U.S. federal income tax purposes) and 65% of the capital stock of certain first-tier foreign subsidiaries and domestic disregarded entities, and mortgages on owned real property in the U.S. having a book value in excess of $10,000. We had $4,855 outstanding under letters of credit as of December 28, 2013. | ||||||||
As noted above, our 2013 Notes were retired from the proceeds of the $970M Credit Facility and available cash and were done without triggering any of the conversion features. As a result of the refinancing and the associated modification and extinguishment of the previous debt agreement, we recognized an extinguishment loss of $389, which is included in interest expense. | ||||||||
We have capital leases for equipment. These leases are capitalized using interest rates considered appropriate at the inception of each lease. Capital lease obligations amounted to $740 and $72 at December 28, 2013 and December 29, 2012, respectively. |
Equity
Equity | 12 Months Ended | |||||||||||||||
Dec. 28, 2013 | ||||||||||||||||
Stockholders' Equity Note [Abstract] | ' | |||||||||||||||
Equity | ' | |||||||||||||||
Earnings Per Share | ||||||||||||||||
Basic earnings per share for 2013, 2012 and 2011 was computed by dividing earnings available to common shareholders for these periods by the weighted average number of common shares outstanding in the respective periods. Diluted earnings per share for these periods was computed by dividing earnings available to common shareholders by the weighted average number of common shares outstanding for each period adjusted for the dilutive effect outstanding stock options and unvested restricted stock. Options to purchase 2,288,926 shares, 4,590,925 shares and 4,249,564 shares were outstanding at December 28, 2013, December 29, 2012 and December 31, 2011, respectively, but were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. In addition, weighted average shares outstanding for 2013, 2012 and 2011 excluded the weighted average impact of 1,096,550, 934,505 and 703,011 shares, respectively, of non-vested fixed restricted stock awards. | ||||||||||||||||
The following table illustrates the reconciliation of the numerator and denominator in the computations of the basic and diluted earnings per share: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||
Numerator: | ||||||||||||||||
Income from continuing operations for purposes of calculating earnings per share | $ | 104,093 | $ | 101,547 | $ | 115,111 | ||||||||||
Income (loss) from discontinued businesses | $ | (1,265 | ) | $ | (4,252 | ) | $ | (5,545 | ) | |||||||
Denominator: | ||||||||||||||||
Weighted-average shares outstanding—Basic | 47,740,167 | 47,912,135 | 50,823,063 | |||||||||||||
Effect of dilutive securities: | ||||||||||||||||
Stock options and contingently issued restricted stock | 749,155 | 494,185 | 495,179 | |||||||||||||
Weighted-average shares outstanding—Diluted | 48,489,322 | 48,406,320 | 51,318,242 | |||||||||||||
Basic earnings per share from continuing operations attributable to common shareholders | $ | 2.18 | $ | 2.12 | $ | 2.26 | ||||||||||
Basic earnings (loss) per share from discontinued operations attributable to common shareholders | $ | (0.03 | ) | $ | (0.09 | ) | $ | (0.11 | ) | |||||||
Diluted earnings per share from continuing operations attributable to common shareholders | $ | 2.15 | $ | 2.1 | $ | 2.24 | ||||||||||
Diluted earnings (loss) per share from discontinued operations attributable to common shareholders | $ | (0.03 | ) | $ | (0.09 | ) | $ | (0.11 | ) | |||||||
The sum of the earnings per share from continuing operations attributable to common shareholders and the earnings (loss) per share from discontinued operations attributable to common shareholders does not necessarily equal the earnings (loss) per share from net income attributable to common shareholders in the consolidated statements of operations due to rounding. | ||||||||||||||||
Treasury Shares | ||||||||||||||||
The Company's Board of Directors has authorized an aggregate stock repurchase program of $1,000,000, which includes $750,000 approved in 2010 and $250,000 approved in 2013. As of December 28, 2013, the Company had $139,099 of remaining authorization under this stock repurchase program. In order to enable us to facilitate, on a more timely and cost efficient basis, the repurchase of a substantial number of our shares pursuant to that stock repurchase authorization, we entered into a series of accelerated stock repurchase (ASR) programs in 2010 and 2011. The ASR programs are recorded as two transactions allocated between the initial purchase of treasury stock and a forward contract indexed to our common stock. The treasury shares result in an immediate reduction of shares on our statement of financial position and in our EPS calculation. | ||||||||||||||||
On August 26, 2010, we entered into an agreement with a third party investment bank to implement an ASR program to repurchase $300,000 of common stock. Under this ASR, we paid $300,000 on August 27, 2010 from cash on hand and available liquidity, including funds borrowed by us under our $750,000 credit facility. The ASR was settled on February 11, 2011 based on a discount to the daily volume weighted average price (VWAP) of our common stock over the course of a calculation period. We received the final 871,829 shares based on the settlement of the ASR, which were recorded at $32,509. | ||||||||||||||||
On February 24, 2011, we entered into an ASR to repurchase $150,000 of common stock. Under the ASR, we paid $150,000 from cash on hand, including funds borrowed under our credit facility. Upon signing the ASR on February 24, 2011, we received the initial delivery of 3,759,398 shares, which was recorded at $135,860 based on the market value at the date of the transaction, and recorded $14,140 as a forward contract indexed to our common stock. The ASR was settled on May 16, 2011 based on a discount to the daily volume weighted average price (VWAP) of our common stock over the course of a calculation period. We received the final 6,505 shares based on the settlement of the ASR, which were recorded at $257. | ||||||||||||||||
During 2013, 2012 and 2011, we repurchased 3,468,031 shares of common stock for $165,717, 1,705,521 shares of common stock for $61,442 and 3,790,762 shares of common stock for $130,853, respectively, under our Rule 10b5-1 Purchase Plans and in open market trading. The timing and amount of any future repurchases will depend on market conditions and corporate considerations. | ||||||||||||||||
Share repurchases through ASR programs and open market purchases during 2013, 2012 and 2011 were as follows: | ||||||||||||||||
Fiscal Year Ended | ||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||
Number of shares of common stock repurchased | 3,468,031 | 1,705,521 | 8,428,494 | |||||||||||||
Total cost of repurchase | $ | 165,717 | $ | 61,442 | $ | 299,479 | ||||||||||
Additionally, our 2000 Incentive Plan permits the netting of common stock upon vesting of restricted stock awards in order to satisfy individual tax withholding requirements. During the fiscal year ended December 28, 2013, December 29, 2012 and December 31, 2011, we acquired shares 113,424 for $4,554, 84,250 shares for $3,047 and 79,704 shares for $2,942, respectively, as a result of such withholdings. | ||||||||||||||||
Accumulated Deficit | ||||||||||||||||
None of our accumulated deficit is restricted due to statutory requirements in the local jurisdiction of a foreign subsidiary as of December 28, 2013 and December 29, 2012. | ||||||||||||||||
Accumulated Other Comprehensive Income | ||||||||||||||||
The composition of accumulated other comprehensive income is as follows: | ||||||||||||||||
Foreign | Pension Gains/(Losses) | Net Unrealized | Accumulated | |||||||||||||
Currency | and Prior Service | Gain on | Other | |||||||||||||
Translation | (Cost)/Credit Not Yet | Marketable | Comprehensive | |||||||||||||
Adjustment | Recognized as | Securities | Income | |||||||||||||
Components of Net | ||||||||||||||||
Periodic Benefit Costs | ||||||||||||||||
Balance at December 31, 2011 | $ | 38,685 | $ | (33,171 | ) | $ | (921 | ) | $ | 4,593 | ||||||
Period change | 5,274 | (5,862 | ) | 921 | 333 | |||||||||||
Tax | 98 | 1,579 | — | 1,677 | ||||||||||||
Balance at December 29, 2012 | $ | 44,057 | $ | (37,454 | ) | $ | — | $ | 6,603 | |||||||
Period change | (15,751 | ) | 22,310 | — | 6,559 | |||||||||||
Tax | 197 | (8,002 | ) | — | (7,805 | ) | ||||||||||
Balance at December 28, 2013 | $ | 28,503 | $ | (23,146 | ) | $ | — | $ | 5,357 | |||||||
Warrants | ||||||||||||||||
Separately and concurrently with the pricing of the 2013 Notes in June 2006, we issued warrants for approximately 7,200,000 shares of our common stock. The warrants give the holders the right to receive, for no additional consideration, cash or shares, at our option, with a value equal to the appreciation in the price of our shares above $59.63 and expire between September 13, 2013 and January 22, 2014 over 90 equal increments. As of December 28, 2013, warrants for approximately 1,271,459 shares were outstanding and none were subsequently exercised. | ||||||||||||||||
Noncontrolling Interests | ||||||||||||||||
A noncontrolling interest resulted from our acquisition of a 75% ownership interest in Vital River. We entered into a joint venture agreement with the noncontrolling interest holders that provides us with the right to purchase, and the noncontrolling interest has the right to require us to purchase, the remaining 25% of the entity for cash at its then appraised fair value beginning in January 2016. See Note 2 for additional information. As the noncontrolling interest holders can require us to purchase the remaining 25% interest for cash, we classify the carrying amount of the noncontrolling interest above the equity section and below liabilities on the consolidated balance sheet and we adjust the carrying amount to fair value at the end of each reporting period. Adjustments to fair value are recorded through additional paid-in capital. The carrying value of the Vital River noncontrolling interest is $20,581 at December 28, 2013. | ||||||||||||||||
We hold investments in several joint ventures. These joint ventures are separate legal entities whose purpose is consistent with our overall operations and represent geographic and business segment expansions of existing markets. The financial results of all joint ventures were consolidated in our results as we have the ability to exercise control over these entities. The interests of the outside joint venture partners in these joint ventures have been recorded as noncontrolling interest totaling $3,093 and $2,395 at December 28, 2013 and December 29, 2012, respectively. |
Income_Taxes
Income Taxes | 12 Months Ended | |||||||||||
Dec. 28, 2013 | ||||||||||||
Income Tax Disclosure [Abstract] | ' | |||||||||||
Income Taxes | ' | |||||||||||
INCOME TAXES | ||||||||||||
An analysis of the components of income from continuing operations before income taxes and the related provision for income taxes is presented below: | ||||||||||||
Fiscal Year Ended | ||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||
Income from continuing operations before income taxes | ||||||||||||
U.S. | $ | 39,900 | $ | 35,504 | $ | 47,158 | ||||||
Non-U.S. | 98,427 | 94,242 | 85,504 | |||||||||
$ | 138,327 | $ | 129,746 | $ | 132,662 | |||||||
Income tax provision | ||||||||||||
Current: | ||||||||||||
Federal | $ | 10,832 | $ | (1,447 | ) | $ | 3,957 | |||||
Foreign | 18,370 | 26,411 | 20,727 | |||||||||
State and local | 4,240 | 1,353 | 1,124 | |||||||||
Total current | $ | 33,442 | $ | 26,317 | $ | 25,808 | ||||||
Deferred: | ||||||||||||
Federal | $ | 5,468 | $ | 13,132 | $ | 2,961 | ||||||
Foreign | (6,431 | ) | (12,683 | ) | (11,649 | ) | ||||||
State and local | 432 | 862 | 20 | |||||||||
Total deferred | $ | (531 | ) | $ | 1,311 | $ | (8,668 | ) | ||||
$ | 32,911 | $ | 27,628 | $ | 17,140 | |||||||
Net deferred taxes, detailed below, recognize the impact of temporary differences between the amounts of assets and liabilities recorded for financial statement purposes and such amounts measured in accordance with tax laws. | ||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||
Compensation | $ | 38,836 | $ | 52,668 | ||||||||
Accruals and reserves | 2,356 | 2,160 | ||||||||||
Inventory reserves and valuations | 1,696 | 3,663 | ||||||||||
Financing related | 1,594 | 2,545 | ||||||||||
Goodwill and other intangibles | (21,826 | ) | (14,982 | ) | ||||||||
Net operating loss and credit carryforwards | 58,891 | 55,067 | ||||||||||
Depreciation related | (22,389 | ) | (37,212 | ) | ||||||||
Non-indefinitely reinvested earnings | — | (146 | ) | |||||||||
Investments in limited partnerships | (2,720 | ) | (405 | ) | ||||||||
Other | (1,640 | ) | (839 | ) | ||||||||
54,798 | 62,519 | |||||||||||
Valuation allowance | (7,071 | ) | (7,504 | ) | ||||||||
Total deferred taxes | $ | 47,727 | $ | 55,015 | ||||||||
Reconciliations of the statutory U.S. Federal income tax rate to effective tax rates are as follows: | ||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||
U.S. statutory income tax rate | 35 | % | 35 | % | 35 | % | ||||||
Foreign tax rate differences | (8.0 | )% | (8.0 | )% | (6.7 | )% | ||||||
State income taxes, net of Federal tax benefit | 1.6 | % | 1.5 | % | 2.1 | % | ||||||
Unbenefitted losses and changes in valuation allowance | 0.4 | % | 0.8 | % | 0.6 | % | ||||||
Impact of repatriation of non-U.S. earnings | — | % | — | % | 0.5 | % | ||||||
Research tax credits and enhanced deductions | (6.6 | )% | (8.2 | )% | (7.6 | )% | ||||||
Enacted tax rate changes | (0.4 | )% | (0.2 | )% | (1.0 | )% | ||||||
Impact of tax uncertainties | 1 | % | (1.2 | )% | (1.0 | )% | ||||||
Releasing valuation allowance on loss from disposition of the Phase 1 Clinical business | — | % | — | % | (8.4 | )% | ||||||
Non taxable gain from settlement of life insurance policy | — | % | — | % | (2.2 | )% | ||||||
Other | 0.8 | % | 1.6 | % | 1.6 | % | ||||||
23.8 | % | 21.3 | % | 12.9 | % | |||||||
As of December 28, 2013, we have non-U.S. net operating loss carryforwards, the tax effect of which is $12,951. Of this amount, $524 will expire in 2014, and $218 will expire between 2014 and 2031. The remainder of $12,209 can be carried forward indefinitely. We have U.S. net operating loss carryforwards at the state level, the tax effect of which is $94, which will expire between 2016 and 2031. We have U.S. foreign tax credit carryforwards of $21,733. Of this amount, $12,783 will expire in 2019, $6,255 will expire in 2020, $2,411 will expire in 2021 and the remaining $284 thereafter. We have Canadian Scientific Research and Experimental Development (SR&ED) credit carryforwards of $23,946, which will expire between 2029 and 2033. In accordance with Canadian Federal tax law, we claim SR&ED credits on qualified research and development costs incurred by our Preclinical service facility in Canada, in the performance of projects for non-Canadian clients. Additionally, in the first quarter of 2013, in accordance with the tax law of the United Kingdom, we claimed enhanced deductions related to qualified research and development costs incurred by our Preclinical service facility in Scotland, in the performance of certain client contracts. As of April 1, 2013, we adopted the new refundable research and development credit that was provided for in a UK tax law change that was enacted in 2013. This credit was recorded as a benefit to operating income. We have realized capital losses in the U.S., the tax effect of which is $166, which will expire in 2017. We have realized and unrealized capital losses in Canada, the tax effect of which is $488. These losses can be carried forward indefinitely. | ||||||||||||
We record deferred tax assets for stock-based awards based on the amount of stock-based compensation recognized in our Consolidated Statements of Income at the statutory tax rate in the jurisdiction in which we will receive a tax deduction. Differences between the deferred tax assets and the actual tax benefit reported on our income tax returns are recorded in additional paid-in capital. If the tax benefit is less that the deferred tax asset, the calculated shortfall reduces our pool of excess tax benefits. If the pool of excess tax benefits is reduced to zero, the subsequent shortfalls would increase our income tax expense. Our pool of excess tax benefits, which is computed in accordance with the long form method, was $7,345 as of December 28, 2013 and $9,558 as of December 29, 2012. During 2013, we recorded a tax benefit of $1,068 to additional paid-in-capital related to the exercise of stock options and vesting of restricted shares. | ||||||||||||
We have fully recognized our deferred tax assets on the belief that it is more likely than not that they will be realized. The only exceptions at December 28, 2013 relate to deferred tax assets primarily for net operating losses in Hong Kong, Luxembourg and the Netherlands, capital losses in the U.S. and Canada, and fixed assets in the U.K. The valuation allowance decreased by $433 from $7,504 at December 29, 2012 to $7,071 at December 28, 2013. | ||||||||||||
At December 28, 2013, the amount recorded for unrecognized tax benefits was $18,475. At December 29, 2012 the amount recorded for unrecognized income tax benefits was $30,996. The $12,521 decrease during 2013 is primarily attributable to a settlement reached during the year with the CRA related to SR&ED credits claimed in 2005 through 2011. This reduction was partially offset by increases primarily due to a new uncertain tax position related to tax incentives claimed by Vital River in prior years, ongoing evaluation of uncertain tax positions in the current and prior periods related to the Canadian SR&ED credits claimed by our Preclinical subsidiary in Montreal, and foreign exchange movement. | ||||||||||||
The amount of unrecognized income tax benefits that, if recognized, would favorably impact the effective tax rate was $17,012 as of December 28, 2013 and $24,386 as of December 29, 2012. The $7,374 decrease is primarily attributable to the settlement reached during 2013 with the CRA related to SR&ED credits claimed in 2005 through 2011, partially offset by the new uncertain tax position related to Vital River and an increase due to the ongoing evaluation of uncertain tax positions for the current and prior periods. It is reasonably possible as of December 28, 2013 that the liability for unrecognized tax benefits for the uncertain tax position associated with an acquisition agreement termination fee could decrease within the next twelve months by approximately $11,000 due to the potential expiration of a statute of limitations. | ||||||||||||
A reconciliation of our beginning and ending unrecognized income tax benefits is as follows: | ||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||
Beginning balance | $ | 30,996 | $ | 27,976 | $ | 33,427 | ||||||
Additions: | ||||||||||||
Tax positions for current year | 2,009 | 1,907 | 1,714 | |||||||||
Tax positions for prior years | 1,709 | 4,196 | — | |||||||||
Reductions: | ||||||||||||
Tax positions for current year | — | — | — | |||||||||
Tax positions for prior years | (732 | ) | (28 | ) | (239 | ) | ||||||
Settlements | (15,246 | ) | (3,055 | ) | (6,926 | ) | ||||||
Expiration of statute of limitations | (261 | ) | — | — | ||||||||
Ending balance | $ | 18,475 | $ | 30,996 | $ | 27,976 | ||||||
We continue to recognize interest and penalties related to unrecognized income tax benefits in income tax expense. The total amount of accrued interest related to unrecognized income tax benefits as of December 28, 2013 and December 29, 2012 was $691 and $1,964, respectively. The $1,273 decrease is primarily due to the Canadian SR&ED settlement for tax years 2005 through 2011. We have not recorded a provision for penalties associated with uncertain tax positions. | ||||||||||||
We conduct business in a number of tax jurisdictions. As a result, we are subject to tax audits on a regular basis including, but not limited to, such major jurisdictions as the United States, the United Kingdom, France, Japan, Germany and Canada. With few exceptions, we are no longer subject to U.S. and international income tax examinations for years before 2006. | ||||||||||||
We and certain of our subsidiaries are currently under audit by various tax authorities in the U.S., Canada, Germany and Finland. We do not anticipate resolution of these audits to have a material impact on our financial statements. | ||||||||||||
We are currently under audit by the Canadian Revenue Authority (CRA) for the years 2006 through 2009. In the fourth quarter of 2012, we received a draft reassessment from the CRA related to the transfer pricing in our Preclinical services operations in Montreal. The CRA proposes to disallow certain deductions related to headquarter service charges for the years 2006 through 2009. We intend to file an objection with the CRA upon receipt of the Notice of Reassessment and apply to the Internal Revenue Service (IRS) and the CRA for relief pursuant to the competent authority procedure provided in the tax treaty between the U.S. and Canada. We believe that the controversy will likely be ultimately settled via the competent authority process. In the fourth quarter of 2012, we established a reserve for this uncertain tax position of $2,408 related to years 2006 through 2012 to reduce the tax benefit recognized for these deductions in Canada to the level that we believe will likely be realized upon the ultimate resolution of this controversy. Additionally, in the fourth quarter of 2012, we recognized a tax asset of $2,981, which is included in Other Assets, that represents the correlative relief that we believe will more likely than not be received in the U.S. via the competent authority process. In the third quarter of 2013, there was a U.S. tax court opinion issued that could impact our ability to recognize the full benefit of the correlative relief recorded in 2012. As a result, in the third quarter of 2013, the U.S. tax asset recorded in the fourth quarter of 2012 was reduced by $2,006 to $975. The actual amounts of the liability for Canadian taxes and the asset for the correlative relieve in the U.S. could be different based upon the agreement reached between the IRS and CRA. | ||||||||||||
During 2012, the Canadian government enacted a reduction in the SR&ED credit, which is applicable for years 2014 and beyond. This change in law will reduce our SR&ED credits by 25% starting in 2014. | ||||||||||||
Subsequent to our December 29, 2012 year end, the French government enacted a tax law change that applies retroactively to 2012. We recorded the 2012 impact of this law change, which limits the deductibility of interest by our French affiliates for 2012 and beyond, as a discrete event in our financial statement for the first quarter ending March 30, 2013. The total 2012 impact from the tax law change is additional tax expense of $703. On December 30, 2013, the French government enacted anti hybrid provisions in an attempt to further restrict the ability of companies to deduct interest in France for 2013 and beyond. We believe that this new tax law should not apply to further restrict the deduction of interest by our French affiliates. However, future changes in or clarifications to the French anti-hybrid provisions could result in the disallowance of interest currently deducted by our French affiliates resulting in an increase to our effective tax rate in 2014 and beyond. | ||||||||||||
On February 25, 2013, the German government enacted a tax law change that restricts the deductibility of losses in Germany. As of December 28, 2013, we believe that this new tax law should not apply to restrict the deduction of losses by our German affiliates. However, future changes in or clarifications to the German tax law may result in disallowing losses currently deducted by our German affiliates and a corresponding increase to our effective tax rate in 2014 and beyond. | ||||||||||||
In accordance with our policy, the remaining undistributed earnings of our non-U.S. subsidiaries remain indefinitely reinvested as of the end of 2013 as they are required to fund needs outside the U.S. and cannot be repatriated in a manner that is substantially tax free. During the third quarter of 2011, we restructured our international operations in a tax-free manner to allow us more flexibility in accessing our offshore cash to fund needs outside the U.S. As of December 28, 2013, the earnings of our non-U.S. subsidiaries considered to be indefinitely reinvested totaled $210,328. No provision for U.S. income taxes has been provided thereon. Upon distribution of these earnings in the form of dividends or otherwise, we would be subject to additional U.S. Federal and state income taxes and foreign income and withholding taxes, which could be material. Determination of the amount of unrecognized deferred income tax liabilities on these earnings is not practicable because of the complexities with the hypothetical calculation. Additionally, the amount of liability is dependent on circumstances existing if and when remittance occurs. |
Employee_Benefit_Plans
Employee Benefit Plans | 12 Months Ended | |||||||||||||||||||||||
Dec. 28, 2013 | ||||||||||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | ' | |||||||||||||||||||||||
Employee Benefits | ' | |||||||||||||||||||||||
Charles River Laboratories Employee Savings Plan | ||||||||||||||||||||||||
Our defined contribution plan, the Charles River Laboratories Employee Savings Plan, qualifies under section 401(k) of the Internal Revenue Code. It covers substantially all U.S. employees and contains a provision whereby we match a percentage of employee contributions. The costs associated with this defined contribution plan totaled $4,718, $4,364 and $4,178, in 2013, 2012 and 2011, respectively. | ||||||||||||||||||||||||
Charles River Laboratories Deferred Compensation Plan and Executive Supplemental Life Insurance Retirement Plan | ||||||||||||||||||||||||
The Charles River Laboratories Deferred Compensation Plan (Deferred Compensation Plan) is designed for select eligible employees, including our Named Executive Officers. Under the Deferred Compensation Plan, participants may elect to defer bonus and salary amounts, and may select the investment returns to be applied to deferred amounts from among a number of reference mutual funds as well as an interest crediting rate. The plan is not qualified under Section 401(a) of the Internal Revenue Code and is not subject to the Employee Retirement Income Security Act of 1974. At the present time, no contributions will be credited to the plan, except as set forth below. Participants must specify the distribution date for deferred amounts at the time of deferral, in accordance with applicable IRS regulations. Generally, amounts may be paid in lump sum or installments upon retirement or termination of employment, or later if the employee terminates employment after age 55 and before age 65. Amounts may also be distributed during employment, subject to a minimum deferral requirement of three years. | ||||||||||||||||||||||||
In addition to the Deferred Compensation Plan, certain officers and key employees also participate, or in the past participated, in our amended and restated Executive Supplemental Life Insurance Retirement Plan (ESLIRP) which is a non-funded, non-qualified arrangement. Annual benefits under this plan will equal a percentage of the highest five consecutive years of compensation, offset by amounts payable under the Charles River Laboratories, Inc. Pension Plan and Social Security. | ||||||||||||||||||||||||
In addition, we provide certain active employees an annual contribution into their Deferred Compensation Plan account of 10% of the employee's base salary plus the lesser of their target annual bonus or actual annual bonus. The costs associated with these defined contribution plans, including the ESLIRP, totaled $3,322, $2,930 and $2,048 in 2013, 2012 and 2011, respectively. | ||||||||||||||||||||||||
We have invested in several corporate-owned key-person life insurance policies as well as mutual funds and U.S. Treasury Securities with the intention of using these investments to fund the ESLIRP and the Deferred Compensation Plan. Participants have no interest in any such investments. At December 28, 2013 and December 29, 2012 the cash surrender value of these life insurance policies were $26,507 and $25,240, respectively. | ||||||||||||||||||||||||
Post-Retirement Health and Life Insurance Plans | ||||||||||||||||||||||||
Our Montreal location offers post-retirement life insurance benefits to its employees and post-retirement medical & dental insurance coverage to certain executives. The plan is non-contributory and unfunded. As of December 28, 2013, the accumulated benefit obligation related to the plan was $1,057. In addition, accumulated other comprehensive income includes $96 of deferred gains, net of tax, as of December 28, 2013, and $105 of deferred losses, net of tax, as of December 29, 2012. Expenses related to the plan were $84, $201 and $188 for 2013, 2012 and 2011, respectively. | ||||||||||||||||||||||||
Pension Plans | ||||||||||||||||||||||||
The Charles River Laboratories, Inc. Pension Plan is a qualified, non-contributory defined benefit plan covering certain US employees. Effective 2002, the plan was amended to exclude new participants from joining and in 2008 the accrual of benefits was frozen. | ||||||||||||||||||||||||
The Charles River Pension Plan is a defined contribution and defined benefit pension plan covering certain UK employees. Benefits are based on participants' final pensionable salary and years of service. Participants' rights vest immediately. Effective December 31, 2002, the plan was amended to exclude new participants from joining the defined benefit section of the plan and a defined contribution section was established for new entrants. Contributions under the defined contribution plan are determined as a percentage of gross salary. | ||||||||||||||||||||||||
The defined benefit pension plans for Japan and our Canadian RMS operation are non-contributory plans that cover substantially all employees of those respective companies. Benefits are based upon length of service and final salary. In addition, our French RMS operation has a defined benefit statutory indemnity plan covering most of its employees. | ||||||||||||||||||||||||
The following tables summarize the funded status of our defined benefit plans and amounts reflected in our consolidated balance sheets. | ||||||||||||||||||||||||
Obligations and Funded Status: | ||||||||||||||||||||||||
Pension Benefits | Supplemental | |||||||||||||||||||||||
Retirement Benefits | ||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||||||
Change in benefit obligations | ||||||||||||||||||||||||
Benefit obligation at beginning of year | $ | 283,063 | $ | 251,916 | $ | 27,372 | $ | 26,456 | ||||||||||||||||
Service cost | 3,368 | 3,729 | 643 | 640 | ||||||||||||||||||||
Interest cost | 11,273 | 11,289 | 708 | 892 | ||||||||||||||||||||
Plan participants' contributions | — | 53 | — | — | ||||||||||||||||||||
Benefit payments | (8,300 | ) | (6,186 | ) | (726 | ) | (743 | ) | ||||||||||||||||
Actuarial loss (gain) | (4,276 | ) | 16,699 | 1,501 | 127 | |||||||||||||||||||
Plan amendments | — | — | — | — | ||||||||||||||||||||
Administrative expenses paid | (308 | ) | (266 | ) | — | — | ||||||||||||||||||
Effect of foreign exchange | 1,392 | 5,829 | — | — | ||||||||||||||||||||
Benefit obligation at end of year | $ | 286,212 | $ | 283,063 | $ | 29,498 | $ | 27,372 | ||||||||||||||||
Change in plan assets | ||||||||||||||||||||||||
Fair value of plan assets at beginning of year | $ | 238,672 | $ | 202,652 | $ | — | $ | — | ||||||||||||||||
Actual return on plan assets | 30,820 | 22,467 | — | — | ||||||||||||||||||||
Settlements | — | — | — | — | ||||||||||||||||||||
Employer contributions | 9,570 | 14,222 | 726 | 743 | ||||||||||||||||||||
Plan participants' contributions | — | 53 | — | — | ||||||||||||||||||||
Benefit payments | (8,300 | ) | (6,186 | ) | (726 | ) | (743 | ) | ||||||||||||||||
Premiums paid | (308 | ) | (266 | ) | — | — | ||||||||||||||||||
Effect of foreign exchange | 2,205 | 5,730 | — | — | ||||||||||||||||||||
Fair value of plan assets at end of year | $ | 272,659 | $ | 238,672 | $ | — | $ | — | ||||||||||||||||
Funded status | ||||||||||||||||||||||||
Projected benefit obligation | $ | 286,212 | $ | 283,063 | $ | 29,498 | $ | 27,372 | ||||||||||||||||
Fair value of plan assets | 272,659 | 238,672 | — | — | ||||||||||||||||||||
Net balance sheet liability | $ | 13,553 | $ | 44,391 | $ | 29,498 | $ | 27,372 | ||||||||||||||||
Classification of net balance sheet asset / liability: | ||||||||||||||||||||||||
Non-current assets | $ | 2,738 | $ | — | $ | — | $ | — | ||||||||||||||||
Current liabilities | 72 | 75 | 789 | 709 | ||||||||||||||||||||
Non-current liabilities | 16,219 | 44,316 | 28,709 | 26,663 | ||||||||||||||||||||
Amounts recognized in statement of financial position as part of accumulated other comprehensive income ("AOCI"): | ||||||||||||||||||||||||
Pension Benefits | Supplemental | |||||||||||||||||||||||
Retirement Benefits | ||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||||||
Net actuarial loss | $ | 35,481 | $ | 58,594 | $ | 4,307 | $ | 3,056 | ||||||||||||||||
Net prior service cost/(credit) | (6,338 | ) | (6,815 | ) | 660 | 1,320 | ||||||||||||||||||
Total | $ | 29,143 | $ | 51,779 | $ | 4,967 | $ | 4,376 | ||||||||||||||||
Information for defined benefit plans with accumulated benefit obligation in excess of plan assets: | ||||||||||||||||||||||||
Pension Benefits | Supplemental | |||||||||||||||||||||||
Retirement Benefits | ||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||||||
Projected benefit obligation | $ | 82,254 | $ | 277,187 | $ | 29,498 | $ | 27,372 | ||||||||||||||||
Accumulated benefit obligation | 81,117 | 271,204 | 27,938 | 26,495 | ||||||||||||||||||||
Fair value of plan assets | 68,430 | 233,182 | — | — | ||||||||||||||||||||
Information for defined benefit plans with projected benefit obligation in excess of plan assets: | ||||||||||||||||||||||||
Pension Benefits | Supplemental | |||||||||||||||||||||||
Retirement Benefits | ||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||||||
Projected benefit obligation | $ | 99,671 | $ | 283,063 | $ | 29,498 | $ | 27,372 | ||||||||||||||||
Accumulated benefit obligation | 93,307 | 275,162 | 27,938 | 26,495 | ||||||||||||||||||||
Fair value of plan assets | 83,379 | 238,672 | — | — | ||||||||||||||||||||
Amounts in AOCI expected to be recognized as components of net periodic benefit cost over the next fiscal year: | ||||||||||||||||||||||||
Pension | Supplemental | |||||||||||||||||||||||
Benefits | Retirement | |||||||||||||||||||||||
Benefits | ||||||||||||||||||||||||
Amortization of net actuarial loss | $ | 923 | $ | 250 | ||||||||||||||||||||
Amortization of net prior service cost/(credit) | (637 | ) | 660 | |||||||||||||||||||||
Components of net periodic benefit cost: | ||||||||||||||||||||||||
Pension Benefits | Supplemental | |||||||||||||||||||||||
Retirement Benefits | ||||||||||||||||||||||||
2013 | 2012 | 2011 | 2013 | 2012 | 2011 | |||||||||||||||||||
Service cost | $ | 3,368 | $ | 3,729 | $ | 3,056 | $ | 643 | $ | 640 | $ | 636 | ||||||||||||
Interest cost | 11,273 | 11,289 | 12,107 | 708 | 892 | 1,201 | ||||||||||||||||||
Expected return on plan assets | (14,672 | ) | (13,799 | ) | (13,677 | ) | — | — | — | |||||||||||||||
Amortization of prior service cost (credit) | 2,711 | 2,461 | (617 | ) | 249 | 260 | 498 | |||||||||||||||||
Amortization of net loss (gain) | (603 | ) | (609 | ) | 978 | 660 | 660 | 210 | ||||||||||||||||
Net periodic benefit cost | 2,077 | 3,071 | 1,847 | 2,260 | 2,452 | 2,545 | ||||||||||||||||||
Settlement | — | — | 23 | — | — | (487 | ) | |||||||||||||||||
Net pension cost | $ | 2,077 | $ | 3,071 | $ | 1,870 | $ | 2,260 | $ | 2,452 | $ | 2,058 | ||||||||||||
Rollforward of accumulated other comprehensive income: | ||||||||||||||||||||||||
Pension Benefits | Supplemental | |||||||||||||||||||||||
Retirement Benefits | ||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||||||
Beginning balance | $ | 51,779 | $ | 45,267 | $ | 4,376 | $ | 5,171 | ||||||||||||||||
Amortization of prior service (cost) or credit | 603 | (2,461 | ) | (660 | ) | (660 | ) | |||||||||||||||||
Amortization of net (loss) gain | (2,710 | ) | 609 | (250 | ) | (260 | ) | |||||||||||||||||
Asset (gain) loss recorded during period | (20,424 | ) | 8,030 | 1,501 | 125 | |||||||||||||||||||
Currency impact | (105 | ) | 334 | — | — | |||||||||||||||||||
Ending balance | $ | 29,143 | $ | 51,779 | $ | 4,967 | $ | 4,376 | ||||||||||||||||
The above table excludes amortization of prior service cost of $32 and asset gains recorded during the period of $297. | ||||||||||||||||||||||||
Assumptions | ||||||||||||||||||||||||
Weighted-average assumptions used to determine benefit obligations: | ||||||||||||||||||||||||
Pension | Supplemental | |||||||||||||||||||||||
Benefits | Retirement Benefits | |||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||||||
Discount rate | 4.54 | % | 4.13 | % | 3.47 | % | 2.63 | % | ||||||||||||||||
Rate of compensation increase | 3.39 | % | 3.04 | % | 3 | % | 2.5 | % | ||||||||||||||||
Weighted-average assumptions used to determine net periodic benefit cost: | ||||||||||||||||||||||||
Pension Benefits | Supplemental | |||||||||||||||||||||||
Retirement Benefits | ||||||||||||||||||||||||
2013 | 2012 | 2011 | 2013 | 2012 | 2011 | |||||||||||||||||||
Discount rate | 4.13 | % | 4.47 | % | 5.2 | % | 2.63 | % | 3.42 | % | 4.34 | % | ||||||||||||
Expected long-term return on plan assets | 6.27 | % | 6.55 | % | 6.79 | % | — | — | — | |||||||||||||||
Rate of compensation increase | 3.04 | % | 3.12 | % | 3.48 | % | 2.5 | % | 2.5 | % | 2.5 | % | ||||||||||||
The discount rates reflect the rates at which amounts that are invested in a portfolio of high-quality debt instruments would provide the future cash flows necessary to pay benefits when they become due. The rate of compensation increase reflects the expected annual salary increases for the plan participants based on historical experience and our current employee compensation strategy. | ||||||||||||||||||||||||
We estimate the expected return on invested pension assets annually. The expected return is intended to match the duration over which our pension plans will provide benefit payments to participants. Each year, we use several data points to estimate the long-term investment return, including our targeted asset allocation, capital market performance estimates prepared by our outside investment advisers, survey information of rates of return used by other public companies and historical return information. The capital models that we use to estimate future market performance do not explicitly allow for historical market rate of return. Rather, these models consider the historical relationships among the economic metrics that influence investment returns, such as interest rates, inflation, price-to-earnings ratios, discounted dividends and earnings growth. The expected return for the asset portfolio is estimated using a geometric average from the expected returns of individual asset classes in the portfolio and is net of investment fees. A 0.5% decrease in the expected rate of return would increase annual pension expense by approximately $1,200. | ||||||||||||||||||||||||
Plan assets | ||||||||||||||||||||||||
Our pension plans' weighted-average asset allocations are as follows: | ||||||||||||||||||||||||
Target | Pension | |||||||||||||||||||||||
Allocation | Benefits | |||||||||||||||||||||||
2014 | 2013 | 2012 | ||||||||||||||||||||||
Equity securities | 60.1 | % | 54.8 | % | 60 | % | ||||||||||||||||||
Fixed income | 31.2 | % | 32.6 | % | 36 | % | ||||||||||||||||||
Other | 8.7 | % | 12.6 | % | 4 | % | ||||||||||||||||||
Total | 100 | % | 100 | % | 100 | % | ||||||||||||||||||
Our investment objective is to obtain the highest possible return commensurate with the level of assumed risk. Fund performances are compared to benchmarks including the S&P 500 Index, Russell 2000, BC Aggregate Index and MSCI EAFE Index. Our Investment Committee meets on a quarterly basis to review plan assets. | ||||||||||||||||||||||||
Plan assets did not include any of our common stock at December 28, 2013 and December 29, 2012, respectively. | ||||||||||||||||||||||||
The fair value of our pension assets by asset category are as follows. | ||||||||||||||||||||||||
Fair Value Measurements at December 28, 2013 | ||||||||||||||||||||||||
Asset Class | Quoted Prices in | Significant Other | Significant | Assets at | ||||||||||||||||||||
Active Markets | Observable | Unobservable | Fair Value | |||||||||||||||||||||
for Identical | Inputs | Inputs | ||||||||||||||||||||||
Assets | Level 2 | Level 3 | ||||||||||||||||||||||
Level 1 | ||||||||||||||||||||||||
Cash | $ | 1,004 | $ | — | $ | — | $ | 1,004 | ||||||||||||||||
Common stock(a) | 97,857 | 5,059 | — | 102,916 | ||||||||||||||||||||
Debt securities(a) | 62,717 | 3,487 | — | 66,204 | ||||||||||||||||||||
Mutual funds(b) | 65,152 | 35,610 | — | 100,762 | ||||||||||||||||||||
Life insurance policies(c) | — | 48 | — | 48 | ||||||||||||||||||||
Other | 299 | — | 1,426 | (d) | 1,725 | |||||||||||||||||||
Total | $ | 227,029 | $ | 44,204 | $ | 1,426 | $ | 272,659 | ||||||||||||||||
(a) | This category comprises investments valued at the closing price reported on the active market on which the individual securities are traded. | |||||||||||||||||||||||
(b) | This category comprises mutual funds valued at the net asset value of shares held at year end. | |||||||||||||||||||||||
(c) | This category comprises life insurance policies valued at cash surrender value at year end. | |||||||||||||||||||||||
(d) | This comprises annuity policies held with various insurance companies valued at face value. | |||||||||||||||||||||||
Fair Value Measurements | ||||||||||||||||||||||||
Using Significant | ||||||||||||||||||||||||
Unobservable | ||||||||||||||||||||||||
Inputs | ||||||||||||||||||||||||
(Level 3) | ||||||||||||||||||||||||
Balance at December 29, 2012 | $ | 1,488 | ||||||||||||||||||||||
Actual return on plan assets: | ||||||||||||||||||||||||
Relating to assets still held at December 28, 2013 | — | |||||||||||||||||||||||
Relating to assets sold during the period | (62 | ) | ||||||||||||||||||||||
Purchases, sales and settlements | — | |||||||||||||||||||||||
Transfers in and/or out of Level 3 | — | |||||||||||||||||||||||
Balance at December 28, 2013 | $ | 1,426 | ||||||||||||||||||||||
Fair Value Measurements at December 29, 2012 | ||||||||||||||||||||||||
Asset Class | Quoted Prices in | Significant Other | Significant | Assets at | ||||||||||||||||||||
Active Markets | Observable | Unobservable | Fair Value | |||||||||||||||||||||
for Identical | Inputs | Inputs | ||||||||||||||||||||||
Assets | Level 2 | Level 3 | ||||||||||||||||||||||
Level 1 | ||||||||||||||||||||||||
Cash | $ | 1,336 | $ | — | $ | — | $ | 1,336 | ||||||||||||||||
Common stock(a) | 100,864 | 4,261 | — | 105,125 | ||||||||||||||||||||
Debt securities(a) | 63,283 | 3,169 | — | 66,452 | ||||||||||||||||||||
Mutual funds(b) | 55,453 | 8,551 | — | 64,004 | ||||||||||||||||||||
Life insurance policies(c) | — | 43 | — | 43 | ||||||||||||||||||||
Other | 224 | — | 1,488 | (d) | 1,712 | |||||||||||||||||||
Total | $ | 221,160 | $ | 16,024 | $ | 1,488 | $ | 238,672 | ||||||||||||||||
(a) | This category comprises investments valued at the closing price reported on the active market on which the individual securities are traded. | |||||||||||||||||||||||
(b) | This category comprises mutual funds valued at the net asset value of shares held at year end. | |||||||||||||||||||||||
(c) | This category comprises life insurance policies valued at cash surrender value at year end. | |||||||||||||||||||||||
(d) | This comprises annuity policies held with various insurance companies valued at face value. | |||||||||||||||||||||||
Fair Value Measurements | ||||||||||||||||||||||||
Using Significant | ||||||||||||||||||||||||
Unobservable | ||||||||||||||||||||||||
Inputs | ||||||||||||||||||||||||
(Level 3) | ||||||||||||||||||||||||
Balance at December 31, 2011 | $ | 1,419 | ||||||||||||||||||||||
Actual return on plan assets: | ||||||||||||||||||||||||
Relating to assets still held at December 29, 2012 | 51 | |||||||||||||||||||||||
Relating to assets sold during the period | — | |||||||||||||||||||||||
Purchases, sales and settlements | (78 | ) | ||||||||||||||||||||||
Transfers in and/or out of Level 3 | 96 | |||||||||||||||||||||||
Balance at December 29, 2012 | $ | 1,488 | ||||||||||||||||||||||
Contributions | ||||||||||||||||||||||||
During 2013, we contributed $9,525 to our pension plans. We expect to contribute $6,477 to our pension plan in 2014. | ||||||||||||||||||||||||
Estimated future benefit payments | ||||||||||||||||||||||||
Pension | Supplemental | |||||||||||||||||||||||
Benefits | Retirement Benefits | |||||||||||||||||||||||
2014 | $ | 6,784 | $ | 805 | ||||||||||||||||||||
2015 | 7,461 | 13,232 | ||||||||||||||||||||||
2016 | 8,470 | 743 | ||||||||||||||||||||||
2017 | 8,475 | 728 | ||||||||||||||||||||||
2018 | 8,914 | 714 | ||||||||||||||||||||||
2019-2022 | $ | 58,164 | $ | 10,152 | ||||||||||||||||||||
Stock_Plans_and_Stock_Based_Co
Stock Plans and Stock Based Compensation | 12 Months Ended | |||||||||||||||||||||||||
Dec. 28, 2013 | ||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | |||||||||||||||||||||||||
Stock Plans and Stock Based Compensation | ' | |||||||||||||||||||||||||
PLANS AND STOCK BASED COMPENSATION | ||||||||||||||||||||||||||
We have share-based compensation plans under which employees and non-employee directors may be granted share based awards. During 2013, 2012 and 2011, the primary share-based awards and their general terms and conditions are as follows: | ||||||||||||||||||||||||||
• | Stock options, which entitle the holder to purchase a specified number of shares of common stock at an exercise price equal to the closing market price of our common stock on the date of grant; vest incrementally, typically over 3 to 4 years; and generally expire 7 to 10 years from date of grant. | |||||||||||||||||||||||||
• | Restricted stock grants, which entitle the holder to receive at no cost, a specified number of shares of common stock that vests incrementally, typically over 3 to 4 years. Recipients are entitled to cash dividends and to vote their respective shares upon grant. | |||||||||||||||||||||||||
• | Performance based stock awards, which entitle the holder to receive at no cost, a specified number of shares of common stock within a range of shares from zero to a specified maximum. Payout of this award is contingent upon achievement of targeted earnings per share with certain defined adjustments and our relative stock price market performance. | |||||||||||||||||||||||||
At the Annual Meeting of Shareholders held on May 8, 2007, our shareholders approved the 2007 Incentive Plan (2007 Plan). The 2007 Plan was subsequently amended in 2009, 2011 and 2013, and in each case the amendments were approved by our shareholders at the respective annual meeting of shareholders. The 2007 Plan provides that effective upon approval, no further awards will be granted under preexisting stock option and incentive plans; provided, however, that any shares that have been forfeited or canceled in accordance with the terms of the applicable award under a preexisting plan may be subsequently awarded in accordance with the terms of the preexisting plan. The 2007 Plan allows a maximum of 18.7 million shares to be awarded of which restricted stock grants and performance based stock awards count as 2.3 shares and stock options count as one share. In the past, we had various employee stock and incentive plans under which stock options and other share-based awards were granted. Stock options and other share-based awards that were granted under prior plans and were outstanding on May 8, 2007, continue in accordance with the terms of the respective plans. | ||||||||||||||||||||||||||
At December 28, 2013, approximately 9.0 million shares were authorized for future grants under our share-based compensation plans. We settle employee share-based compensation awards with newly issued shares. The estimated fair value of our stock-based awards, less expected forfeitures, is amortized over the awards' vesting period on a straight-line basis. The following table presents stock-based compensation included in our consolidated statement of income: | ||||||||||||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||||||||||||
Stock-based compensation expense in: | ||||||||||||||||||||||||||
Cost of sales | $ | 5,381 | $ | 5,470 | $ | 5,983 | ||||||||||||||||||||
Selling and administration | 19,161 | 16,385 | 15,723 | |||||||||||||||||||||||
Income from continuing operations, before income taxes | 24,542 | 21,855 | 21,706 | |||||||||||||||||||||||
Provision for income taxes | (8,658 | ) | (7,793 | ) | (7,784 | ) | ||||||||||||||||||||
Net income attributable to common shareholders | $ | 15,884 | $ | 14,062 | $ | 13,922 | ||||||||||||||||||||
We capitalized no stock-based compensation related costs for the years ended 2013, 2012 and 2011. | ||||||||||||||||||||||||||
The fair value of stock-based awards granted during 2013, 2012 and 2011 was estimated on the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions: | ||||||||||||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||||||||||||
Expected life (in years) | 4.2 | 4.5 | 4.2 | |||||||||||||||||||||||
Expected volatility | 33 | % | 35 | % | 33 | % | ||||||||||||||||||||
Risk-free interest rate | 0.8 | % | 0.84 | % | 2.21 | % | ||||||||||||||||||||
Expected dividend yield | 0 | % | 0 | % | 0 | % | ||||||||||||||||||||
Weighted—average grant date fair value | $ | 11.17 | $ | 10.94 | $ | 11.32 | ||||||||||||||||||||
Stock Options | ||||||||||||||||||||||||||
The following table summarizes stock option activities under our plans: | ||||||||||||||||||||||||||
Shares | Weighted Average | Weighted Average | Aggregate | |||||||||||||||||||||||
Exercise Price | Remaining | Intrinsic | ||||||||||||||||||||||||
Contractual Life | Value | |||||||||||||||||||||||||
(in years) | ||||||||||||||||||||||||||
Options outstanding as of December 29, 2012 | 5,860,403 | $ | 39.11 | |||||||||||||||||||||||
Options granted | 600,249 | $ | 40.63 | |||||||||||||||||||||||
Options exercised | (2,557,744 | ) | $ | 36.68 | ||||||||||||||||||||||
Options canceled | (134,175 | ) | $ | 44.73 | ||||||||||||||||||||||
Options outstanding as of December 28, 2013 | 3,768,733 | $ | 40.81 | |||||||||||||||||||||||
Options exercisable as of December 28, 2013 | 2,188,734 | $ | 42.63 | 2.12 | $ | 26,039 | ||||||||||||||||||||
As of December 28, 2013, the unrecognized compensation cost related to 1,564,777 unvested stock options expected to vest was $10,589. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 27.4 months. | ||||||||||||||||||||||||||
The total intrinsic value of options exercised during the fiscal years ending December 28, 2013, December 29, 2012 and December 31, 2011 was $24,737, $5,135 and $7,950, respectively, with intrinsic value defined as the difference between the market price on the date of exercise and the grant date price. The total amount of cash received from the exercise of options during 2013 was $93,789. The actual tax benefit realized for the tax deductions from option exercises totaled $8,983 for the year ended December 28, 2013. | ||||||||||||||||||||||||||
The following table summarizes significant ranges of outstanding and exercisable options as of December 28, 2013: | ||||||||||||||||||||||||||
Options Outstanding | Options Exercisable | |||||||||||||||||||||||||
Range of Exercise Prices | Number | Weighted | Weighted | Aggregate | Options | Weighted | Weighted | Aggregate | ||||||||||||||||||
Outstanding | Average | Average | Intrinsic | Exercisable | Average | Average | Intrinsic | |||||||||||||||||||
Remaining | Exercise | Value | Remaining | Exercise | Value | |||||||||||||||||||||
Contractual | Price | Contractual | Price | |||||||||||||||||||||||
Life | Life | |||||||||||||||||||||||||
(In years) | (In years) | |||||||||||||||||||||||||
$20.01–$30.00 | 370,567 | 2.15 | 25.62 | 10,269 | 368,762 | 2.14 | 25.6 | 10,224 | ||||||||||||||||||
$30.01–$40.00 | 1,674,154 | 4.1 | 36.82 | 27,639 | 680,617 | 3.76 | 36.71 | 11,312 | ||||||||||||||||||
$40.01–$50.00 | 1,225,667 | 3.54 | 43.64 | 11,873 | 641,010 | 1.14 | 46.39 | 4,449 | ||||||||||||||||||
$50.01–$60.00 | 463,105 | 1.11 | 58.17 | 54 | 463,105 | 1.11 | 58.17 | 54 | ||||||||||||||||||
$60.01–$70.00 | 35,240 | 1.28 | 62.78 | — | 35,240 | 1.28 | 62.78 | — | ||||||||||||||||||
Totals | 3,768,733 | 3.33 | $ | 40.8 | $ | 49,835 | 2,188,734 | 2.12 | $ | 42.63 | $ | 26,039 | ||||||||||||||
The aggregate intrinsic value in the preceding table represents the total intrinsic value, based on a closing stock price of $53.33 as of December 28, 2013, that would have been received by the option holders had all option holders exercised their options as of that date. The total number of in-the-money options exercisable as of December 28, 2013 was 1,709,189. | ||||||||||||||||||||||||||
The following table summarizes the non-vested stock option activity in the equity incentive plans for the fiscal year ending December 28, 2013: | ||||||||||||||||||||||||||
Non-vested Stock Options | Weighted Average | |||||||||||||||||||||||||
Exercise Price | ||||||||||||||||||||||||||
December 29, 2012 | 1,989,722 | $ | 34.91 | |||||||||||||||||||||||
Granted | 600,249 | 40.63 | ||||||||||||||||||||||||
Forfeited | (41,901 | ) | 36.98 | |||||||||||||||||||||||
Vested | (968,071 | ) | 32.9 | |||||||||||||||||||||||
December 28, 2013 | 1,579,999 | $ | 38.26 | |||||||||||||||||||||||
Restricted Stock | ||||||||||||||||||||||||||
Stock compensation expense associated with restricted common stock is charged for the market value on the date of grant, less estimated forfeitures, and is amortized over the awards' vesting period on a straight-line basis. | ||||||||||||||||||||||||||
The following table summarizes the restricted stock activity for 2013: | ||||||||||||||||||||||||||
Restricted Stock | Weighted | |||||||||||||||||||||||||
Average | ||||||||||||||||||||||||||
Grant Date | ||||||||||||||||||||||||||
Fair Value | ||||||||||||||||||||||||||
Outstanding as of December 29, 2012 | 934,505 | $ | 35.83 | |||||||||||||||||||||||
Granted | 571,499 | 40.6 | ||||||||||||||||||||||||
Vested | (373,548 | ) | 40.41 | |||||||||||||||||||||||
Canceled | (35,906 | ) | 45.32 | |||||||||||||||||||||||
Outstanding as of December 28, 2013 | 1,096,550 | $ | 36.44 | |||||||||||||||||||||||
As of December 28, 2013, the unrecognized compensation cost related to shares of unvested restricted stock expected to vest was $28,313. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 29.7 months. The total fair value of restricted stock grants that vested during the fiscal years ending December 28, 2013, December 29, 2012 and December 31, 2011 was $15,095, $10,385 and $10,989, respectively. The actual tax benefit realized for the tax deductions from restricted stock grants that vested totaled $5,372 for the year ended December 28, 2013. | ||||||||||||||||||||||||||
Performance Based Stock Award Program | ||||||||||||||||||||||||||
In February 2013, we granted 163,847 performance-based stock awards ("Performance Share Units", or "PSUs") to certain executive officers. The PSUs will be paid out in our common stock based upon the results of two metrics: (1) performance based on our earnings per share with certain defined adjustments and (2) our relative stock price market performance based on a 3-year relative Total Shareholder Return calculation. Accordingly, the actual total number of our shares into which the granted PSUs will convert can range from zero shares to 327,694 shares. The PSUs will be fully vested in December 2015 and will be paid out in the form of our common stock in the first quarter of 2016. | ||||||||||||||||||||||||||
Compensation expense associated these awards, along with performance-based awards made in prior years, was $2,171, $(28) and $188 for the years ended December 28, 2013, December 29, 2012 and December 31, 2011, respectively. |
Commitments_and_Contingencies
Commitments and Contingencies | 12 Months Ended | |||
Dec. 28, 2013 | ||||
Commitments and Contingencies Disclosure [Abstract] | ' | |||
Commitments and Contingencies | ' | |||
Operating Leases | ||||
We have commitments for various operating leases for machinery and equipment, vehicles, office equipment, land and office space. As a matter of ordinary business course, we occasionally guarantee certain lease commitments to landlords. Rent expense for all operating leases was $16,731, $18,246 and $18,778 in 2013, 2012 and 2011, respectively. | ||||
Future minimum payments by year and in the aggregate, under non-cancellable operating leases with initial or remaining terms of one year or more, consist of the following at December 28, 2013: | ||||
2014 | $ | 13,978 | ||
2015 | 10,688 | |||
2016 | 8,061 | |||
2017 | 6,008 | |||
2018 | 4,544 | |||
Thereafter | 11,839 | |||
Insurance | ||||
We maintain various insurance policies that maintain large deductibles up to $750, some with or without stop-loss limits, depending on market availability. Deductibles for certain property insurance policies in the event of a catastrophic event for certain locations based on a percentage of the insured assets, which may exceed $750. | ||||
Litigation | ||||
Various lawsuits, claims and proceedings of a nature considered normal to our business are pending against us. In the opinion of management, the outcome of such proceedings and litigation currently pending will not materially affect our consolidated financial statements. We expense as incurred legal costs expected to be incurred in connection with loss contingencies. | ||||
In May 2013, the Company commenced an investigation into inaccurate billing with respect to certain government contracts. The Company promptly reported these matters to the relevant government contracting officers, the Department of Health and Human Services' Office of the Inspector General, and the Department of Justice, and we are cooperating with these agencies to ensure the proper repayment and resolution of this matter. The Company identified approximately $1,500 in excess amounts billed on these contracts since January 1, 2007 and reserved such amount. Because of the preliminary stage of discussions with the government and complex nature of this matter, the Company believes that it is reasonably possible that additional losses may be incurred. However, the Company cannot at this time estimate the potential range of loss beyond the current reserve of $1,500. | ||||
In July 2012, a Mauritius supplier of large animal models submitted an Application for Arbitration with The Permanent Secretariat, The Permanent Court of Arbitration, The Mauritius Chamber of Commerce and Industry in Port Louis, Mauritius. The supplier asserted that the Company failed to pay certain invoices and the supplier was therefore permitted to terminate the supply agreement. The Company filed a counterclaim asserting that the supplier had failed to meet its contractual obligations under the supply agreement. The arbitration hearing relating to this contract dispute took place in Mauritius from August 13-15, 2013. While no prediction may be made as to the outcome of arbitration, the Company intends to defend against this proceeding vigorously and therefore an estimate of the possible loss or range of loss cannot be made. |
Business_Segment_and_Geographi
Business Segment and Geographic Information | 12 Months Ended | |||||||||||||||||||||||
Dec. 28, 2013 | ||||||||||||||||||||||||
Segment Reporting [Abstract] | ' | |||||||||||||||||||||||
Business Segment and Geographic Information | ' | |||||||||||||||||||||||
SEGMENT AND GEOGRAPHIC INFORMATION | ||||||||||||||||||||||||
We report two business segments, Research Models and Services (RMS) and Preclinical Services (PCS). Our RMS segment includes sales of research models, genetically engineered models and services (GEMS), insourcing solutions (IS), research animal diagnostic services (RADS), discovery research services (DRS), Endotoxin and Microbial Detection (EMD) products and services and avian vaccine products and services. Our PCS segment includes services required to take a drug through the development process, which includes DRS, safety assessment and Biologics Testing Solutions. | ||||||||||||||||||||||||
The following table presents sales and other financial information by business segment. Net sales represent sales originating in entities primarily engaged in either provision of RMS or PCS. Long-lived assets include property, plant and equipment and other long-lived assets | ||||||||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||||||
Research Models and Services | ||||||||||||||||||||||||
Net sales | $ | 707,126 | $ | 695,083 | $ | 705,419 | ||||||||||||||||||
Gross profit | 284,808 | 289,750 | 297,327 | |||||||||||||||||||||
Operating income | 181,321 | 202,362 | 206,319 | |||||||||||||||||||||
Total assets | 752,499 | 698,134 | 687,346 | |||||||||||||||||||||
Long-lived assets | 264,706 | 272,559 | 282,388 | |||||||||||||||||||||
Depreciation and amortization | 54,822 | 37,541 | 37,240 | |||||||||||||||||||||
Capital expenditures | 24,384 | 36,856 | 34,257 | |||||||||||||||||||||
Preclinical Services | ||||||||||||||||||||||||
Net sales | $ | 458,402 | $ | 434,447 | $ | 437,228 | ||||||||||||||||||
Gross profit | 110,093 | 102,331 | 104,915 | |||||||||||||||||||||
Operating income | 44,056 | 34,628 | 24,925 | |||||||||||||||||||||
Total assets | 892,122 | 888,210 | 869,881 | |||||||||||||||||||||
Long-lived assets | 473,440 | 493,120 | 513,302 | |||||||||||||||||||||
Depreciation and amortization | 41,814 | 43,734 | 47,990 | |||||||||||||||||||||
Capital expenditures | 14,770 | 10,678 | 14,886 | |||||||||||||||||||||
A reconciliation of segment operating income to consolidated operating income is as follows: | ||||||||||||||||||||||||
Fiscal Year Ended | ||||||||||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||||||||||
Total segment operating income | $ | 225,377 | $ | 236,990 | $ | 231,244 | ||||||||||||||||||
Unallocated corporate overhead | (73,976 | ) | (71,225 | ) | (56,938 | ) | ||||||||||||||||||
Consolidated operating income | $ | 151,401 | $ | 165,765 | $ | 174,306 | ||||||||||||||||||
Net sales for each significant product or service offering are as follows: | ||||||||||||||||||||||||
Fiscal Year Ended | ||||||||||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||||||||||
Research models | $ | 381,561 | $ | 381,790 | $ | 401,660 | ||||||||||||||||||
Research model services | 212,647 | 219,671 | 220,698 | |||||||||||||||||||||
EMD | 112,918 | 93,622 | 83,061 | |||||||||||||||||||||
Total research models | 707,126 | 695,083 | 705,419 | |||||||||||||||||||||
Total preclinical services | 458,402 | 434,447 | 437,228 | |||||||||||||||||||||
Total sales | $ | 1,165,528 | $ | 1,129,530 | $ | 1,142,647 | ||||||||||||||||||
A summary of unallocated corporate overhead consists of the following: | ||||||||||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||||||||||
Stock-based compensation expense | $ | 13,411 | $ | 11,724 | $ | 11,159 | ||||||||||||||||||
U.S. retirement plans | 4,877 | 4,831 | 3,802 | |||||||||||||||||||||
Audit, tax and related expense | 4,365 | 3,019 | 3,069 | |||||||||||||||||||||
Salary and bonus | 21,983 | 20,050 | 18,421 | |||||||||||||||||||||
Global IT | 11,646 | 12,622 | 11,785 | |||||||||||||||||||||
Employee health, LDP and fringe benefit expense | (3,414 | ) | (4,569 | ) | (2,952 | ) | ||||||||||||||||||
Consulting and professional services | 4,301 | 4,434 | 8,432 | |||||||||||||||||||||
Depreciation expense | 6,334 | 6,260 | 6,312 | |||||||||||||||||||||
Transaction (acquisition/disposition) costs | 1,752 | 3,772 | 1,329 | |||||||||||||||||||||
Contingent consideration write-down | — | — | (5,598 | ) | ||||||||||||||||||||
Other general unallocated corporate expenses | 8,721 | 9,082 | 1,179 | |||||||||||||||||||||
Total unallocated corporate overhead costs | $ | 73,976 | $ | 71,225 | $ | 56,938 | ||||||||||||||||||
Other general unallocated corporate expenses consist of various departmental costs including those associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury and investor relations. | ||||||||||||||||||||||||
The following table presents sales and other financial information by geographic regions. Included in the other non-U.S. category below are operations located in China, Korea, Australia, Singapore and India. Sales to unaffiliated clients represent net sales originating in entities physically located in the identified geographic area. Long-lived assets include property, plant and equipment and other long-lived assets. | ||||||||||||||||||||||||
U.S. | Europe | Canada | Japan | Other Non-U.S. | Consolidated | |||||||||||||||||||
2013 | ||||||||||||||||||||||||
Sales to unaffiliated clients | $ | 551,340 | $ | 353,688 | $ | 162,404 | $ | 59,370 | $ | 38,726 | $ | 1,165,528 | ||||||||||||
Long lived assets | 447,829 | 130,855 | 109,811 | 30,589 | 19,062 | 738,146 | ||||||||||||||||||
2012 | ||||||||||||||||||||||||
Sales to unaffiliated clients | $ | 534,817 | $ | 341,550 | $ | 160,004 | $ | 77,707 | $ | 15,452 | $ | 1,129,530 | ||||||||||||
Long lived assets | 476,927 | 122,351 | 124,302 | 39,642 | 2,457 | 765,679 | ||||||||||||||||||
2011 | ||||||||||||||||||||||||
Sales to unaffiliated clients | $ | 545,185 | $ | 348,455 | $ | 158,997 | $ | 75,992 | $ | 14,018 | $ | 1,142,647 | ||||||||||||
Long lived assets | 497,197 | 123,634 | 127,531 | 45,857 | 1,470 | 795,689 | ||||||||||||||||||
Discontinued_Operations
Discontinued Operations | 12 Months Ended | ||||||||||
Dec. 28, 2013 | |||||||||||
Discontinued Operations and Disposal Groups [Abstract] | ' | ||||||||||
Discontinued Operations | ' | ||||||||||
In 2011, we disposed of our Phase I clinical business for a nominal amount. As part of the disposition we remained the guarantor of the Phase I facility lease. During the second quarter of 2011, we recognized the value of the guarantee net of the buyer's related indemnity as a liability of $2,994, which we are amortizing ratably over the remaining term of the lease. The facility lease runs through January 2021 with remaining lease payments totaling $12,086 as of December 28, 2013. | |||||||||||
In 2012, we concluded that the decreasing financial viability of the lessee increased the probability that we would be required to make future lease payments as guarantor. As a result, we recorded an additional contingent loss of $7,158 for the guarantee, reflecting our estimate of the total future lease payments less sublease income. | |||||||||||
In April 2013, the buyer of our Phase I clinical business filed for Chapter 11 bankruptcy. As a result, we revised our estimate of the total future lease payments, less estimated sublease income, resulting in an additional charge of $1,316. In July 2013, the bankruptcy court approved the rejection of the lease, and effective July 1, 2013, we assumed control of the leased property and assumed obligations under the lease consistent with the guarantee. The total carrying amount of the liability for our obligation under the lease as of December 28, 2013 is $9,787 and is reflected on the consolidated balance sheet as a liability of discontinued operations. | |||||||||||
The consolidated financial statements have been reclassified to segregate, as discontinued operations, the assets and liabilities, operating results and cash flows, of the businesses being discontinued for all periods presented. Operating results from discontinued operations are as follows: | |||||||||||
Fiscal Year Ended | |||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | |||||||||
Net sales | $ | — | $ | — | 2,112 | ||||||
Income (loss) from operations of discontinued businesses, before income taxes | (2,035 | ) | (6,986 | ) | (8,964 | ) | |||||
Provision (benefit) for income taxes | (770 | ) | (2,734 | ) | (3,419 | ) | |||||
Income (loss) from operations of discontinued businesses, net of taxes | $ | (1,265 | ) | $ | (4,252 | ) | (5,545 | ) | |||
Assets and liabilities of discontinued operations at December 2013 and December 2012 consisted of the following: | |||||||||||
December 28, | December 29, | ||||||||||
2013 | 2012 | ||||||||||
Current assets | $ | 750 | $ | 495 | |||||||
Long-term assets | 3,151 | 3,328 | |||||||||
Total assets | $ | 3,901 | $ | 3,823 | |||||||
Current liabilities | $ | 1,931 | $ | 1,802 | |||||||
Long-term liabilities | 8,080 | 8,795 | |||||||||
Total liabilities | $ | 10,011 | $ | 10,597 | |||||||
Current assets include a current deferred tax asset. Non-current assets include a long-term deferred tax asset. Current and long-term liabilities consist of a lease guarantee. |
Description_of_Business_and_Su1
Description of Business and Summary of Significant Accounting Policies (Policies) | 12 Months Ended | |
Dec. 28, 2013 | ||
Description of Business and Summary of Significant Accounting Policies [Abstract] | ' | |
Principles of Consolidation | ' | |
Principles of Consolidation | ||
The consolidated financial statements include all majority-owned subsidiaries. Intercompany accounts, transactions and profits are eliminated. | ||
Reclassifications | ' | |
Reclassifications | ||
Certain reclassifications have been made to prior year statements to conform to the current year presentation. These reclassifications have no impact on period reported net income or cash flow. | ||
Use of Estimates | ' | |
Use of Estimates | ||
The financial statements have been prepared in conformity with generally accepted accounting principles and, as such, include amounts based on informed estimates and judgments of management with consideration given to materiality. Estimates and assumptions are reviewed on an ongoing basis and the effect of revisions to the estimates and assumptions is reflected in the consolidated statements prospectively in the period in which they are revised. | ||
Cash and Cash Equivalents | ' | |
Cash and Cash Equivalents | ||
Cash equivalents include time deposits and highly liquid investments with original maturities at the purchase date of three months or less. | ||
Trade Receivables | ' | |
Trade Receivables | ||
We record trade receivables net of an allowance for doubtful accounts. We establish an allowance for doubtful accounts based on historical collection information, a review of major client accounts receivable balances and current economic conditions in the geographies in which we operate. | ||
Concentration of Credit Risk | ' | |
Concentrations of Credit Risk | ||
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and trade receivables. We place our cash and cash equivalents in various financial institutions with high credit rating and limit the amount of credit exposure to any one financial institution. Our trade receivables are from clients in the pharmaceutical and biotechnology industries. | ||
Marketable Securities | ' | |
Marketable Securities | ||
Investments in marketable securities are reported at fair value and consist of time deposits with original maturities of greater than three months. Realized gains and losses on these securities are included in other income (expense) and are determined using the specific identification method. | ||
Inventories | ' | |
Inventories | ||
Inventories are stated at the lower of cost or market. Cost is determined on the average cost method for our small model business and first-in-first-out (FIFO) for our large model and EMD businesses. For our small model business, cost includes direct materials such as feed and bedding, costs of personnel directly involved in the care of the models, and an allocation of facility overhead. For our large model business, cost is primarily the external cost we pay to acquire the model. Certain of our businesses value inventory based on standard costs, which are periodically compared to and adjusted to actual costs. We determine market value based on either replacement cost or estimated selling price less cost to sell and a normal profit margin. Inventory costs are charged to cost of sales in the period the products are sold to an external party. Inventory reserves are recorded to reduce the carrying value for inventory determined to be damaged, obsolete or otherwise unable to be sold. | ||
Property, Plant and Equipment | ' | |
Property, Plant and Equipment | ||
Property, plant and equipment, including improvements that significantly add to productive capacity or extend useful life, are recorded at cost, while maintenance and repairs are expensed as incurred. We capitalize interest on certain capital projects which amounted to $243 in 2013, $467 in 2012 and $298 in 2011, respectively. We also capitalize internal and external costs incurred during the application development stage of internal use software. Depreciation is calculated for financial reporting purposes using the straight-line method based on the estimated useful lives of the assets as follows: buildings, 20 to 40 years; machinery and equipment, 3 to 20 years; furniture and fixtures, 5 to 10 years; vehicles, 3 to 5 years; computer hardware and software, 3 to 8 years and leasehold improvements, the shorter of estimated useful life or the lease periods. We begin to depreciate capital projects in the first full month the asset is placed in service. | ||
Valuation and Impairment of Goodiwll and Other Intangible Assets | ' | |
Valuation and Impairment of Goodwill and Indefinite-Lived Intangible Assets | ||
Goodwill and other indefinite-lived intangibles are not amortized and are reviewed for impairment at least annually. Valuation of goodwill requires significant judgment. Assumptions and estimates are used in determining the fair value of assets acquired and liabilities assumed in a business acquisition. A significant portion of the purchase price in our acquisitions is assigned to intangible assets and goodwill. Assigning value to intangible assets requires that we use significant judgment in determining (i) the fair value and (ii) whether such intangibles are amortizable or non-amortizable and, if the former, the period and the method by which the intangible assets will be amortized. We utilize commonly accepted valuation techniques, such as the income approach and the cost approach, as appropriate, in establishing the fair value of intangible assets. Typically, key assumptions include: projected revenues and expenses that will be generated or expended from the use of the intangible asset, costs that would be avoided due to our ownership of the asset, client turn-over in the case of client relationships intangible assets, and the discount rate reflecting the risk associated with achieving these key assumptions. | ||
We test goodwill for impairment annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. We have elected not apply the guidance available in ASU 2011-08, Testing Goodwill for Impairment, to assess purely qualitative factors as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. We perform the first step of the two-step goodwill impairment test for each of our reporting units as of the first day of fiscal November. The first step, identifying a potential impairment, compares the fair value of the reporting unit with its carrying amount. If the carrying amount exceeds fair value, the second step would need to be performed; otherwise, no further step is required. The second step, measuring the impairment loss, compares the implied fair value of the reporting unit's goodwill with its carrying amount. Any excess of the goodwill carrying amount over the implied fair value is recognized as an impairment loss, and the carrying value of goodwill is written down to fair value. | ||
Valuation and Impairment of Long-Lived Assets | ' | |
Valuation and Impairment of Long-Lived Assets | ||
We assess the carrying value of property, plant and equipment and definite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not limited to the following: | ||
• | significant financial underperformance relative to expected future operating results; | |
• | significant negative industry, market or economic trends; or | |
• | significant changes in our operating strategy that negatively affect the utilization of our long-lived assets. | |
We assign long-lived assets to groups based on the lowest level at which cash flows are largely independent from other cash flows. Should we determine that a trigger has been met, we determine the recoverability of the long-lived asset group based on an estimate of undiscounted future cash flows resulting from the use of the asset group, including its eventual disposition. Should we determine that the carrying value of held-for-use long-lived assets may not be recoverable, we then measure any resulting impairment based on the fair value of the long-lived asset group. In some cases, fair value is based on the income approach using projected discounted cash flows and using a discount rate commensurate with the risk inherent in our current business model. We may also estimate fair value based on market prices for similar assets, as appropriate. Significant judgments are required to estimate future cash flows, including the selection of appropriate discount rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value for these assets. | ||
Long-lived asset groups are classified as held-for-sale when the following conditions are met: we have committed to a plan to sell the asset group and it is unlikely that significant changes will be made to the plan; the asset group is available for immediate sale in its present condition and it is probable that the sale will be completed within one year; and an active program to locate a buyer has been initiated and the asset group is being marketed at a sale price that is reasonable in relation to its current fair value. Should we determine that the carrying value of held-for-sale long-lived assets exceeds its fair value, we will measure any impairment based on this difference. Subsequent adjustments to the carrying amount of held-for-sale assets based on changes in fair value are recorded but only to the extent of the carrying amount of the asset group when it entered the held-for-sale category. | ||
Accounting for Investment in Life Insurance Contracts | ' | |
Accounting for Investment in Life Insurance Contracts | ||
Our investments in life insurance contracts are recorded at cash surrender value. Accordingly, we recognize the initial investment at the transaction price and remeasure the investment at cash surrender value based on fair value of underlying investments or contractual value each reporting period. Investments in and redemptions of these life insurance contracts are reported as cash flows from investing activities in the consolidated statement of cash flows. | ||
Restructuring and Contract Termination Costs | ' | |
Restructuring and Contract Termination Costs | ||
We recognize obligations associated with restructuring activities and contract termination costs by recording a liability at fair value for the costs associated with an exit or disposal activity as well as costs to terminate a contract or an operating lease. The overall purpose of our restructuring actions is to lower operating costs and improve profitability by reducing excess capacities. Restructuring charges are typically recorded in the period in which the plan is approved by our senior management and, where material, our Board of Directors, and when the liability is incurred. A liability for costs that will continue to be incurred under a contract for its remaining term without economic benefit to us is recognized and measured at its fair value when we cease using the right conveyed by the contract. | ||
Stock-Based Compensation Plans | ' | |
Stock-Based Compensation Plans | ||
We grant stock options and restricted stock to employees and non-employee directors under our stock-based compensation plans. Stock-based compensation cost is measured at grant date, based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period. We estimate the fair value of stock options using the Black-Scholes valuation model. Key inputs and assumptions used to estimate the fair value of stock options include the exercise price of the award, the expected option term, the risk-free interest rate over the option's expected term, the expected annual dividend yield and the expected stock price volatility. The expected stock price volatility assumption is determined using the historical volatility of our common stock over the expected life of the option. The risk-free interest rate is based on the market yield for the five year U.S. Treasury security. The expected life of options is determined using historical option exercise activity. | ||
We record deferred tax assets for stock-based awards based on the amount of stock-based compensation recognized in our consolidated statements of income at the statutory tax rate for the jurisdiction in which we will receive a tax deduction. Differences between the deferred tax assets and the actual tax deduction reported on our income tax returns are recorded in additional paid-in capital. If the tax deduction is less than the deferred tax asset, the calculated shortfall reduces our pool of excess tax benefits. If the pool of excess tax benefits is reduced to zero, then subsequent shortfalls would increase our income tax expense. Our pool of excess tax benefits is computed in accordance with the long-form method. | ||
Revenue Recognition | ' | |
Revenue Recognition | ||
We recognize revenue related to our products, which include research models, endotoxin and microbial detection (EMD) technology and avian vaccine support products, when persuasive evidence of an arrangement exists, generally in the form of client purchase orders, title and risk of loss have transferred, which generally occurs upon delivery of the products, the sales price is fixed or determinable and collectability is reasonably assured. For large models, in some cases clients pay in advance of delivery of the product. These advances are deferred and recognized as revenue upon delivery of the product. | ||
Our service revenue is generally evidenced by client contracts and is recognized upon the completion of the agreed upon performance criteria. These performance criteria are generally in the form of either study protocols or specified activities or procedures that we are engaged to perform. These performance criteria are established by our clients and do not contain acceptance provisions based upon the achievement of certain study or laboratory testing results. Revenue of agreed upon rate per unit contracts is recognized as services are performed, based upon rates specified in the contract. Revenue of fixed fee contracts is recognized as services are performed in relation to total estimated costs to complete procedures specified by clients in the form of study protocols. In general, such amounts become billable in accordance with predetermined payment schedules, but are recognized as revenue as services are performed. Revisions in estimated effort to complete the contract are reflected in the period in which the change became known. | ||
Deferred and unbilled revenue are recognized in our consolidated balance sheets. In some cases, a portion of the contract fee is paid at the time the services are initiated. These advances are recorded as deferred revenue and recognized as revenue as services are performed. Conversely, in some cases, revenue is recorded based on the level of service performed in advance of billing the client and recognized as unbilled receivable. | ||
Guarantees | ' | |
Guarantees | ||
We include standard indemnification provisions in client contracts, which include standard provisions limiting our liability under such contracts, including our indemnification obligations, with certain exceptions. In addition, we are the guarantor of certain facility leases for businesses that have been sold to other parties. When we sell the business, we recognize the retained lease guarantee as a liability on our books at fair value and we amortize the liability ratably as our obligation decreases. In addition, we record contingent losses on the guarantee when it is probable that we will be required to make lease payments in excess of the remaining carrying amount of the guarantee liability and the additional payments are reasonably estimable. | ||
Derivatives and Hedging Activities | ' | |
Derivatives and Hedging Activities | ||
During the three years ended December 28, 2013, we entered into forward foreign currency contracts in order to hedge the foreign exchange impact of cash collections at our Canadian facility related to accounts receivable denominated in U.S. dollars and an intercompany loan between two of our subsidiaries with different functional currencies. | ||
Fair Value | ' | |
Fair Value | ||
We hold cash equivalents, investments and certain other assets and liabilities that are carried at fair value. We generally determine fair value using a market approach based on quoted prices of identical instruments when available. When market quotes of identical instruments are not readily accessible or available, we determine fair value based on quoted market prices of similar instruments. As of December 28, 2013, we do not have any significant non-recurring measurements of non-financial assets and non-financial liabilities other than the adjustment of our PCS Massachusetts facility to fair value in the fourth quarter of 2013 based on an impairment charge recorded in the period. | ||
The valuation hierarchy for disclosure of the inputs used to measure fair value prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from or corroborated by observable market data through correlation. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. | ||
The valuation methodologies used for assets and liabilities measured at fair value are as follows: | ||
• | Time deposits—Valued at their ending balances as reported by the financial institutions that hold our securities, which approximates fair value. | |
• | Investments in life insurance policies—Valued at cash surrender value based on fair value of underlying investments. | |
• | Long-lived assets impaired during the period—Valued at fair value at the date of the impairment based upon the income or market approach. | |
• | Hedge contracts (such as forward currency contracts)—Valued at fair value by management based on our foreign exchange rates and forward points provided by banks. | |
• | Redeemable noncontrolling interest—Valued using a weighted combination of a market-based approach, utilizing information about our company as well as publicly available industry information to determine revenue and earnings multiples, and an income approach based on estimated future cash flows based on projected financial data discounted by a weighted average cost of capital. Significant assumptions include a discount rate of 18.5% and a long-term pretax operating margin of approximately 31.7%. | |
Income Taxes | ' | |
Income Taxes | ||
We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and tax basis of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence both positive and negative, it is more likely than not that we will not realize some or all of the deferred tax assets. | ||
As of December 28, 2013, earnings of non-U.S. subsidiaries considered to be indefinitely reinvested totaled $210,328. No provision for U.S. income taxes has been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, we would be subject to additional U.S. Federal and state income taxes and foreign income and withholding taxes, which could be material. It is our policy to indefinitely reinvest the earnings of our non-U.S. subsidiaries unless they can be repatriated in a manner that generates a tax benefit or an unforeseen cash need arises in the United States and the earnings can be repatriated in a manner that is substantially tax free. Determination of the amount of unrecognized deferred income tax liabilities on these earnings is not practicable due to the complexities with the hypothetical calculation. Additionally, the amount of the liability is dependent upon the circumstances existing if and when the remittance occurs. | ||
We are a worldwide business and operate in various tax jurisdictions where tax laws and tax rates are subject to change given the political and economic climate in these countries. We report and pay income taxes based upon operational results and applicable law. Our current and deferred tax provision is based upon enacted tax rates in effect for the current and future periods. Any significant fluctuation in tax rates or changes in tax laws and regulations or changes to interpretation of existing tax laws and regulations could cause our estimate of taxes to change resulting in either increases or decreases in our effective tax rate. | ||
We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, based on the technical merits of the tax position. The tax benefits recognized in our financial statements from such positions are measured based upon the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. | ||
Foreign Currency Translation | ' | |
Foreign Currency Translation | ||
The functional currency of each of our operating foreign subsidiaries is local currency. The financial statements of these subsidiaries are translated into U.S. dollars as follows: assets and liabilities at year-end exchange rates; income, expenses and cash flows at average exchange rates; and equity at historical exchange rates. The resulting translation adjustment is recorded as a component of accumulated other comprehensive income in the accompanying balance sheet. Exchange gains and losses on foreign currency transactions are recorded as other income or expense. | ||
Other Comprehensive Income | ' | |
Other Comprehensive Income | ||
Our other comprehensive income (OCI) consists of unrealized gains (losses) on available-for-sale marketable securities, foreign currency translation adjustments and unrecognized pension gains and losses and prior service costs and credits. These items are presented, before tax effects, in the consolidated statements of other comprehensive income. We disclose the tax effects on each item included in Note 6. | ||
Pension Plans | ' | |
Pension Plans | ||
Our defined benefit pension plans' assets, liabilities and expenses are calculated using various assumptions. These assumptions are reviewed annually, or whenever otherwise required, based on reviews of current plan information and consultations with independent investment advisers and actuaries. The selection of assumptions requires a high degree of judgment and may materially change from period to period. | ||
We recognize the funded status of our benefit plans on our consolidated balance sheets. We recognize gains, losses and prior service costs or credits that arise during the period that are not recognized as components of net periodic benefit cost as a component of accumulated other comprehensive income, net of tax. We measure plan assets and obligations as of the date of our fiscal year-end balance sheet. Additional information about certain effects on net periodic benefit cost for the next fiscal year that arise from delayed recognition of the gains or losses, prior service costs or credits, and transition asset or obligation are disclosed in the Note 8 of these financial statements. | ||
Our defined benefit pension plans' assets, liabilities and expenses are calculated by accredited independent actuaries using various assumptions, which are approved by management. The actuarial computations require the use of assumptions to estimate the total benefits ultimately payable to employees and to allocate this cost to the service periods. The key assumptions used to calculate pension costs are determined and reviewed annually by management after consulting with outside investment advisers and actuaries. The key assumptions include the discount rate, the expected return on plan assets and expected future rate of salary increases. In addition, our actuaries utilize other assumptions such as withdrawal and mortality rate. The assumed discount rate, which is intended to be the rate at which benefits could effectively be settled, is adjusted based on the change in the long-term bond yield as of the measurement date. | ||
We estimate the future return on invested pension assets annually based on information prepared by our outside actuaries and investment advisers, our targeted asset allocations and our own assumptions about that market. Our forward-looking pension assumptions, such as the rate of return on invested assets, are approved annually by our pension committee in the first quarter of the year and are updated as needed as of year-end. The rate of return on invested plan assets is primarily based on capital market models prepared by our advisers. These models use asset-class specific expected returns, standard deviations and correlation coefficients to derive a distribution of expected average portfolio return over the future duration of the pension plan's liabilities. | ||
Differences between actual investment returns and estimated investment returns are recorded in accumulated other comprehensive income (loss) (AOCI) and are amortized over the remaining duration of the pension plans. As of December 28, 2013, the Company's AOCI includes $39,788 of net actuarial losses, which will be amortized over approximately 22 years. | ||
Earnings (Loss) Per Share | ' | |
Earnings Per Share | ||
Basic earnings per share are calculated by dividing net income attributable to common shareholders by the weighted average number of common shares outstanding. Diluted earnings per common share are calculated by adjusting the weighted average number of common shares outstanding to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued, to the extent these additional shares are not anti-dilutive. | ||
Discontinued Operations | ' | |
Discontinued Operations | ||
The results of discontinued operations, less applicable income taxes (benefit) and assets and liabilities, are reported as a separate component in the accompanying statement of income and consolidated balance sheets for the current and prior periods. The statement of cash flows also reflects separate disclosure of cash flows pertaining to discontinued operations consistently for all periods presented. |
Description_of_Business_and_Su2
Description of Business and Summary of Significant Accounting Policies (Tables) | 12 Months Ended | |||||||||||||||
Dec. 28, 2013 | ||||||||||||||||
Description of Business and Summary of Significant Accounting Policies [Abstract] | ' | |||||||||||||||
Composition of Trade Receivables | ' | |||||||||||||||
The composition of net trade receivables is as follows: | ||||||||||||||||
28-Dec-13 | 29-Dec-12 | |||||||||||||||
Client receivables | $ | 190,423 | $ | 174,774 | ||||||||||||
Unbilled revenue | 35,184 | 32,494 | ||||||||||||||
Total | 225,607 | 207,268 | ||||||||||||||
Less allowance for doubtful accounts | (4,977 | ) | (4,267 | ) | ||||||||||||
Net trade receivables | $ | 220,630 | $ | 203,001 | ||||||||||||
Schedule of Marketable Securities by Major Security Type | ' | |||||||||||||||
The amortized cost, gross unrealized gains, gross unrealized losses and fair value for marketable securities by major security type were as follows: | ||||||||||||||||
December 28, 2013 | ||||||||||||||||
Amortized | Gross | Gross | Fair | |||||||||||||
Cost | Unrealized | Unrealized | Value | |||||||||||||
Gains | Losses | |||||||||||||||
Time deposits | $ | 11,158 | $ | — | $ | — | $ | 11,158 | ||||||||
$ | 11,158 | $ | — | $ | — | $ | 11,158 | |||||||||
December 29, 2012 | ||||||||||||||||
Amortized | Gross | Gross | Fair | |||||||||||||
Cost | Unrealized | Unrealized | Value | |||||||||||||
Gains | Losses | |||||||||||||||
Time deposits | $ | 6,781 | $ | — | $ | — | $ | 6,781 | ||||||||
$ | 6,781 | $ | — | $ | — | $ | 6,781 | |||||||||
Schedule of Maturities of Debt Securities | ' | |||||||||||||||
Maturities of debt securities were as follows: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Amortized | Fair | Amortized | Fair | |||||||||||||
Cost | Value | Cost | Value | |||||||||||||
Due less than one year | $ | 11,158 | $ | 11,158 | $ | 6,781 | $ | 6,781 | ||||||||
Due after one year through five years | — | — | — | — | ||||||||||||
Due after ten years | — | — | — | — | ||||||||||||
$ | 11,158 | $ | 11,158 | $ | 6,781 | $ | 6,781 | |||||||||
Composition of Inventories | ' | |||||||||||||||
The composition of inventories is as follows: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Raw materials and supplies | $ | 15,028 | $ | 14,525 | ||||||||||||
Work in process | 11,715 | 11,082 | ||||||||||||||
Finished products | 62,653 | 62,863 | ||||||||||||||
Inventories | $ | 89,396 | $ | 88,470 | ||||||||||||
Composition of Other Current Assets | ' | |||||||||||||||
Other current assets consist of assets we expect to settle within the next twelve months. | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Prepaid assets | $ | 20,058 | $ | 20,404 | ||||||||||||
Deferred tax asset | 29,139 | 30,018 | ||||||||||||||
Marketable securities | 11,158 | 6,781 | ||||||||||||||
Prepaid income tax | 25,247 | 26,169 | ||||||||||||||
Restricted cash | 245 | 229 | ||||||||||||||
Other current assets | $ | 85,847 | $ | 83,601 | ||||||||||||
Composition of Net Property, Plant and Equipment | ' | |||||||||||||||
The composition of net property, plant and equipment is as follows: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Land | $ | 40,157 | $ | 40,812 | ||||||||||||
Buildings | 694,074 | 697,547 | ||||||||||||||
Machinery and equipment | 367,244 | 356,960 | ||||||||||||||
Leasehold improvements | 37,959 | 34,916 | ||||||||||||||
Furniture and fixtures | 24,013 | 25,681 | ||||||||||||||
Vehicles | 3,859 | 3,736 | ||||||||||||||
Computer hardware and software | 112,328 | 107,171 | ||||||||||||||
Construction in progress | 42,075 | 46,186 | ||||||||||||||
Total | 1,321,709 | 1,313,009 | ||||||||||||||
Less accumulated depreciation | (645,527 | ) | (595,989 | ) | ||||||||||||
Net property, plant and equipment | $ | 676,182 | $ | 717,020 | ||||||||||||
Composition of Other Assets | ' | |||||||||||||||
The composition of other assets is as follows: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Deferred financing costs | $ | 7,126 | $ | 6,424 | ||||||||||||
Cash surrender value of life insurance policies | 26,507 | 25,240 | ||||||||||||||
Investments in limited partnerships | 17,911 | 8,492 | ||||||||||||||
Other assets | 10,420 | 8,503 | ||||||||||||||
Other assets | $ | 61,964 | $ | 48,659 | ||||||||||||
Schedule of Restructuring and Contract Termination Costs | ' | |||||||||||||||
The following table rolls forward our severance and retention cost liability: | ||||||||||||||||
Severance and Retention Costs | ||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||
Balance, beginning of period | $ | 3,636 | $ | 3,374 | $ | 10,658 | ||||||||||
Expense | 3,223 | 2,576 | 5,462 | |||||||||||||
Payments/utilization | (4,077 | ) | (2,314 | ) | (12,746 | ) | ||||||||||
Balance, end of period | $ | 2,782 | $ | 3,636 | $ | 3,374 | ||||||||||
The following table presents severance and retention costs by classification on the income statement: | ||||||||||||||||
Fiscal Year Ended | ||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||
Severance charges included in cost of sales | $ | 1,477 | $ | 1,203 | $ | 1,012 | ||||||||||
Severance charges included in selling, general and administrative expense | 1,746 | 1,373 | 4,450 | |||||||||||||
Total expense | $ | 3,223 | $ | 2,576 | $ | 5,462 | ||||||||||
The following table presents severance and retention cost by segment: | ||||||||||||||||
Fiscal Year Ended | ||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||
Research models and services | $ | 2,055 | $ | 1,068 | $ | 1,196 | ||||||||||
Preclinical services | 1,164 | 1,508 | 4,372 | |||||||||||||
Corporate | 4 | — | (106 | ) | ||||||||||||
Total expense | $ | 3,223 | $ | 2,576 | $ | 5,462 | ||||||||||
Composition of Other Current Liabilities | ' | |||||||||||||||
The composition of other current liabilities is as follows: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Accrued income taxes | $ | 18,773 | $ | 18,216 | ||||||||||||
Current deferred tax liability | 1,960 | 410 | ||||||||||||||
Accrued interest and other | 1,813 | 2,636 | ||||||||||||||
Other current liabilities | $ | 22,546 | $ | 21,262 | ||||||||||||
Composition of Other Long-Term Liabilities | ' | |||||||||||||||
The composition of other long-term liabilities is as follows: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||
Deferred tax liability | $ | 14,988 | $ | 13,147 | ||||||||||||
Long-term pension liability | 16,219 | 44,316 | ||||||||||||||
Accrued Executive Supplemental Life Insurance Retirement Plan and Deferred Compensation Plan | 28,708 | 26,663 | ||||||||||||||
Other long-term liabilities | 22,582 | 20,840 | ||||||||||||||
Other long-term liabilities | $ | 82,497 | $ | 104,966 | ||||||||||||
Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis | ' | |||||||||||||||
Assets and liabilities measured at fair value on a recurring basis are summarized below: | ||||||||||||||||
Fair Value Measurements at December 28, 2013 | ||||||||||||||||
Quoted Prices in Active Markets for Identical Assets Level 1 | Significant Other Observable Inputs Level 2 | Significant Unobservable Inputs Level 3 | Assets and Liabilities at Fair Value | |||||||||||||
Time deposits | $ | — | $ | 11,158 | $ | — | $ | 11,158 | ||||||||
Life insurance policies | — | 19,534 | — | 19,534 | ||||||||||||
Total assets measured at fair value | — | 30,692 | — | 30,692 | ||||||||||||
Redeemable noncontrolling interest | — | — | 20,581 | 20,581 | ||||||||||||
Total liabilities measured at fair value | $ | — | $ | — | $ | 20,581 | $ | 20,581 | ||||||||
Fair Value Measurements at December 29, 2012 | ||||||||||||||||
Quoted Prices in Active Markets for Identical Assets Level 1 | Significant Other Observable Inputs Level 2 | Significant Unobservable Inputs Level 3 | Assets and Liabilities at Fair Value | |||||||||||||
Time deposits | $ | — | $ | 6,781 | $ | — | $ | 6,781 | ||||||||
Life insurance policies | — | 19,555 | — | 19,555 | ||||||||||||
Hedge contract | — | 16 | — | 16 | ||||||||||||
Total assets measured at fair value | $ | — | $ | 26,352 | $ | — | $ | 26,352 | ||||||||
Reconcilliation of Assets and Liabilities Measured at Fair Value on Recurring Basis (Level 3) | ' | |||||||||||||||
The following table presents a reconciliation for all liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the years ended December 28, 2013 and December 29, 2012. | ||||||||||||||||
Fair Value Measurements | ||||||||||||||||
Using Significant | ||||||||||||||||
Unobservable Inputs | ||||||||||||||||
(Level 3) | ||||||||||||||||
Year ended | ||||||||||||||||
Redeemable Noncontrolling Interest (Liability) | December 28, 2013 | |||||||||||||||
Beginning balance | $ | — | ||||||||||||||
Transfers in and/or out of Level 3 | — | |||||||||||||||
Purchases, issuances and settlements | 8,963 | |||||||||||||||
Total gains or losses (realized/unrealized): | ||||||||||||||||
Included in other income (expense) | 687 | |||||||||||||||
Included in other comprehensive income (CTA) | 367 | |||||||||||||||
Included in additional paid-in capital | 10,564 | |||||||||||||||
Ending balance | $ | 20,581 | ||||||||||||||
Business_Acquisitions_Tables
Business Acquisitions (Tables) | 12 Months Ended | ||||
Dec. 28, 2013 | |||||
Business Acquisition [Line Items] | ' | ||||
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] | ' | ||||
The breakout of definite-lived intangible assets acquired is as follows: | |||||
Weighted average amortization life (in years) | |||||
Client relationships | $ | 1,870 | 8 | ||
Other intangible assets | 15 | 2 | |||
Total definite-lived intangible assets | $ | 1,885 | 8 | ||
The definite-lived intangibles are largely attributed to the expected cash flows related to client relationships existing at the acquisition closing date. The goodwill resulting from the transaction is primarily attributed to the potential growth of the business in Southeast Asia. The goodwill is not deductible for tax purposes. The accounting for this acquisition is not yet complete due to our ongoing assessment of the fair value of assets acquired and associated income tax accounting thereon. We expect to complete the acquisition accounting in 2014. | |||||
Vital River [Member] | ' | ||||
Business Acquisition [Line Items] | ' | ||||
Schedule of Business Acquisitions, by Acquisition [Table Text Block] | ' | ||||
Vital River | |||||
In October 2012, we entered into an agreement to acquire a 75% ownership interest of Vital River, a commercial provider of research models and related services in China, for $26,890 in cash, subject to certain closing adjustments. The acquisition closed in January 2013. Vital River's financial results are included in our RMS reportable business segment. | |||||
The purchase price allocation, net of $2,671 of cash acquired, is as follows: | |||||
Current assets (excluding cash) | $ | 3,092 | |||
Property, plant and equipment | 10,468 | ||||
Other long-term assets | 2,242 | ||||
Definite-lived intangible assets | 16,954 | ||||
Goodwill | 16,989 | ||||
Current liabilities | (11,303 | ) | |||
Long term liabilities | (5,260 | ) | |||
Redeemable noncontrolling interest | (8,963 | ) | |||
Total purchase price allocation | $ | 24,219 | |||
EMD [Member] | ' | ||||
Business Acquisition [Line Items] | ' | ||||
Schedule of Business Acquisitions, by Acquisition [Table Text Block] | ' | ||||
EMD Singapore | |||||
On October 4, 2013, we acquired an EMD products and service provider located in Singapore for approximately $4,934 in cash, subject to certain closing adjustments. The financial results of the acquired entity will be included in our RMS reportable business segment. | |||||
The preliminary purchase price allocation is as follows: | |||||
Current assets | $ | 300 | |||
Property, plant and equipment | 154 | ||||
Definite-lived intangible assets | 1,885 | ||||
Goodwill | 2,659 | ||||
Current liabilities | (64 | ) | |||
Total purchase price allocation | $ | 4,934 | |||
Accugenix [Member] | ' | ||||
Business Acquisition [Line Items] | ' | ||||
Schedule of Business Acquisitions, by Acquisition [Table Text Block] | ' | ||||
The purchase price allocation, net of $1,547 of cash acquired is as follows: | |||||
Current assets (excluding cash) | $ | 2,162 | |||
Property, plant and equipment | 549 | ||||
Current liabilities | (911 | ) | |||
Long term liabilities | (3,700 | ) | |||
Definite-lived intangible assets | 8,400 | ||||
Goodwill | 10,361 | ||||
Total purchase price allocation | $ | 16,861 | |||
The definite-lived intangible assets acquired are as follows: | |||||
Weighted average amortization life (in years) | |||||
Client relationships | $ | 1,500 | 13 | ||
Proprietary database | 4,100 | 11 | |||
Standard operating procedures | 2,500 | 4 | |||
Trademarks | 300 | 12 | |||
Total definite-lived intangible assets | $ | 8,400 | 9.3 | ||
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] | ' | ||||
The breakout of definite-lived intangible assets acquired is as follows: | |||||
Weighted average amortization life (in years) | |||||
Client relationships | $ | 14,741 | 11.7 | ||
Reacquired rights | 2,053 | 1.3 | |||
Other intangible assets | 160 | 2.8 | |||
Total definite-lived intangible assets | $ | 16,954 | 10.4 | ||
The definite-lived intangibles are largely attributed to the expected cash flows related to client relationships existing at the acquisition closing date. In addition, the Company reacquired a right previously granted to the entity related to a royalty agreement for the distribution of products in China. The value assigned to the reacquired right is being amortized over the remaining life of the existing royalty agreement. The goodwill resulting from the transaction is primarily attributed to the potential growth of the business in China. The goodwill is not deductible for tax purposes. | |||||
Concurrent with the acquisition, the Company entered into a joint venture agreement with the noncontrolling interest holders that provide the Company with the right to purchase the remaining 25% of the entity for cash at its then appraised value beginning in January 2016. Additionally, the noncontrolling interest holders were granted the right to require the Company to purchase the remaining 25% of the entity at its then appraised value beginning in January 2016 for cash. These rights are accelerated in certain events. As the noncontrolling interest holders can require the Company to purchase for cash the remaining 25% interest, we classify the carrying amount of the noncontrolling interest above the equity section and below liabilities on the consolidated balance sheet. The acquisition-date fair value of the noncontrolling interest was determined based on the fair value of the consideration exchanged for the 75% of Vital River. Subsequent to the acquisition, each quarter we adjust the carrying amount of the noncontrolling interest to fair value using a weighted combination of a market-based approach and an income approach. The income approach uses estimated future cash flows based on projected financial data discounted by a rate which considers the Company's weighted average cost of capital and the specific risks of achieving these cash flows. Adjustments to fair value are recorded through additional paid-in capital. |
Goodwill_and_Other_Intangible_1
Goodwill and Other Intangible Assets (Tables) | 12 Months Ended | |||||||||||||||||||||||||||
Dec. 28, 2013 | ||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | |||||||||||||||||||||||||||
Schedule of finite-lived intangible assets by major class | ' | |||||||||||||||||||||||||||
The following table displays the gross carrying amount and accumulated amortization of definite-lived intangible assets by major class: | ||||||||||||||||||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||||||||||||||||||
Gross carrying amount | Accumulated amortization | Gross carrying amount | Accumulated amortization | |||||||||||||||||||||||||
Backlog | $ | 2,916 | $ | (2,507 | ) | $ | 2,875 | $ | (2,375 | ) | ||||||||||||||||||
Client relationships | 311,507 | (238,002 | ) | 305,178 | (231,902 | ) | ||||||||||||||||||||||
Client contracts | 15,633 | (15,633 | ) | 15,366 | (15,366 | ) | ||||||||||||||||||||||
Trademarks and trade names | 5,399 | (4,997 | ) | 5,326 | (4,821 | ) | ||||||||||||||||||||||
Standard operating procedures | 2,754 | (1,498 | ) | 2,751 | (863 | ) | ||||||||||||||||||||||
Other identifiable intangible assets | 10,432 | (4,905 | ) | 10,033 | (4,718 | ) | ||||||||||||||||||||||
Total definite-lived intangible assets | $ | 348,641 | $ | (267,542 | ) | $ | 341,529 | $ | (260,045 | ) | ||||||||||||||||||
Schedule of changes in the gross carrying amount and accumulated amortization of goodwill | ' | |||||||||||||||||||||||||||
The following is a schedule of goodwill by reportable segment and changes in the gross carrying amount and accumulated amortization of goodwill: | ||||||||||||||||||||||||||||
Adjustments to Goodwill | Adjustments to Goodwill | |||||||||||||||||||||||||||
Balance at December 31, 2011 | Acquisitions | Foreign Exchange/ Impairment | Balance at December 29, 2012 | Acquisitions | Foreign Exchange/ Impairment | Balance at December 28, 2013 | ||||||||||||||||||||||
Research Models and Services | ||||||||||||||||||||||||||||
Gross carrying amount | $ | 52,681 | $ | 10,361 | $ | 97 | $ | 63,139 | $ | 19,647 | $ | 765 | $ | 83,551 | ||||||||||||||
Preclinical Services | ||||||||||||||||||||||||||||
Gross carrying amount | 1,149,880 | — | 590 | 1,150,470 | — | 1,680 | 1,152,150 | |||||||||||||||||||||
Accumulated impairment loss | (1,005,000 | ) | — | — | (1,005,000 | ) | — | — | (1,005,000 | ) | ||||||||||||||||||
Total | ||||||||||||||||||||||||||||
Gross carrying amount | $ | 1,202,561 | $ | 10,361 | $ | 687 | $ | 1,213,609 | $ | 19,647 | $ | 2,445 | $ | 1,235,701 | ||||||||||||||
Accumulated impairment loss | (1,005,000 | ) | — | (1,005,000 | ) | (1,005,000 | ) | |||||||||||||||||||||
Goodwill, net | $ | 197,561 | $ | 208,609 | $ | 230,701 | ||||||||||||||||||||||
Schedule of estimated amortization expense | ' | |||||||||||||||||||||||||||
Estimated amortization expense for intangible assets for each of the next five fiscal years is expected to be as follows: | ||||||||||||||||||||||||||||
2014 | $ | 16,396 | ||||||||||||||||||||||||||
2015 | 13,281 | |||||||||||||||||||||||||||
2016 | 11,351 | |||||||||||||||||||||||||||
2017 | 10,057 | |||||||||||||||||||||||||||
2018 | 9,181 | |||||||||||||||||||||||||||
LongTerm_Debt_and_Capital_Leas1
Long-Term Debt and Capital Lease Obligations (Tables) | 3 Months Ended | 12 Months Ended | |||||||
Mar. 30, 2013 | Dec. 28, 2013 | ||||||||
Debt Disclosure [Abstract] | ' | ' | |||||||
Components of long-term debt | ' | ' | |||||||
Long-term debt consists of the following: | |||||||||
December 28, 2013 | December 29, 2012 | ||||||||
2.25% Senior convertible debentures: | |||||||||
Principal | $ | — | $ | 349,995 | |||||
Unamortized debt discount | — | (6,726 | ) | ||||||
Net carrying amount of senior convertible debentures | — | 343,269 | |||||||
Term loan facility | 409,500 | 290,947 | |||||||
Revolving credit facility | 253,308 | 32,000 | |||||||
Other long-term debt | 241 | 232 | |||||||
Total debt | 663,049 | 666,448 | |||||||
Less: current portion of long-term debt | (21,241 | ) | (139,373 | ) | |||||
Long-term debt | $ | 641,808 | $ | 527,075 | |||||
Schedule of principal maturities of existing debt excluding unamortized debt discount | ' | ' | |||||||
Minimum future principal payments of long-term debt at December 28, 2013 are as follows: | |||||||||
Fiscal Year | |||||||||
2014 | $ | 21,241 | |||||||
2015 | 42,000 | ||||||||
2016 | 47,250 | ||||||||
2017 | 68,250 | ||||||||
2018 | 484,308 | ||||||||
Total | $ | 663,049 | |||||||
Debt covenants | 'These covenants include (1) maintenance of a ratio of consolidated earnings before interest, taxes, depreciation and amortization less capital expenditures to consolidated cash interest expense, for any period of four consecutive fiscal quarters, of no less than 3.5 to 1.0 as well as (2) maintenance of a ratio of consolidated indebtedness to consolidated earnings before interest, taxes, depreciation and amortization for any period of four consecutive fiscal quarters, of no more than 3.75 to 1.0. In addition, we must maintain a ratio of consolidated indebtedness to quarterly consolidated earnings before interest, taxes, depreciation and amortization of 3.5 to 1.0 for our first and second fiscal quarters of 2014 and of 3.25 to 1.0 for each fiscal quarter thereafter. | ' |
Equity_Tables
Equity (Tables) | 12 Months Ended | |||||||||||||||
Dec. 28, 2013 | ||||||||||||||||
Stockholders' Equity Note [Abstract] | ' | |||||||||||||||
Reconciliation of the numerator and denominator in the computations of the basic and diluted earnings per share | ' | |||||||||||||||
The following table illustrates the reconciliation of the numerator and denominator in the computations of the basic and diluted earnings per share: | ||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||
Numerator: | ||||||||||||||||
Income from continuing operations for purposes of calculating earnings per share | $ | 104,093 | $ | 101,547 | $ | 115,111 | ||||||||||
Income (loss) from discontinued businesses | $ | (1,265 | ) | $ | (4,252 | ) | $ | (5,545 | ) | |||||||
Denominator: | ||||||||||||||||
Weighted-average shares outstanding—Basic | 47,740,167 | 47,912,135 | 50,823,063 | |||||||||||||
Effect of dilutive securities: | ||||||||||||||||
Stock options and contingently issued restricted stock | 749,155 | 494,185 | 495,179 | |||||||||||||
Weighted-average shares outstanding—Diluted | 48,489,322 | 48,406,320 | 51,318,242 | |||||||||||||
Basic earnings per share from continuing operations attributable to common shareholders | $ | 2.18 | $ | 2.12 | $ | 2.26 | ||||||||||
Basic earnings (loss) per share from discontinued operations attributable to common shareholders | $ | (0.03 | ) | $ | (0.09 | ) | $ | (0.11 | ) | |||||||
Diluted earnings per share from continuing operations attributable to common shareholders | $ | 2.15 | $ | 2.1 | $ | 2.24 | ||||||||||
Diluted earnings (loss) per share from discontinued operations attributable to common shareholders | $ | (0.03 | ) | $ | (0.09 | ) | $ | (0.11 | ) | |||||||
Schedule of number of shares repurchased and the total cost of repurchase | ' | |||||||||||||||
Share repurchases through ASR programs and open market purchases during 2013, 2012 and 2011 were as follows: | ||||||||||||||||
Fiscal Year Ended | ||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||
Number of shares of common stock repurchased | 3,468,031 | 1,705,521 | 8,428,494 | |||||||||||||
Total cost of repurchase | $ | 165,717 | $ | 61,442 | $ | 299,479 | ||||||||||
Schedule of composition of accumulated other comprehensive income | ' | |||||||||||||||
The composition of accumulated other comprehensive income is as follows: | ||||||||||||||||
Foreign | Pension Gains/(Losses) | Net Unrealized | Accumulated | |||||||||||||
Currency | and Prior Service | Gain on | Other | |||||||||||||
Translation | (Cost)/Credit Not Yet | Marketable | Comprehensive | |||||||||||||
Adjustment | Recognized as | Securities | Income | |||||||||||||
Components of Net | ||||||||||||||||
Periodic Benefit Costs | ||||||||||||||||
Balance at December 31, 2011 | $ | 38,685 | $ | (33,171 | ) | $ | (921 | ) | $ | 4,593 | ||||||
Period change | 5,274 | (5,862 | ) | 921 | 333 | |||||||||||
Tax | 98 | 1,579 | — | 1,677 | ||||||||||||
Balance at December 29, 2012 | $ | 44,057 | $ | (37,454 | ) | $ | — | $ | 6,603 | |||||||
Period change | (15,751 | ) | 22,310 | — | 6,559 | |||||||||||
Tax | 197 | (8,002 | ) | — | (7,805 | ) | ||||||||||
Balance at December 28, 2013 | $ | 28,503 | $ | (23,146 | ) | $ | — | $ | 5,357 | |||||||
Income_Taxes_Tables
Income Taxes (Tables) | 12 Months Ended | |||||||||||
Dec. 28, 2013 | ||||||||||||
Income Tax Disclosure [Abstract] | ' | |||||||||||
Deferred Tax Liability Not Recognized, Determination of Deferred Tax Liability is Not Practicable, Undistributed Earnings of Foreign Subsidiaries | 'In accordance with our policy, the remaining undistributed earnings of our non-U.S. subsidiaries remain indefinitely reinvested as of the end of 2013 as they are required to fund needs outside the U.S. and cannot be repatriated in a manner that is substantially tax free. During the third quarter of 2011, we restructured our international operations in a tax-free manner to allow us more flexibility in accessing our offshore cash to fund needs outside the U.S. As of DecemberB 28, 2013, the earnings of our non-U.S. subsidiaries considered to be indefinitely reinvested totaled $210,328. No provision for U.S. income taxes has been provided thereon. Upon distribution of these earnings in the form of dividends or otherwise, we would be subject to additional U.S. Federal and state income taxes and foreign income and withholding taxes, which could be material. Determination of the amount of unrecognized deferred income tax liabilities on these earnings is not practicable because of the complexities with the hypothetical calculation. Additionally, the amount of liability is dependent on circumstances existing if and when remittance occurs. | |||||||||||
Analysis of the components of income (loss) from continuing operations before income taxes and the related provision for income taxes | ' | |||||||||||
An analysis of the components of income from continuing operations before income taxes and the related provision for income taxes is presented below: | ||||||||||||
Fiscal Year Ended | ||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||
Income from continuing operations before income taxes | ||||||||||||
U.S. | $ | 39,900 | $ | 35,504 | $ | 47,158 | ||||||
Non-U.S. | 98,427 | 94,242 | 85,504 | |||||||||
$ | 138,327 | $ | 129,746 | $ | 132,662 | |||||||
Income tax provision | ||||||||||||
Current: | ||||||||||||
Federal | $ | 10,832 | $ | (1,447 | ) | $ | 3,957 | |||||
Foreign | 18,370 | 26,411 | 20,727 | |||||||||
State and local | 4,240 | 1,353 | 1,124 | |||||||||
Total current | $ | 33,442 | $ | 26,317 | $ | 25,808 | ||||||
Deferred: | ||||||||||||
Federal | $ | 5,468 | $ | 13,132 | $ | 2,961 | ||||||
Foreign | (6,431 | ) | (12,683 | ) | (11,649 | ) | ||||||
State and local | 432 | 862 | 20 | |||||||||
Total deferred | $ | (531 | ) | $ | 1,311 | $ | (8,668 | ) | ||||
$ | 32,911 | $ | 27,628 | $ | 17,140 | |||||||
Schedule of net deferred taxes | ' | |||||||||||
Net deferred taxes, detailed below, recognize the impact of temporary differences between the amounts of assets and liabilities recorded for financial statement purposes and such amounts measured in accordance with tax laws. | ||||||||||||
December 28, 2013 | December 29, 2012 | |||||||||||
Compensation | $ | 38,836 | $ | 52,668 | ||||||||
Accruals and reserves | 2,356 | 2,160 | ||||||||||
Inventory reserves and valuations | 1,696 | 3,663 | ||||||||||
Financing related | 1,594 | 2,545 | ||||||||||
Goodwill and other intangibles | (21,826 | ) | (14,982 | ) | ||||||||
Net operating loss and credit carryforwards | 58,891 | 55,067 | ||||||||||
Depreciation related | (22,389 | ) | (37,212 | ) | ||||||||
Non-indefinitely reinvested earnings | — | (146 | ) | |||||||||
Investments in limited partnerships | (2,720 | ) | (405 | ) | ||||||||
Other | (1,640 | ) | (839 | ) | ||||||||
54,798 | 62,519 | |||||||||||
Valuation allowance | (7,071 | ) | (7,504 | ) | ||||||||
Total deferred taxes | $ | 47,727 | $ | 55,015 | ||||||||
Reconciliation of statutory U.S. Federal income tax rate to effective tax rates | ' | |||||||||||
Reconciliations of the statutory U.S. Federal income tax rate to effective tax rates are as follows: | ||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||
U.S. statutory income tax rate | 35 | % | 35 | % | 35 | % | ||||||
Foreign tax rate differences | (8.0 | )% | (8.0 | )% | (6.7 | )% | ||||||
State income taxes, net of Federal tax benefit | 1.6 | % | 1.5 | % | 2.1 | % | ||||||
Unbenefitted losses and changes in valuation allowance | 0.4 | % | 0.8 | % | 0.6 | % | ||||||
Impact of repatriation of non-U.S. earnings | — | % | — | % | 0.5 | % | ||||||
Research tax credits and enhanced deductions | (6.6 | )% | (8.2 | )% | (7.6 | )% | ||||||
Enacted tax rate changes | (0.4 | )% | (0.2 | )% | (1.0 | )% | ||||||
Impact of tax uncertainties | 1 | % | (1.2 | )% | (1.0 | )% | ||||||
Releasing valuation allowance on loss from disposition of the Phase 1 Clinical business | — | % | — | % | (8.4 | )% | ||||||
Non taxable gain from settlement of life insurance policy | — | % | — | % | (2.2 | )% | ||||||
Other | 0.8 | % | 1.6 | % | 1.6 | % | ||||||
23.8 | % | 21.3 | % | 12.9 | % | |||||||
Reconciliation of unrecognized income tax benefits | ' | |||||||||||
A reconciliation of our beginning and ending unrecognized income tax benefits is as follows: | ||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||
Beginning balance | $ | 30,996 | $ | 27,976 | $ | 33,427 | ||||||
Additions: | ||||||||||||
Tax positions for current year | 2,009 | 1,907 | 1,714 | |||||||||
Tax positions for prior years | 1,709 | 4,196 | — | |||||||||
Reductions: | ||||||||||||
Tax positions for current year | — | — | — | |||||||||
Tax positions for prior years | (732 | ) | (28 | ) | (239 | ) | ||||||
Settlements | (15,246 | ) | (3,055 | ) | (6,926 | ) | ||||||
Expiration of statute of limitations | (261 | ) | — | — | ||||||||
Ending balance | $ | 18,475 | $ | 30,996 | $ | 27,976 | ||||||
Employee_Benefit_Plans_Tables
Employee Benefit Plans (Tables) | 12 Months Ended | |||||||||||||||||||||||
Dec. 28, 2013 | ||||||||||||||||||||||||
Employee benefits | ' | |||||||||||||||||||||||
Schedule of obligations and funded status | ' | |||||||||||||||||||||||
The following tables summarize t | ||||||||||||||||||||||||
Schedule of amounts recognized as part of accumulated other comprehensive income | ' | |||||||||||||||||||||||
Amounts recognized in statement of financial position as part of accumulated other comprehensive income ("AOCI"): | ||||||||||||||||||||||||
Pension Benefits | Supplemental | |||||||||||||||||||||||
Retirement Benefits | ||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||||||
Net actuarial loss | $ | 35,481 | $ | 58,594 | $ | 4,307 | $ | 3,056 | ||||||||||||||||
Net prior service cost/(credit) | (6,338 | ) | (6,815 | ) | 660 | 1,320 | ||||||||||||||||||
Total | $ | 29,143 | $ | 51,779 | $ | 4,967 | $ | 4,376 | ||||||||||||||||
Schedule of defined benefit plans with accumulated benefit obligation in excess of plan assets | ' | |||||||||||||||||||||||
Information for defined benefit plans with accumulated benefit obligation in excess of plan assets: | ||||||||||||||||||||||||
Pension Benefits | Supplemental | |||||||||||||||||||||||
Retirement Benefits | ||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||||||
Projected benefit obligation | $ | 82,254 | $ | 277,187 | $ | 29,498 | $ | 27,372 | ||||||||||||||||
Accumulated benefit obligation | 81,117 | 271,204 | 27,938 | 26,495 | ||||||||||||||||||||
Fair value of plan assets | 68,430 | 233,182 | — | — | ||||||||||||||||||||
Schedule of defined benefit plans with projected benefit obligations in excess of plan assets | ' | |||||||||||||||||||||||
Information for defined benefit plans with projected benefit obligation in excess of plan assets: | ||||||||||||||||||||||||
Pension Benefits | Supplemental | |||||||||||||||||||||||
Retirement Benefits | ||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||||||
Projected benefit obligation | $ | 99,671 | $ | 283,063 | $ | 29,498 | $ | 27,372 | ||||||||||||||||
Accumulated benefit obligation | 93,307 | 275,162 | 27,938 | 26,495 | ||||||||||||||||||||
Fair value of plan assets | 83,379 | 238,672 | — | — | ||||||||||||||||||||
Schedule of amounts in AOCI expected to be recognized as components of net periodic benefit cost over the next fiscal year | ' | |||||||||||||||||||||||
Amounts in AOCI expected to be recognized as components of net periodic benefit cost over the next fiscal year: | ||||||||||||||||||||||||
Pension | Supplemental | |||||||||||||||||||||||
Benefits | Retirement | |||||||||||||||||||||||
Benefits | ||||||||||||||||||||||||
Amortization of net actuarial loss | $ | 923 | $ | 250 | ||||||||||||||||||||
Amortization of net prior service cost/(credit) | (637 | ) | 660 | |||||||||||||||||||||
Components of net periodic benefit cost for defined benefit plans | ' | |||||||||||||||||||||||
Components of net periodic benefit cost: | ||||||||||||||||||||||||
Pension Benefits | Supplemental | |||||||||||||||||||||||
Retirement Benefits | ||||||||||||||||||||||||
2013 | 2012 | 2011 | 2013 | 2012 | 2011 | |||||||||||||||||||
Service cost | $ | 3,368 | $ | 3,729 | $ | 3,056 | $ | 643 | $ | 640 | $ | 636 | ||||||||||||
Interest cost | 11,273 | 11,289 | 12,107 | 708 | 892 | 1,201 | ||||||||||||||||||
Expected return on plan assets | (14,672 | ) | (13,799 | ) | (13,677 | ) | — | — | — | |||||||||||||||
Amortization of prior service cost (credit) | 2,711 | 2,461 | (617 | ) | 249 | 260 | 498 | |||||||||||||||||
Amortization of net loss (gain) | (603 | ) | (609 | ) | 978 | 660 | 660 | 210 | ||||||||||||||||
Net periodic benefit cost | 2,077 | 3,071 | 1,847 | 2,260 | 2,452 | 2,545 | ||||||||||||||||||
Settlement | — | — | 23 | — | — | (487 | ) | |||||||||||||||||
Net pension cost | $ | 2,077 | $ | 3,071 | $ | 1,870 | $ | 2,260 | $ | 2,452 | $ | 2,058 | ||||||||||||
Schedule of rollforward of accumulated other comprehensive income | ' | |||||||||||||||||||||||
Rollforward of accumulated other comprehensive income: | ||||||||||||||||||||||||
Pension Benefits | Supplemental | |||||||||||||||||||||||
Retirement Benefits | ||||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||||||
Beginning balance | $ | 51,779 | $ | 45,267 | $ | 4,376 | $ | 5,171 | ||||||||||||||||
Amortization of prior service (cost) or credit | 603 | (2,461 | ) | (660 | ) | (660 | ) | |||||||||||||||||
Amortization of net (loss) gain | (2,710 | ) | 609 | (250 | ) | (260 | ) | |||||||||||||||||
Asset (gain) loss recorded during period | (20,424 | ) | 8,030 | 1,501 | 125 | |||||||||||||||||||
Currency impact | (105 | ) | 334 | — | — | |||||||||||||||||||
Ending balance | $ | 29,143 | $ | 51,779 | $ | 4,967 | $ | 4,376 | ||||||||||||||||
Schedule of weighted-average assumptions | ' | |||||||||||||||||||||||
Weighted-average assumptions used to determine benefit obligations: | ||||||||||||||||||||||||
Pension | Supplemental | |||||||||||||||||||||||
Benefits | Retirement Benefits | |||||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | |||||||||||||||||||||
Discount rate | 4.54 | % | 4.13 | % | 3.47 | % | 2.63 | % | ||||||||||||||||
Rate of compensation increase | 3.39 | % | 3.04 | % | 3 | % | 2.5 | % | ||||||||||||||||
Weighted-average assumptions used to determine net periodic benefit cost: | ||||||||||||||||||||||||
Pension Benefits | Supplemental | |||||||||||||||||||||||
Retirement Benefits | ||||||||||||||||||||||||
2013 | 2012 | 2011 | 2013 | 2012 | 2011 | |||||||||||||||||||
Discount rate | 4.13 | % | 4.47 | % | 5.2 | % | 2.63 | % | 3.42 | % | 4.34 | % | ||||||||||||
Expected long-term return on plan assets | 6.27 | % | 6.55 | % | 6.79 | % | — | — | — | |||||||||||||||
Rate of compensation increase | 3.04 | % | 3.12 | % | 3.48 | % | 2.5 | % | 2.5 | % | 2.5 | % | ||||||||||||
Schedule of plan asset allocations | ' | |||||||||||||||||||||||
Our pension plans' weighted-average asset allocations are as follows: | ||||||||||||||||||||||||
Target | Pension | |||||||||||||||||||||||
Allocation | Benefits | |||||||||||||||||||||||
2014 | 2013 | 2012 | ||||||||||||||||||||||
Equity securities | 60.1 | % | 54.8 | % | 60 | % | ||||||||||||||||||
Fixed income | 31.2 | % | 32.6 | % | 36 | % | ||||||||||||||||||
Other | 8.7 | % | 12.6 | % | 4 | % | ||||||||||||||||||
Total | 100 | % | 100 | % | 100 | % | ||||||||||||||||||
Defined Benefit Plan, Additional Disclosures about Plan Assets | 'The fair value of our pension assets by asset category are as follows.B Fair Value Measurements at December 28, 2013Asset ClassQuoted Prices inActive Marketsfor IdenticalAssetsLevelB 1B Significant OtherObservableInputsLevelB 2B SignificantUnobservableInputsLevelB 3B Assets atFair ValueCash$1,004B $bB $bB $1,004Common stock(a)97,857B 5,059B bB 102,916Debt securities(a)62,717B 3,487B bB 66,204Mutual funds(b)65,152B 35,610B bB 100,762Life insurance policies(c)bB 48B bB 48Other299B bB 1,426(d)1,725Total$227,029B $44,204B $1,426B $272,659(a)This category comprises investments valued at the closing price reported on the active market on which the individual securities are traded.(b)This category comprises mutual funds valued at the net asset value of shares held at year end.(c)This category comprises life insurance policies valued at cash surrender value at year end.(d)This comprises annuity policies held with various insurance companies valued at face value. | |||||||||||||||||||||||
Schedule of Level 3 plan asset rollforward | ' | |||||||||||||||||||||||
Fair Value Measurements | ||||||||||||||||||||||||
Using Significant | ||||||||||||||||||||||||
Unobservable | ||||||||||||||||||||||||
Inputs | ||||||||||||||||||||||||
(Level 3) | ||||||||||||||||||||||||
Balance at December 29, 2012 | $ | 1,488 | ||||||||||||||||||||||
Actual return on plan assets: | ||||||||||||||||||||||||
Relating to assets still held at December 28, 2013 | — | |||||||||||||||||||||||
Relating to assets sold during the period | (62 | ) | ||||||||||||||||||||||
Purchases, sales and settlements | — | |||||||||||||||||||||||
Transfers in and/or out of Level 3 | — | |||||||||||||||||||||||
Balance at December 28, 2013 | $ | 1,426 | ||||||||||||||||||||||
Schedule of estimated future benefit payments | ' | |||||||||||||||||||||||
Estimated future benefit payments | ||||||||||||||||||||||||
Pension | Supplemental | |||||||||||||||||||||||
Benefits | Retirement Benefits | |||||||||||||||||||||||
2014 | $ | 6,784 | $ | 805 | ||||||||||||||||||||
2015 | 7,461 | 13,232 | ||||||||||||||||||||||
2016 | 8,470 | 743 | ||||||||||||||||||||||
2017 | 8,475 | 728 | ||||||||||||||||||||||
2018 | 8,914 | 714 | ||||||||||||||||||||||
2019-2022 | $ | 58,164 | $ | 10,152 | ||||||||||||||||||||
Stock_Plans_and_Stock_Based_Co1
Stock Plans and Stock Based Compensation (Tables) | 12 Months Ended | |||||||||||||||||||||||||
Dec. 28, 2013 | ||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | |||||||||||||||||||||||||
Schedule of stock-based compensation expense | ' | |||||||||||||||||||||||||
The following table presents stock-based compensation included in our consolidated statement of income: | ||||||||||||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||||||||||||
Stock-based compensation expense in: | ||||||||||||||||||||||||||
Cost of sales | $ | 5,381 | $ | 5,470 | $ | 5,983 | ||||||||||||||||||||
Selling and administration | 19,161 | 16,385 | 15,723 | |||||||||||||||||||||||
Income from continuing operations, before income taxes | 24,542 | 21,855 | 21,706 | |||||||||||||||||||||||
Provision for income taxes | (8,658 | ) | (7,793 | ) | (7,784 | ) | ||||||||||||||||||||
Net income attributable to common shareholders | $ | 15,884 | $ | 14,062 | $ | 13,922 | ||||||||||||||||||||
Schedule of weighted-average assumptions | ' | |||||||||||||||||||||||||
The fair value of stock-based awards granted during 2013, 2012 and 2011 was estimated on the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions: | ||||||||||||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||||||||||||
Expected life (in years) | 4.2 | 4.5 | 4.2 | |||||||||||||||||||||||
Expected volatility | 33 | % | 35 | % | 33 | % | ||||||||||||||||||||
Risk-free interest rate | 0.8 | % | 0.84 | % | 2.21 | % | ||||||||||||||||||||
Expected dividend yield | 0 | % | 0 | % | 0 | % | ||||||||||||||||||||
Weighted—average grant date fair value | $ | 11.17 | $ | 10.94 | $ | 11.32 | ||||||||||||||||||||
Summary of stock option activity in equity incentive plans | ' | |||||||||||||||||||||||||
The following table summarizes stock option activities under our plans: | ||||||||||||||||||||||||||
Shares | Weighted Average | Weighted Average | Aggregate | |||||||||||||||||||||||
Exercise Price | Remaining | Intrinsic | ||||||||||||||||||||||||
Contractual Life | Value | |||||||||||||||||||||||||
(in years) | ||||||||||||||||||||||||||
Options outstanding as of December 29, 2012 | 5,860,403 | $ | 39.11 | |||||||||||||||||||||||
Options granted | 600,249 | $ | 40.63 | |||||||||||||||||||||||
Options exercised | (2,557,744 | ) | $ | 36.68 | ||||||||||||||||||||||
Options canceled | (134,175 | ) | $ | 44.73 | ||||||||||||||||||||||
Options outstanding as of December 28, 2013 | 3,768,733 | $ | 40.81 | |||||||||||||||||||||||
Options exercisable as of December 28, 2013 | 2,188,734 | $ | 42.63 | 2.12 | $ | 26,039 | ||||||||||||||||||||
Summary of significant ranges of outstanding and exercisable options | ' | |||||||||||||||||||||||||
The following table summarizes significant ranges of outstanding and exercisable options as of December 28, 2013: | ||||||||||||||||||||||||||
Options Outstanding | Options Exercisable | |||||||||||||||||||||||||
Range of Exercise Prices | Number | Weighted | Weighted | Aggregate | Options | Weighted | Weighted | Aggregate | ||||||||||||||||||
Outstanding | Average | Average | Intrinsic | Exercisable | Average | Average | Intrinsic | |||||||||||||||||||
Remaining | Exercise | Value | Remaining | Exercise | Value | |||||||||||||||||||||
Contractual | Price | Contractual | Price | |||||||||||||||||||||||
Life | Life | |||||||||||||||||||||||||
(In years) | (In years) | |||||||||||||||||||||||||
$20.01–$30.00 | 370,567 | 2.15 | 25.62 | 10,269 | 368,762 | 2.14 | 25.6 | 10,224 | ||||||||||||||||||
$30.01–$40.00 | 1,674,154 | 4.1 | 36.82 | 27,639 | 680,617 | 3.76 | 36.71 | 11,312 | ||||||||||||||||||
$40.01–$50.00 | 1,225,667 | 3.54 | 43.64 | 11,873 | 641,010 | 1.14 | 46.39 | 4,449 | ||||||||||||||||||
$50.01–$60.00 | 463,105 | 1.11 | 58.17 | 54 | 463,105 | 1.11 | 58.17 | 54 | ||||||||||||||||||
$60.01–$70.00 | 35,240 | 1.28 | 62.78 | — | 35,240 | 1.28 | 62.78 | — | ||||||||||||||||||
Totals | 3,768,733 | 3.33 | $ | 40.8 | $ | 49,835 | 2,188,734 | 2.12 | $ | 42.63 | $ | 26,039 | ||||||||||||||
Summary of non-vested stock option activity | ' | |||||||||||||||||||||||||
The following table summarizes the non-vested stock option activity in the equity incentive plans for the fiscal year ending December 28, 2013: | ||||||||||||||||||||||||||
Non-vested Stock Options | Weighted Average | |||||||||||||||||||||||||
Exercise Price | ||||||||||||||||||||||||||
December 29, 2012 | 1,989,722 | $ | 34.91 | |||||||||||||||||||||||
Granted | 600,249 | 40.63 | ||||||||||||||||||||||||
Forfeited | (41,901 | ) | 36.98 | |||||||||||||||||||||||
Vested | (968,071 | ) | 32.9 | |||||||||||||||||||||||
December 28, 2013 | 1,579,999 | $ | 38.26 | |||||||||||||||||||||||
Summary of restricted stock activity | ' | |||||||||||||||||||||||||
The following table summarizes the restricted stock activity for 2013: | ||||||||||||||||||||||||||
Restricted Stock | Weighted | |||||||||||||||||||||||||
Average | ||||||||||||||||||||||||||
Grant Date | ||||||||||||||||||||||||||
Fair Value | ||||||||||||||||||||||||||
Outstanding as of December 29, 2012 | 934,505 | $ | 35.83 | |||||||||||||||||||||||
Granted | 571,499 | 40.6 | ||||||||||||||||||||||||
Vested | (373,548 | ) | 40.41 | |||||||||||||||||||||||
Canceled | (35,906 | ) | 45.32 | |||||||||||||||||||||||
Outstanding as of December 28, 2013 | 1,096,550 | $ | 36.44 | |||||||||||||||||||||||
Commitments_and_Contingencies_
Commitments and Contingencies (Tables) | 12 Months Ended | |||
Dec. 28, 2013 | ||||
Commitments and Contingencies Disclosure [Abstract] | ' | |||
Schedule of future minimum payments under noncancellable operating leases | ' | |||
Future minimum payments by year and in the aggregate, under non-cancellable operating leases with initial or remaining terms of one year or more, consist of the following at December 28, 2013: | ||||
2014 | $ | 13,978 | ||
2015 | 10,688 | |||
2016 | 8,061 | |||
2017 | 6,008 | |||
2018 | 4,544 | |||
Thereafter | 11,839 | |||
Business_Segment_and_Geographi1
Business Segment and Geographic Information (Tables) | 12 Months Ended | |||||||||||||||||||||||
Dec. 28, 2013 | ||||||||||||||||||||||||
Segment Reporting [Abstract] | ' | |||||||||||||||||||||||
Schedule of sales and other financial information by business segment | ' | |||||||||||||||||||||||
The following table presents sales and other financial information by business segment. Net sales represent sales originating in entities primarily engaged in either provision of RMS or PCS. Long-lived assets include property, plant and equipment and other long-lived assets | ||||||||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||||||
Research Models and Services | ||||||||||||||||||||||||
Net sales | $ | 707,126 | $ | 695,083 | $ | 705,419 | ||||||||||||||||||
Gross profit | 284,808 | 289,750 | 297,327 | |||||||||||||||||||||
Operating income | 181,321 | 202,362 | 206,319 | |||||||||||||||||||||
Total assets | 752,499 | 698,134 | 687,346 | |||||||||||||||||||||
Long-lived assets | 264,706 | 272,559 | 282,388 | |||||||||||||||||||||
Depreciation and amortization | 54,822 | 37,541 | 37,240 | |||||||||||||||||||||
Capital expenditures | 24,384 | 36,856 | 34,257 | |||||||||||||||||||||
Preclinical Services | ||||||||||||||||||||||||
Net sales | $ | 458,402 | $ | 434,447 | $ | 437,228 | ||||||||||||||||||
Gross profit | 110,093 | 102,331 | 104,915 | |||||||||||||||||||||
Operating income | 44,056 | 34,628 | 24,925 | |||||||||||||||||||||
Total assets | 892,122 | 888,210 | 869,881 | |||||||||||||||||||||
Long-lived assets | 473,440 | 493,120 | 513,302 | |||||||||||||||||||||
Depreciation and amortization | 41,814 | 43,734 | 47,990 | |||||||||||||||||||||
Capital expenditures | 14,770 | 10,678 | 14,886 | |||||||||||||||||||||
Reconciliation of segment operating income to consolidated operating income | ' | |||||||||||||||||||||||
A reconciliation of segment operating income to consolidated operating income is as follows: | ||||||||||||||||||||||||
Fiscal Year Ended | ||||||||||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||||||||||
Total segment operating income | $ | 225,377 | $ | 236,990 | $ | 231,244 | ||||||||||||||||||
Unallocated corporate overhead | (73,976 | ) | (71,225 | ) | (56,938 | ) | ||||||||||||||||||
Consolidated operating income | $ | 151,401 | $ | 165,765 | $ | 174,306 | ||||||||||||||||||
Schedule of net sales for each significant service area | ' | |||||||||||||||||||||||
Net sales for each significant product or service offering are as follows: | ||||||||||||||||||||||||
Fiscal Year Ended | ||||||||||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||||||||||
Research models | $ | 381,561 | $ | 381,790 | $ | 401,660 | ||||||||||||||||||
Research model services | 212,647 | 219,671 | 220,698 | |||||||||||||||||||||
EMD | 112,918 | 93,622 | 83,061 | |||||||||||||||||||||
Total research models | 707,126 | 695,083 | 705,419 | |||||||||||||||||||||
Total preclinical services | 458,402 | 434,447 | 437,228 | |||||||||||||||||||||
Total sales | $ | 1,165,528 | $ | 1,129,530 | $ | 1,142,647 | ||||||||||||||||||
Summary of unallocated corporate overhead | ' | |||||||||||||||||||||||
A summary of unallocated corporate overhead consists of the following: | ||||||||||||||||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | ||||||||||||||||||||||
Stock-based compensation expense | $ | 13,411 | $ | 11,724 | $ | 11,159 | ||||||||||||||||||
U.S. retirement plans | 4,877 | 4,831 | 3,802 | |||||||||||||||||||||
Audit, tax and related expense | 4,365 | 3,019 | 3,069 | |||||||||||||||||||||
Salary and bonus | 21,983 | 20,050 | 18,421 | |||||||||||||||||||||
Global IT | 11,646 | 12,622 | 11,785 | |||||||||||||||||||||
Employee health, LDP and fringe benefit expense | (3,414 | ) | (4,569 | ) | (2,952 | ) | ||||||||||||||||||
Consulting and professional services | 4,301 | 4,434 | 8,432 | |||||||||||||||||||||
Depreciation expense | 6,334 | 6,260 | 6,312 | |||||||||||||||||||||
Transaction (acquisition/disposition) costs | 1,752 | 3,772 | 1,329 | |||||||||||||||||||||
Contingent consideration write-down | — | — | (5,598 | ) | ||||||||||||||||||||
Other general unallocated corporate expenses | 8,721 | 9,082 | 1,179 | |||||||||||||||||||||
Total unallocated corporate overhead costs | $ | 73,976 | $ | 71,225 | $ | 56,938 | ||||||||||||||||||
Schedule of sales and other financial information by geographic regions | ' | |||||||||||||||||||||||
The following table presents sales and other financial information by geographic regions. Included in the other non-U.S. category below are operations located in China, Korea, Australia, Singapore and India. Sales to unaffiliated clients represent net sales originating in entities physically located in the identified geographic area. Long-lived assets include property, plant and equipment and other long-lived assets. | ||||||||||||||||||||||||
U.S. | Europe | Canada | Japan | Other Non-U.S. | Consolidated | |||||||||||||||||||
2013 | ||||||||||||||||||||||||
Sales to unaffiliated clients | $ | 551,340 | $ | 353,688 | $ | 162,404 | $ | 59,370 | $ | 38,726 | $ | 1,165,528 | ||||||||||||
Long lived assets | 447,829 | 130,855 | 109,811 | 30,589 | 19,062 | 738,146 | ||||||||||||||||||
2012 | ||||||||||||||||||||||||
Sales to unaffiliated clients | $ | 534,817 | $ | 341,550 | $ | 160,004 | $ | 77,707 | $ | 15,452 | $ | 1,129,530 | ||||||||||||
Long lived assets | 476,927 | 122,351 | 124,302 | 39,642 | 2,457 | 765,679 | ||||||||||||||||||
2011 | ||||||||||||||||||||||||
Sales to unaffiliated clients | $ | 545,185 | $ | 348,455 | $ | 158,997 | $ | 75,992 | $ | 14,018 | $ | 1,142,647 | ||||||||||||
Long lived assets | 497,197 | 123,634 | 127,531 | 45,857 | 1,470 | 795,689 | ||||||||||||||||||
Discontinued_Operations_Tables
Discontinued Operations (Tables) | 12 Months Ended | ||||||||||
Dec. 28, 2013 | |||||||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ||||||||||
Schedule of operating results from discontinued operations | ' | ||||||||||
Operating results from discontinued operations are as follows: | |||||||||||
Fiscal Year Ended | |||||||||||
December 28, 2013 | December 29, 2012 | December 31, 2011 | |||||||||
Net sales | $ | — | $ | — | 2,112 | ||||||
Income (loss) from operations of discontinued businesses, before income taxes | (2,035 | ) | (6,986 | ) | (8,964 | ) | |||||
Provision (benefit) for income taxes | (770 | ) | (2,734 | ) | (3,419 | ) | |||||
Income (loss) from operations of discontinued businesses, net of taxes | $ | (1,265 | ) | $ | (4,252 | ) | (5,545 | ) | |||
Schedule of assets and liabilities of discontinued operations | ' | ||||||||||
Assets and liabilities of discontinued operations at December 2013 and December 2012 consisted of the following: | |||||||||||
December 28, | December 29, | ||||||||||
2013 | 2012 | ||||||||||
Current assets | $ | 750 | $ | 495 | |||||||
Long-term assets | 3,151 | 3,328 | |||||||||
Total assets | $ | 3,901 | $ | 3,823 | |||||||
Current liabilities | $ | 1,931 | $ | 1,802 | |||||||
Long-term liabilities | 8,080 | 8,795 | |||||||||
Total liabilities | $ | 10,011 | $ | 10,597 | |||||||
Description_of_Business_and_Su3
Description of Business and Summary of Significant Accounting Policies (Cash and Cash Equivalents, Trade Receivables and Concentrations of Credit Risk) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Concentration Risk [Line Items] | ' | ' | ' |
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value | $367 | ' | ' |
Time deposits and highly liquid investments, maturity period | '3 | ' | ' |
Composition of trade receivables | ' | ' | ' |
Client receivables | 190,423 | 174,774 | ' |
Unbilled revenue | 35,184 | 32,494 | ' |
Total | 225,607 | 207,268 | ' |
Less allowance for doubtful accounts | -4,977 | -4,267 | ' |
Net trade receivables | 220,630 | 203,001 | ' |
Provisions to the allowance for doubtful accounts | 1,332 | 947 | 426 |
Write offs to the allowance for doubtful accounts | $373 | $697 | $1,228 |
Client Concentration Risk [Member] | ' | ' | ' |
Composition of trade receivables | ' | ' | ' |
Number of clients representing large percentage of sales or trade receivables | 0 | ' | ' |
Max percentage, clients representing large percentage of sales or trade receivables | 5.00% | ' | ' |
Description_of_Business_and_Su4
Description of Business and Summary of Significant Accounting Policies (Marketable Securities) (Details) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 |
Marketable securities | ' | ' |
Fair value, marketable securities | $11,158 | $6,781 |
Gross Unrealized Gains | ' | 0 |
Gross Unrealized Losses | ' | 0 |
Maturities of debt securities, Amortized Cost | ' | ' |
Due less than one year, Amortized Cost | 11,158 | 6,781 |
Due after one year through five years, Amortized Cost | 0 | 0 |
Due after ten years, Amortized Cost | 0 | 0 |
Amortized Cost | 11,158 | 6,781 |
Maturities of debt securities, Fair Value | ' | ' |
Due less than one year, Fair Value | 11,158 | 6,781 |
Due after one year through five years, Fair Value | 0 | 0 |
Due after ten years, Fair Value | 0 | 0 |
Time Deposits [Member] | ' | ' |
Marketable securities | ' | ' |
Fair value, marketable securities | ' | 6,781 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Maturities of debt securities, Fair Value | ' | ' |
Due less than one year, Fair Value | 11,158 | ' |
Marketable Securities, Current | ' | $6,781 |
Description_of_Business_and_Su5
Description of Business and Summary of Significant Accounting Policies (Inventories) (Details) (USD $) | Dec. 28, 2013 | Dec. 29, 2012 |
In Thousands, unless otherwise specified | ||
Inventory [Line Items] | ' | ' |
Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis | $11,158 | $6,781 |
Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value | 11,158 | 6,781 |
Available-for-sale Securities, Amortized Cost Basis | 11,158 | 6,781 |
Composition of inventories | ' | ' |
Raw materials and supplies | 15,028 | 14,525 |
Work in process | 11,715 | 11,082 |
Finished products | 62,653 | 62,863 |
Inventories | 89,396 | 88,470 |
Bank Time Deposits [Member] | ' | ' |
Inventory [Line Items] | ' | ' |
Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value | 11,158 | ' |
Available-for-sale Securities, Amortized Cost Basis | ' | $6,781 |
Description_of_Business_and_Su6
Description of Business and Summary of Significant Accounting Policies (Long-lived Assets) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Property, Plant and Equipment | ' | ' | ' |
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures | $17,911 | $8,492 | ' |
Capitalized interest | 243 | 467 | 298 |
Net property, plant and equipment | ' | ' | ' |
Gross property, plant and equipment | 1,321,709 | 1,313,009 | ' |
Less accumulated depreciation | -645,527 | -595,989 | ' |
Net property, plant and equipment | 676,182 | 717,020 | ' |
Depreciation expense | 78,830 | 63,207 | 63,435 |
Land [Member] | ' | ' | ' |
Net property, plant and equipment | ' | ' | ' |
Gross property, plant and equipment | 40,157 | 40,812 | ' |
Buildings [Member] | ' | ' | ' |
Net property, plant and equipment | ' | ' | ' |
Gross property, plant and equipment | 694,074 | 697,547 | ' |
Machinery and Equipment [Member] | ' | ' | ' |
Net property, plant and equipment | ' | ' | ' |
Gross property, plant and equipment | 367,244 | 356,960 | ' |
Leashold Improvements [Member] | ' | ' | ' |
Net property, plant and equipment | ' | ' | ' |
Gross property, plant and equipment | 37,959 | 34,916 | ' |
Furniture and Fixtures [Member] | ' | ' | ' |
Net property, plant and equipment | ' | ' | ' |
Gross property, plant and equipment | 24,013 | 25,681 | ' |
Vehicles [Member] | ' | ' | ' |
Net property, plant and equipment | ' | ' | ' |
Gross property, plant and equipment | 3,859 | 3,736 | ' |
Computer Hardware and Software [Member] | ' | ' | ' |
Net property, plant and equipment | ' | ' | ' |
Gross property, plant and equipment | 112,328 | 107,171 | ' |
Construction in Progress [Member] | ' | ' | ' |
Net property, plant and equipment | ' | ' | ' |
Gross property, plant and equipment | $42,075 | $46,186 | ' |
Minimum [Member] | Buildings [Member] | ' | ' | ' |
Property, Plant and Equipment | ' | ' | ' |
Minimum estimated useful life (in years) | '20 years | ' | ' |
Minimum [Member] | Machinery and Equipment [Member] | ' | ' | ' |
Property, Plant and Equipment | ' | ' | ' |
Minimum estimated useful life (in years) | '3 years | ' | ' |
Minimum [Member] | Furniture and Fixtures [Member] | ' | ' | ' |
Property, Plant and Equipment | ' | ' | ' |
Minimum estimated useful life (in years) | '5 years | ' | ' |
Minimum [Member] | Vehicles [Member] | ' | ' | ' |
Property, Plant and Equipment | ' | ' | ' |
Minimum estimated useful life (in years) | '3 years | ' | ' |
Minimum [Member] | Computer Hardware and Software [Member] | ' | ' | ' |
Property, Plant and Equipment | ' | ' | ' |
Minimum estimated useful life (in years) | '3 years | ' | ' |
Maximum [Member] | Buildings [Member] | ' | ' | ' |
Property, Plant and Equipment | ' | ' | ' |
Minimum estimated useful life (in years) | '40 years | ' | ' |
Maximum [Member] | Machinery and Equipment [Member] | ' | ' | ' |
Property, Plant and Equipment | ' | ' | ' |
Minimum estimated useful life (in years) | '20 years | ' | ' |
Maximum [Member] | Furniture and Fixtures [Member] | ' | ' | ' |
Property, Plant and Equipment | ' | ' | ' |
Minimum estimated useful life (in years) | '10 years | ' | ' |
Maximum [Member] | Vehicles [Member] | ' | ' | ' |
Property, Plant and Equipment | ' | ' | ' |
Minimum estimated useful life (in years) | '5 years | ' | ' |
Maximum [Member] | Computer Hardware and Software [Member] | ' | ' | ' |
Property, Plant and Equipment | ' | ' | ' |
Minimum estimated useful life (in years) | '8 years | ' | ' |
Description_of_Business_and_Su7
Description of Business and Summary of Significant Accounting Policies (Equity Method Affiliates) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Schedule of Equity Method Investments [Line Items] | ' | ' | ' |
Equity Method Affiliates | $17,911 | $8,492 | ' |
Biotechnology and Medical Device Companies [Member] | ' | ' | ' |
Schedule of Equity Method Investments [Line Items] | ' | ' | ' |
Limited partnership, committed contribution | 12,375 | ' | ' |
Income (loss) from limited partnership | 5,864 | -618 | 869 |
Limited partnership, total committed contributions | $35,000 | ' | ' |
Minimum [Member] | ' | ' | ' |
Schedule of Equity Method Investments [Line Items] | ' | ' | ' |
Limited partnership, ownership (in percent) | 3.80% | ' | ' |
Maximum [Member] | ' | ' | ' |
Schedule of Equity Method Investments [Line Items] | ' | ' | ' |
Limited partnership, ownership (in percent) | 12.10% | ' | ' |
Description_of_Business_and_Su8
Description of Business and Summary of Significant Accounting Policies (Restructuring and Contract Termination Costs) (Details) (USD $) | 12 Months Ended | |||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | Dec. 26, 2009 |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Severance Costs | $3,223 | $2,576 | $5,462 | ' |
Severance and Retention Costs | ' | ' | ' | ' |
Balance, beginning of period | 3,636 | 3,374 | 3,374 | 10,658 |
Expense | 3,223 | 2,576 | 5,462 | ' |
Payments/utilization | 4,077 | 2,314 | 12,746 | ' |
Balance, end of period | 2,782 | 3,636 | 3,374 | 10,658 |
Research Models and Services | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Severance Costs | 2,055 | 1,068 | 1,196 | ' |
Preclinical Services | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Severance Costs | 1,164 | 1,508 | 4,372 | ' |
Corporate [Member] | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Severance Costs | 4 | 0 | -106 | ' |
Cost of Sales [Member] | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Severance Costs | 1,477 | 1,203 | 1,012 | ' |
General and Administrative Expense [Member] | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' |
Severance Costs | 1,746 | 1,373 | 4,450 | ' |
Accrued Compensation [Member] | ' | ' | ' | ' |
Restructuring and Contract Termination Costs | ' | ' | ' | ' |
Severance and retention costs, current | 1,475 | 1,885 | ' | ' |
Other Long-Term Liabilities [Member] | ' | ' | ' | ' |
Restructuring and Contract Termination Costs | ' | ' | ' | ' |
Severance and retention costs, noncurrent | $1,307 | $1,751 | ' | ' |
Description_of_Business_and_Su9
Description of Business and Summary of Significant Accounting Policies (Other Current and Long-Term Assets and Liabilities) (Details) (USD $) | Dec. 28, 2013 | Dec. 29, 2012 |
In Thousands, unless otherwise specified | ||
Composition of other current assets | ' | ' |
Prepaid assets | $20,058 | $20,404 |
Deferred tax asset | 29,139 | 30,018 |
Prepaid income tax | 25,247 | 26,169 |
Restricted cash | 245 | 229 |
Other current assets | 85,847 | 83,601 |
Composition of other assets, noncurrent | ' | ' |
Deferred financing costs | 7,126 | 6,424 |
Cash surrender value of life insurance policies | 26,507 | 25,240 |
Other assets | 10,420 | 8,503 |
Other assets, noncurrent | 61,964 | 48,659 |
Composition of other current liabilities | ' | ' |
Accrued income taxes | 18,773 | 18,216 |
Current deferred tax liability | 1,960 | 410 |
Accrued intereset and other | 1,813 | 2,636 |
Other current liabilities | 22,546 | 21,262 |
Composition of other long-term liabilities | ' | ' |
Deferred tax liability | 14,988 | 13,147 |
Long-term pension liability | 16,219 | 44,316 |
Accrued Executive Supplemental Life Insurance Retirement Plan and Deferred Compensation Plan | 28,708 | 26,663 |
Other long-term liabilities | 22,582 | 20,840 |
Other long-term liabilities | 82,497 | 104,966 |
Bank Time Deposits [Member] | ' | ' |
Composition of other current assets | ' | ' |
Marketable securities | ' | $6,781 |
Recovered_Sheet1
Description of Business and Summary of Significant Accounting Policies (Derivatives and Hedging Acitivities) (Details) (Forward Contracts [Member], USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Forward Contracts [Member] | ' | ' | ' |
Derivative [Line Items] | ' | ' | ' |
Hedge gain (loss) recorded | ($853) | ($1,260) | ($6,287) |
Recovered_Sheet2
Description of Business and Summary of Significant Accounting Policies (Fair Value) (Details) (USD $) | 12 Months Ended | 12 Months Ended | 3 Months Ended | |||||||||||||||||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 29, 2012 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 28, 2013 | Sep. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 |
Auction Rate Securities [Member] | Time Deposits [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Unobservable Inputs Level 3 [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Measurements, Nonrecurring [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Measurements, Recurring [Member] | Auction Rate Securities [Member] | |||
Significant Unobservable Inputs Level 3 [Member] | Time Deposits [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | ||||||||||||
Time Deposits [Member] | ||||||||||||||||||||
Assets measured at fair value on a recurring basis | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | $20,581 | ' | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $687 |
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases | 8,963 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Impaired Long-Lived Assets Held and Used, Asset Description | ' | ' | ' | ' | ' | ' | ' | ' | '39500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair value, marketable securities | 11,158 | 6,781 | ' | 6,781 | ' | ' | ' | ' | ' | ' | ' | 11,158 | ' | ' | ' | ' | 11,158 | ' | ' | ' |
Life policies | ' | ' | ' | ' | ' | ' | ' | ' | ' | 19,534 | ' | ' | ' | ' | 19,534 | ' | ' | ' | ' | ' |
Assets, Fair Value Disclosure | ' | ' | ' | ' | ' | ' | ' | ' | ' | 30,692 | 26,352 | ' | 0 | 0 | 30,692 | 26,352 | ' | 0 | 0 | ' |
Redeemable noncontrolling interest | 20,581 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Reconciliation of all assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Balance at the end of the period | 367 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Redeemable Noncontrolling Interest, Equity, Fair Value | $20,581 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair Value, Measurement Inputs, Disclosure [Text Block] | '10564.077 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair Value, Measurement Inputs, Disclosure [Text Block] | ' | ' | ' | ' | '0 | '0 | '20581 | '20581 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Recovered_Sheet3
Description of Business and Summary of Significant Accounting Policies (Life Insurance Contracts) (Details) (USD $) | Dec. 28, 2013 |
In Thousands, unless otherwise specified | contracts |
Investments, All Other Investments [Abstract] | ' |
Life Settlement Contracts, Investment Method, Face Value | $67,482 |
Life Settlement Contracts, Investment Method, Carrying Amount | $26,507 |
Life Settlement Contracts, Investment Method, Number of Contracts | 30 |
Recovered_Sheet4
Description of Business and Summary of Significant Accounting Policies (Income Taxes) (Details) (USD $) | Dec. 28, 2013 |
In Thousands, unless otherwise specified | |
Accounting Policies [Abstract] | ' |
Undistributed Earnings of Foreign Subsidiaries | $210,328 |
Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries | $0 |
Recovered_Sheet5
Description of Business and Summary of Significant Accounting Policies (Foreign Currency Translation) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Accounting Policies [Abstract] | ' | ' | ' |
Foreign Currency Transaction Gain (Loss), before Tax | $136 | ($892) | $6,237 |
Business_Acquisitions_Purchase
Business Acquisitions Purchase Price Allocation (Details) (USD $) | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 28, 2013 |
In Thousands, unless otherwise specified | EMD Singapore [Member] | Accugenix [Member] | Accugenix [Member] | Vital River [Member] | Vital River [Member] | Other Intangible Assets [Member] | Other Intangible Assets [Member] | |||
EMD Singapore [Member] | Vital River [Member] | |||||||||
Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Payments to Acquire Businesses, Gross | ' | ' | ' | $4,934 | $18,408 | ' | ' | $26,890 | ' | ' |
Business Acquisition, Percentage of Voting Interests Acquired | ' | ' | ' | ' | 100.00% | ' | ' | ' | ' | ' |
Cash Acquired from Acquisition | ' | ' | ' | ' | 1,547 | ' | 2,671 | ' | ' | ' |
Purchase price allocation, current assets | ' | ' | ' | 300 | 2,162 | ' | 3,092 | ' | ' | ' |
Purchase price allocation, property, plant, and equipment | ' | ' | ' | 154 | 549 | ' | 10,468 | ' | ' | ' |
Purchase price allocation, other noncurrent assets | ' | ' | ' | ' | ' | ' | 2,242 | ' | ' | ' |
Purchase price allocation, Finite-Lived Intangibles | ' | ' | ' | 1,885 | ' | 8,400 | 16,954 | ' | ' | ' |
Goodwill | 230,701 | 208,609 | 197,561 | 2,659 | 10,361 | ' | 16,989 | ' | ' | ' |
Purchase price allocation, current liabilities | ' | ' | ' | -64 | -911 | ' | -11,303 | ' | ' | ' |
Purchase price allocation, noncurrent liabilities | ' | ' | ' | ' | -3,700 | ' | -5,260 | ' | ' | ' |
Purchase price allocation, redeemable noncontrolling interest | ' | ' | ' | ' | ' | ' | -8,963 | ' | ' | ' |
Purchase price allocation, total | ' | ' | ' | 4,934 | 16,861 | ' | 24,219 | ' | ' | ' |
Definite-lived intangible assets | ' | ' | ' | ' | ' | ' | $16,954 | ' | $15 | $160 |
Business_Acquisitions_Finiteli
Business Acquisitions Finite-lived intangible assets (Details) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets | 1,885 | ' |
Client relationships | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life | ' | '13 years |
Databases [Member] | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life | ' | '11 years |
Standard operating procedures | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life | ' | '4 years |
Vital River [Member] | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Amount | 16,954 | ' |
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life | '10 years 4 months 24 days | ' |
Purchase price allocation, Finite-Lived Intangibles | 16,954 | ' |
Vital River [Member] | Client relationships | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Amount | 14,741 | ' |
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life | '11 years 8 months 12 days | ' |
Vital River [Member] | Distribution Rights [Member] | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Amount | 2,053 | ' |
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life | '1 year 3 months 18 days | ' |
Vital River [Member] | Other Intangible Assets [Member] | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Amount | 160 | ' |
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life | '2 years 9 months 18 days | ' |
EMD Singapore [Member] | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life | '8 years | ' |
Purchase price allocation, Finite-Lived Intangibles | 1,885 | ' |
EMD Singapore [Member] | Client relationships | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Amount | 1,870 | ' |
EMD Singapore [Member] | Other Intangible Assets [Member] | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Amount | 15 | ' |
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life | '2 years | ' |
Accugenix [Member] | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life | '9 years 3 months 18 days | ' |
Purchase price allocation, Finite-Lived Intangibles | 8,400 | ' |
Accugenix [Member] | Client relationships | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Amount | ' | 1,500 |
Accugenix [Member] | Databases [Member] | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Amount | ' | 4,100 |
Accugenix [Member] | Standard operating procedures | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Amount | ' | 2,500 |
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life | '12 years | ' |
Accugenix [Member] | Trademarks [Member] | ' | ' |
Acquired Finite-Lived Intangible Assets [Line Items] | ' | ' |
Acquired Finite-lived Intangible Asset, Amount | ' | $300 |
Goodwill_and_Other_Intangible_2
Goodwill and Other Intangible Assets (Schedule of Finite-Lived Intangible Assets) (Details) (USD $) | Dec. 28, 2013 | Dec. 29, 2012 |
In Thousands, unless otherwise specified | ||
Finite-lived intangible assets | ' | ' |
Finite-lived intangible assets, Gross Carrying Amount | $348,641 | $341,529 |
Finite-lived intangible assets, accumulated amortization | -267,542 | -260,045 |
Backlog | ' | ' |
Finite-lived intangible assets | ' | ' |
Finite-lived intangible assets, Gross Carrying Amount | ' | 2,875 |
Finite-lived intangible assets, accumulated amortization | ' | -2,375 |
Client relationships | ' | ' |
Finite-lived intangible assets | ' | ' |
Finite-lived intangible assets, Gross Carrying Amount | ' | 305,178 |
Finite-lived intangible assets, accumulated amortization | ' | -231,902 |
Client contracts | ' | ' |
Finite-lived intangible assets | ' | ' |
Finite-lived intangible assets, Gross Carrying Amount | ' | 15,366 |
Finite-lived intangible assets, accumulated amortization | ' | -15,366 |
Trademarks and trade names | ' | ' |
Finite-lived intangible assets | ' | ' |
Finite-lived intangible assets, Gross Carrying Amount | ' | 5,326 |
Finite-lived intangible assets, accumulated amortization | ' | -4,821 |
Standard operating procedures | ' | ' |
Finite-lived intangible assets | ' | ' |
Finite-lived intangible assets, Gross Carrying Amount | ' | 2,751 |
Finite-lived intangible assets, accumulated amortization | ' | -863 |
Other identifiable intangible assets | ' | ' |
Finite-lived intangible assets | ' | ' |
Finite-lived intangible assets, Gross Carrying Amount | ' | 10,033 |
Finite-lived intangible assets, accumulated amortization | ' | ($4,718) |
Goodwill_and_Other_Intangible_3
Goodwill and Other Intangible Assets (Indefinite-lived intangible assets) (Details) (USD $) | Dec. 28, 2013 |
In Thousands, unless otherwise specified | |
Indefinite-lived Intangible Assets by Major Class [Line Items] | ' |
Indefinite-lived Intangible Assets | $3,438 |
Goodwill_and_Other_Intangible_4
Goodwill and Other Intangible Assets (Gross Carrying Amount and Accumulated Amortization of Goodwill) (Details) (USD $) | 12 Months Ended | ||
Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | |
Goodwill | ' | ' | ' |
Goodwill, Gross | $1,235,701,000 | $1,213,609,000 | $1,202,561,000 |
Goodwill, Acquired During Period | 19,647,000 | 10,361,000 | ' |
Goodwill, Other Changes | 2,445,000 | 687,000 | ' |
Goodwill, Impairment Loss | ' | 0 | ' |
Goodwill | 230,701,000 | 208,609,000 | 197,561,000 |
Research Models and Services | ' | ' | ' |
Goodwill | ' | ' | ' |
Goodwill, Gross | ' | 63,139,000 | 52,681,000 |
Goodwill, Acquired During Period | ' | 10,361,000 | ' |
Goodwill, Other Changes | ' | 97,000 | ' |
Preclinical Services | ' | ' | ' |
Goodwill | ' | ' | ' |
Goodwill, Gross | ' | 1,150,470,000 | 1,149,880,000 |
Goodwill, Impaired, Accumulated Impairment Loss | 1,005,000,000 | 1,005,000,000 | 1,005,000,000 |
Goodwill, Acquired During Period | ' | 0 | ' |
Goodwill, Other Changes | ' | 590,000 | ' |
Goodwill, Impairment Loss | ' | $0 | ' |
Goodwill_and_Other_Intangible_5
Goodwill and Other Intangible Assets (Amortization Expense) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Goodwill and Intangible Assets Disclosure [Abstract] | ' | ' | ' |
Amortization of intangible assets | $17,806 | $18,068 | $21,796 |
Estimated amortization expense for each of the next five fiscal years | ' | ' | ' |
Estimated amortization expense, 2014 | 16,396 | ' | ' |
Estimated amortization expense, 2015 | 13,281 | ' | ' |
Estimated amortization expense, 2016 | 11,351 | ' | ' |
Estimated amortization expense, 2017 | 10,057 | ' | ' |
Estimated amortization expense, 2018 | $9,181 | ' | ' |
Restructuring_and_Asset_Impair1
Restructuring and Asset Impairments (Details) (USD $) | 12 Months Ended | 3 Months Ended | 12 Months Ended | |||||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | Dec. 31, 2011 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 31, 2011 |
Research Models and Services | Research Models and Services | Research Models and Services | PCS-China [Member] | Massachusetts [Member] | Hollister, CA facility [Member] | U.S. Biologics [Member] | In Process Research And Development [Member] | |
Preclinical Services | ||||||||
Impaired Long-Lived Assets Held and Used [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' |
Long-lived assets impairment charges | $449 | $3,548 | $692 | ' | $3,753 | ' | ' | ' |
Long-Lived Assets to be Abandoned, Carrying Value of Asset | ' | ' | ' | ' | 39,500 | ' | ' | ' |
Restructuring and Related Cost, Accelerated Depreciation | ' | ' | ' | ' | ' | 13,531 | 1,864 | ' |
Indefinite-lived intangible asset impairment charges | ' | ' | ' | ' | ' | ' | ' | 6,800 |
Proceeds from transfer and sale of assets | ' | ' | ' | 4,593 | ' | ' | ' | ' |
Gain from transfer and sale of assets | ' | ' | ' | $3,776 | ' | ' | ' | ' |
LongTerm_Debt_and_Capital_Leas2
Long-Term Debt and Capital Lease Obligations (Long-Term Debt) (Details) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 |
Debt Instrument | ' | ' |
Long-term Debt, Maturities, Repayments of Principal in Year Four | $68,250 | ' |
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months | 21,241 | ' |
Long-term Debt, Maturities, Repayments of Principal in Year Two | 42,000 | ' |
Extinguishment of Debt, Amount | 389 | ' |
Long-term Debt, Maturities, Repayments of Principal in Year Five | 484,308 | ' |
Principal | 663,049 | ' |
Total debt | 663,049 | 666,448 |
Less: current portion of long-term debt | -21,241 | -139,373 |
Long-term debt | 641,808 | 527,075 |
Capital Lease Obligations | 740 | 72 |
Revolving Credit Facility [Member] | ' | ' |
Debt Instrument | ' | ' |
Total debt | 550,000 | ' |
Credit Agreement [Member] | ' | ' |
Debt Instrument | ' | ' |
Total debt | 970,000 | ' |
Line of Credit Facility Collateral Percentage of Domestic Subsidiaries Excluding Disregarded Entities Capital Stock | 100.00% | ' |
Line of Credit Facility Collateral Percentage of First Tier Foreign Subsidiaries and Domestic Disregarded Entities Capital Stock | 65.00% | ' |
U.S. Term Loan [Member] | ' | ' |
Debt Instrument | ' | ' |
Total debt | 420,000 | ' |
Line of Credit Facility Collateral Domestically Owned Real Property Book Value Minimum [Member] | ' | ' |
Debt Instrument | ' | ' |
Line of Credit Facility Collateral Domestically Owned Real Property Book Value Minimum | 10,000 | ' |
Other long-term debt | ' | ' |
Debt Instrument | ' | ' |
Total debt | 241 | 232 |
Revolving credit facility | ' | ' |
Debt Instrument | ' | ' |
Total debt | 253,308 | 32,000 |
Term loan facilities | ' | ' |
Debt Instrument | ' | ' |
Total debt | 409,500 | 290,947 |
Convertible Debt [Member] | ' | ' |
Debt Instrument | ' | ' |
Principal | 0 | 349,995 |
Unamortized debt discount | 0 | -6,726 |
Total debt | 0 | 343,269 |
Letter of Credit [Member] | ' | ' |
Debt Instrument | ' | ' |
Letters of Credit Outstanding, Amount | $4,855 | ' |
LIBOR [Member] | Credit Agreement [Member] | ' | ' |
Debt Instrument | ' | ' |
Debt Instrument, Basis Spread on Variable Rate | 1.25% | ' |
LongTerm_Debt_and_Capital_Leas3
Long-Term Debt and Capital Lease Obligations (Additional Disclosures) (Details) (USD $) | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 28, 2013 |
In Thousands, unless otherwise specified | Convertible Debt [Member] | Convertible Debt [Member] | Credit agreement | Credit agreement | Term loan facilities | Term loan facilities | Term loan | Revolving Credit Facility [Member] | Revolving credit facility | Revolving credit facility | Line of Credit Facility Collateral Domestically Owned Real Property Book Value Minimum [Member] | Letter of Credit [Member] | ||
LIBOR | ||||||||||||||
Debt Instrument [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term Debt | $663,049 | $666,448 | $0 | $343,269 | $970,000 | ' | $409,500 | $290,947 | $420,000 | $550,000 | $253,308 | $32,000 | ' | ' |
Percentage of capital stock of domestic subsidiaries (excluding disregarded entities) pledged as collateral for borrowings (as a percent) | ' | ' | ' | ' | 100.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility Collateral Percentage of First Tier Foreign Subsidiaries and Domestic Disregarded Entities Capital Stock | ' | ' | ' | ' | 65.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Minimum book value on owned real property in the U.S. whose mortgages are pledged as collateral for borrowings | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,000 | ' |
Interest rate margin (as a percent) | ' | ' | ' | ' | ' | 1.25% | ' | ' | ' | ' | ' | ' | ' | ' |
Outstanding under letters of credit | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,855 |
Unamortized debt discount | ' | ' | 0 | 6,726 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Capital lease obligations | 740 | 72 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Principal maturities of existing debt excluding unamortized debt discount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2014 | 21,241 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2015 | 42,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2016 | 47,250 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2017 | 68,250 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2018 | 484,308 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total | $663,049 | ' | $0 | $349,995 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Equity_Earnings_Per_Share_Deta
Equity (Earnings Per Share) (Details) (USD $) | 12 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Numerator: | ' | ' | ' |
Income (loss) from continuing operations for purposes of calculating earnings per share | $104,093 | $101,547 | $115,111 |
Income (loss) from discontinued operations, net of taxes | ($1,265) | ($4,252) | ($5,545) |
Denominator: | ' | ' | ' |
Weighted average shares outstanding-Basic (in shares) | 47,740,167 | 47,912,135 | 50,823,063 |
Effect of dilutive securities: | ' | ' | ' |
Stock options and contingently issued restricted stock (in shares) | 749,155 | 494,185 | 495,179 |
Weighted average shares outstanding-Diluted (in shares) | 48,489,322 | 48,406,320 | 51,318,242 |
Basic earnings (loss) per share from continuing operations attributable to common shareowners (in dollars per share) | $2.18 | $2.12 | $2.26 |
Basic earnings (loss) per share from discontinued operations attributable to common shareowners (in dollars per share) | ($0.03) | ($0.09) | ($0.11) |
Diluted earnings (loss) per share from continuing operations attributable to common shareowners (in dollars per share) | $2.15 | $2.10 | $2.24 |
Diluted earnings (loss) per share from discontinued operations attributable to common shareowners (in dollars per share) | ($0.03) | ($0.09) | ($0.11) |
Stock options | ' | ' | ' |
Antidilutive securities excluded from computation of earnings per share amount | ' | ' | ' |
Antidilutive securities excluded from computation of earnings per share amount (in shares) | 2,288,926 | 4,590,925 | 4,249,564 |
Effect of dilutive securities: | ' | ' | ' |
Weighted average shares outstanding-Diluted (in shares) | 1,096,550 | 934,505 | 703,011 |
Equity_Treasury_Stock_Details
Equity (Treasury Stock) (Details) (USD $) | 0 Months Ended | 3 Months Ended | 12 Months Ended | 0 Months Ended | 10 Months Ended | 0 Months Ended | 12 Months Ended | ||||||||||
In Thousands, except Share data, unless otherwise specified | Oct. 20, 2010 | Aug. 26, 2010 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | Aug. 27, 2010 | Dec. 31, 2011 | 16-May-11 | Feb. 24, 2011 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | Aug. 26, 2010 |
Accelerated stock repurchase program entered into on August 26, 2010 | Accelerated stock repurchase program entered into on August 26, 2010 | Accelerated stock repurchase program entered into on February 24, 2011 | Accelerated stock repurchase program entered into on February 24, 2011 | Open market repurchases | Open market repurchases | Open market repurchases | 2000 Incentive Plan and 2007 Incentive Plan | 2000 Incentive Plan and 2007 Incentive Plan | 2000 Incentive Plan and 2007 Incentive Plan | Credit Agreement [Member] | |||||||
Treasury Shares and Accelerated Stock Repurchase Program (ASR) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Authorized amount of stock repurchase | $750,000 | $300,000 | $1,000,000 | $250,000 | ' | ' | ' | ' | ' | $150,000 | ' | ' | ' | ' | ' | ' | ' |
Stock Repurchase Program, Remaining Authorized Repurchase Amount | ' | ' | ' | 139,099 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Purchase of treasury stock and Accelerated Stock Repurchase Program | ' | ' | ' | 165,932 | 64,189 | 283,795 | 300,000 | ' | ' | 150,000 | ' | ' | ' | ' | ' | ' | ' |
Number of shares of common stock repurchased (in shares) | ' | ' | ' | ' | 1,705,521 | 3,790,762 | ' | 871,829 | 6,505 | 3,759,398 | 3,468,031 | 1,705,521 | 8,428,494 | 113,424 | 84,250 | 79,704 | ' |
Fair market value of treasury shares purchased | ' | ' | ' | -170,271 | -64,489 | -269,655 | ' | 32,509 | 257 | 135,860 | ' | ' | ' | ' | ' | ' | ' |
Total cost of repurchase of treasury shares | ' | ' | ' | ' | 61,442 | 130,853 | ' | ' | ' | ' | 165,717 | 61,442 | 299,479 | 4,554 | 3,047 | 2,942 | ' |
Maximum borrowing capacity | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 750,000 |
Forward contract indexed to common stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | $14,140 | ' | ' | ' | ' | ' | ' | ' |
Equity_Accumulated_Other_Compr
Equity (Accumulated Other Comprehensive Income (Loss)) (Details) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 |
Stockholders' Equity Note [Abstract] | ' | ' |
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Beginning Balance | $44,057 | $38,685 |
Accumulated Other Comprehensive Income (Loss), Pension Gains/(Losses) and Prior Service (Cost)/Credit Not Yet Recognized as Components of Net Periodic Benefit Costs, Beginning Balance | 37,454 | 33,171 |
Accumulated Other Comprehensive Income (Loss), Net Unrealized Gain on Marketable Securities, Beginning Balance | 0 | -921 |
Accumulated Other Comprehensive Income (Loss), Beginning Balance | 6,603 | 4,593 |
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Period Change | -15,751 | 5,274 |
Other Comprehensive Income (Loss), Pension Gains/(Losses) and Prior Service (Cost)/Credit Not Yet Recognized as Components of Net Periodic Benefit Costs, Period change | 22,310 | -5,862 |
Other Comprehensive Income (Loss), Net Unrealized Gain on Marketable Securities, Period change | 0 | 921 |
Other Comprehensive Income (Loss), Period change | 6,559 | 333 |
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax | 197 | 98 |
Other Comprehensive Income (Loss), Pension Gains/(Losses) and Prior Service (Cost)/Credit Not Yet Recognized as Components of Net Periodic Benefit Costs, Tax | -8,002 | 1,579 |
Other Comprehensive Income (Loss), Net Unrealized Gain on Marketable Securities, Tax | 0 | 0 |
Other Comprehensive Income (Loss), Tax | -7,805 | 1,677 |
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Ending Balance | 28,503 | 44,057 |
Accumulated Other Comprehensive Income (Loss), Pension Gains/(Losses) and Prior Service (Cost)/Credit Not Yet Recognized as Components of Net Periodic Benefit Costs, Ending Balance | 23,146 | 37,454 |
Accumulated Other Comprehensive Income (Loss), Net Unrealized Gain on Marketable Securities, Ending Balance | 0 | 0 |
Accumulated Other Comprehensive Income (Loss), Ending Balance | $5,357 | $6,603 |
Equity_Warrants_Details
Equity (Warrants) (Details) (USD $) | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 |
In Thousands, except Share data, unless otherwise specified | Warrants [Member] | ||
increments | |||
Class of Warrant or Right [Line Items] | ' | ' | ' |
Warrants issued (in shares) | ' | ' | 7,200,000 |
Warrants | $59.63 | ' | ' |
Number of equal increments over which the warrants will expire between September 13, 2013 and January 22, 2014 | ' | ' | 90 |
Warrants and Rights Outstanding | $1,271,459 | ' | ' |
Stockholders' Equity Attributable to Noncontrolling Interest | $3,093 | $2,395 | ' |
Equity_Noncontrolling_Interest
Equity (Noncontrolling Interests) (Details) (USD $) | Dec. 28, 2013 | Dec. 29, 2012 |
In Thousands, unless otherwise specified | ||
Schedule of Equity Method Investments [Line Items] | ' | ' |
Redeemable noncontrolling interest | $20,581 | $0 |
Stockholders' Equity Attributable to Noncontrolling Interest | $3,093 | $2,395 |
Income_Taxes_Components_of_Inc
Income Taxes (Components of Income from Continuing Operations Before Income Taxes) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Income from continuing operations before income taxes | ' | ' | ' |
U.S. | ' | $35,504 | $47,158 |
Non-U.S. | ' | 94,242 | 85,504 |
Income from continuing operations, before income taxes | 138,327 | 129,746 | 132,662 |
Current: | ' | ' | ' |
Federal | ' | -1,447 | 3,957 |
Foreign | ' | 26,411 | 20,727 |
State and local | ' | 1,353 | 1,124 |
Total current | ' | ' | 25,808 |
Deferred: | ' | ' | ' |
Federal | ' | 13,132 | 2,961 |
Foreign | ' | -12,683 | -11,649 |
State and local | ' | 862 | 20 |
Total deferred | ' | ' | -8,668 |
Provision for income taxes | $32,911 | $27,628 | $17,140 |
Income_Taxes_Deferred_Taxes_an
Income Taxes (Deferred Taxes and Effective Tax Rate Reconciliation) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2012 | Dec. 31, 2011 | Dec. 28, 2013 |
Components of Deferred Tax Assets and Liabilities [Abstract] | ' | ' | ' |
Compensation | $52,668 | ' | ' |
Accruals and reserves | 2,160 | ' | ' |
Deferred Tax Assets, Inventory | 3,663 | ' | 1,696 |
Financing related | 2,545 | ' | ' |
Goodwill and other intangibles | -14,982 | ' | ' |
Net operating loss and credit carryforwards | 55,067 | ' | ' |
Depreciation related | -37,212 | ' | ' |
Non-indefinitely reinvested earnings | -146 | ' | ' |
Deferred Tax Assets, Equity Method Investments | -405 | ' | -2,720 |
Other | -839 | ' | ' |
Deferred Tax Assets, Gross | 62,519 | ' | 54,798 |
Valuation allowance | -7,504 | ' | -7,071 |
Total deferred taxes | $55,015 | ' | ' |
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract] | ' | ' | ' |
U.S. statutory income tax rate | 35.00% | 35.00% | ' |
Foreign tax rate differences | -8.00% | -6.70% | ' |
State income taxes, net of Federal tax benefit | 1.50% | 2.10% | ' |
Unbenefitted losses and valuation allowances | 0.80% | 0.60% | ' |
Impact of repatriation of non-U.S. earnings | 0.00% | 0.50% | ' |
Research tax credits and enhanced deductions | -8.20% | -7.60% | ' |
Enacted tax rate changes | -0.20% | -1.00% | ' |
Impact of tax uncertainties | -1.20% | -1.00% | ' |
Releasing valuation allowance on loss from disposition of the Phase I Clinical business | 0.00% | -8.40% | ' |
Non taxable gain from settlement of life insurance policy | 0.00% | -2.20% | ' |
Other | 1.60% | 1.60% | ' |
Effective tax rate | 21.30% | 12.90% | ' |
Income_Taxes_Operating_Loss_Ca
Income Taxes (Operating Loss Carryforwards) (Details) (USD $) | Dec. 28, 2013 |
In Thousands, unless otherwise specified | |
Foreign Jurisdiction [Member] | ' |
Operating Loss Carryforwards [Line Items] | ' |
Net operating loss carryforwards | $12,951 |
Net Operating Loss Carryforward, Expiring 2014 to 2031 [Member] | Foreign Jurisdiction [Member] | ' |
Operating Loss Carryforwards [Line Items] | ' |
Net operating loss carryforwards | 218 |
Net Operating Loss Carryforward, Expiring in 2014 [Member] | Foreign Jurisdiction [Member] | ' |
Operating Loss Carryforwards [Line Items] | ' |
Net operating loss carryforwards | 524 |
Net Operating Loss Carryforward, Expiring 2016 to 2031 [Member] | State Jurisdiction [Member] | ' |
Operating Loss Carryforwards [Line Items] | ' |
Net operating loss carryforwards | 94 |
Carried Forward Indefinitely [Member] | Foreign Jurisdiction [Member] | ' |
Operating Loss Carryforwards [Line Items] | ' |
Net operating loss carryforwards | $12,209 |
Income_Taxes_Tax_Credit_Carryf
Income Taxes (Tax Credit Carryforwards) (Details) (USD $) | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 28, 2013 |
In Thousands, unless otherwise specified | Tax Credit Carryforwards, Expiring in 2019 [Member] | Tax Credit Carryforwards, Expiring in 2020 [Member] | Tax Credit Carryforwards, Expiring in 2021 [Member] | Tax Credit Carryforwards, Expiring Thereafter [Member] | Tax Credit Carryforwards, Expiring 2029 to 2033 [Member] | |
Internal Revenue Service (IRS) [Member] | Internal Revenue Service (IRS) [Member] | Internal Revenue Service (IRS) [Member] | Internal Revenue Service (IRS) [Member] | Canada | ||
Tax Credit Carryforward [Line Items] | ' | ' | ' | ' | ' | ' |
Impact Of Change In SHED Law On Credits | 25.00% | ' | ' | ' | ' | ' |
Tax Credit Carryforwards | ' | $12,783 | $6,255 | $2,411 | $284 | $23,946 |
Income_Taxes_Unrecognized_Tax_
Income Taxes (Unrecognized Tax Benefits) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Income Tax Contingency [Line Items] | ' | ' | ' |
Decrease in unrecognized tax benefits | $12,521 | ' | ' |
Unrecognized tax benefits that would impact effective tax rate favorably, if recognized | 17,012 | 24,386 | ' |
Decrease in unrecognized tax benefits, that if recognized would impact the effective tax rate | -7,374 | ' | ' |
Reconciliation of unrecognized tax benefits | ' | ' | ' |
Beginning balance | 30,996 | 27,976 | 33,427 |
Additions, Tax positions for current year | ' | 1,907 | 1,714 |
Additions, Tax positions for prior years | ' | 4,196 | 0 |
Reductions, Tax positions for current year | ' | 0 | 0 |
Reductions, Tax positions for prior years | ' | -28 | -239 |
Reductions, Settlements | ' | -3,055 | -6,926 |
Reductions, Expiration of statute of limitations | ' | 0 | 0 |
Ending balance | 18,475 | 30,996 | 27,976 |
Unrecognized tax benefits, income tax interest accrued | ' | ' | ' |
Interest related to unrecognized income tax benefits | 691 | 1,964 | ' |
Change in accrued interest related to unrecognized income tax benefits | -1,273 | ' | ' |
SHED [Member] | ' | ' | ' |
Income Tax Contingency [Line Items] | ' | ' | ' |
Decrease in unrecognized tax benefits | ' | $2,408 | ' |
Income_Taxes_Narrative_Details
Income Taxes (Narrative) (Details) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 |
Income Tax Contingency [Line Items] | ' | ' |
Impact of French Tax Law Change | ' | $703 |
Other assets, noncurrent | 61,964 | 48,659 |
Pool of excess tax benefits | 7,345 | 9,558 |
Tax benefit recorded to additional pain-in-capital related to exercise of stock options and vesting of restricted shares | -1,068 | ' |
Change in valuation allowance | 433 | ' |
Valuation allowance | 7,071 | 7,504 |
Earnings of non-U.S. subsidiaries considered indefinitely reinvested | 210,328 | ' |
U.S. | ' | ' |
Income Tax Contingency [Line Items] | ' | ' |
Other assets, noncurrent | ' | $2,981 |
Employee_Benefit_Plans_Defined
Employee Benefit Plans (Defined Contribution and Deferred Compensaion Plans) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Defined Contribution Plans Disclosure [Line Items] | ' | ' | ' |
Cash surrender value of life insurance policies | $26,507 | $25,240 | ' |
401(k) [Member] | ' | ' | ' |
Defined Contribution Plans Disclosure [Line Items] | ' | ' | ' |
Costs associated with defined contribution plan | 4,718 | 4,364 | 4,178 |
Deferred Compensation Plan [Member] | ' | ' | ' |
Defined Contribution Plans Disclosure [Line Items] | ' | ' | ' |
Costs associated with defined contribution plan | $3,322 | $2,930 | $2,048 |
Employee_Benefit_Plans_Obligat
Employee Benefit Plans (Obligations and Funded Status) (Details) (USD $) | 12 Months Ended | ||
Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Pension and Other Postretirement Defined Benefit Plans, Liabilities | $1,057,000 | ' | ' |
Funded status | ' | ' | ' |
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent | -297,000 | ' | ' |
Pension Benefits [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax | 29,143,000 | 51,779,000 | 45,267,000 |
Change in benefit obligations | ' | ' | ' |
Benefit obligation at beginning of year | 283,063,000 | 251,916,000 | ' |
Service cost | 3,368,000 | 3,729,000 | 3,056,000 |
Interest cost | 11,273,000 | 11,289,000 | 12,107,000 |
Plan participants' contributions | 0 | 53,000 | ' |
Benefit payments | -8,300,000 | -6,186,000 | ' |
Actuarial loss (gain) | -4,276,000 | 16,699,000 | ' |
Plan amendments | 0 | 0 | ' |
Administrative expenses paid | -308,000 | -266,000 | ' |
Effect of foreign exchange | 1,392,000 | 5,829,000 | ' |
Benefit obligation at end of year | 286,212,000 | 283,063,000 | 251,916,000 |
Change in plan assets | ' | ' | ' |
Fair value of plan assets at beginning of year | 238,672,000 | 202,652,000 | ' |
Actual return on plan assets | 30,820,000 | 22,467,000 | ' |
Settlements | 0 | 0 | ' |
Employer contributions | 9,570,000 | 14,222,000 | ' |
Premiums paid | -308,000 | -266,000 | ' |
Effect of foreign exchange | 2,205,000 | 5,730,000 | ' |
Fair value of plan assets at end of year | 272,659,000 | 238,672,000 | 202,652,000 |
Funded status | ' | ' | ' |
Net balance sheet liability | 13,553,000 | 44,391,000 | ' |
Non-current assets | 2,738,000 | 0 | ' |
Current liabilities | 72,000 | 75,000 | ' |
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent | 16,219,000 | 44,316,000 | ' |
Supplemental Retirement Benefits [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax | 4,967,000 | 4,376,000 | 5,171,000 |
Change in benefit obligations | ' | ' | ' |
Benefit obligation at beginning of year | 27,372,000 | 26,456,000 | ' |
Service cost | 643,000 | 640,000 | 636,000 |
Interest cost | 708,000 | 892,000 | 1,201,000 |
Plan participants' contributions | 0 | 0 | ' |
Benefit payments | -726,000 | -743,000 | ' |
Actuarial loss (gain) | 1,501,000 | 127,000 | ' |
Plan amendments | 0 | 0 | ' |
Administrative expenses paid | 0 | 0 | ' |
Effect of foreign exchange | 0 | 0 | ' |
Benefit obligation at end of year | 29,498,000 | 27,372,000 | 26,456,000 |
Change in plan assets | ' | ' | ' |
Fair value of plan assets at beginning of year | 0 | 0 | ' |
Actual return on plan assets | 0 | 0 | ' |
Settlements | 0 | 0 | ' |
Employer contributions | 726,000 | 743,000 | ' |
Premiums paid | 0 | 0 | ' |
Effect of foreign exchange | 0 | 0 | ' |
Fair value of plan assets at end of year | 0 | 0 | 0 |
Funded status | ' | ' | ' |
Net balance sheet liability | 29,498,000 | 27,372,000 | ' |
Non-current assets | 0 | 0 | ' |
Current liabilities | 789,000 | 709,000 | ' |
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent | $28,709,000 | $26,663,000 | ' |
Employee_Benefit_Plans_Accumul
Employee Benefit Plans (Accumulated Other Comprehensive Income) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Accumulated Other Comprehensive Income [Roll Forward] | ' | ' | ' |
Amortization of prior service cost | ($297) | ' | ' |
Amortization of net gain (loss) | 3,017 | 2,772 | 1,068 |
Other Pension Plan, Postretirement or Supplemental Plans, Defined Benefit [Member] | ' | ' | ' |
Accumulated Other Comprehensive Income [Roll Forward] | ' | ' | ' |
Amortization of prior service cost | 32 | ' | ' |
Pension Benefits [Member] | ' | ' | ' |
Amounts recognized in statement of financial position as part of accumulated other comprehensive income | ' | ' | ' |
Net actuarial (gain)/loss | 35,481 | 58,594 | ' |
Net prior service cost/(credit) | -6,338 | -6,815 | ' |
Total | 29,143 | 51,779 | ' |
Amounts in AOCI expected to be recognized as components of net periodic benefit cost over the next fiscal year | ' | ' | ' |
Amortization of net actuarial (gain)/loss | 923 | ' | ' |
Amortization of net prior service cost/(credit) | -637 | ' | ' |
Accumulated Other Comprehensive Income [Roll Forward] | ' | ' | ' |
Beginning balance | 51,779 | 45,267 | ' |
Other Comprehensive (Income) Loss, Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax | 603 | -2,461 | ' |
Amortization of prior service cost | 16,219 | 44,316 | ' |
Amortization of net gain (loss) | 2,710 | 609 | ' |
Asset loss/(gain) | -20,424 | 8,030 | ' |
Currency impact | -105 | 334 | ' |
Ending balance | 29,143 | 51,779 | ' |
Supplemental Retirement Benefits [Member] | ' | ' | ' |
Amounts recognized in statement of financial position as part of accumulated other comprehensive income | ' | ' | ' |
Net actuarial (gain)/loss | 4,307 | 3,056 | ' |
Net prior service cost/(credit) | 660 | 1,320 | ' |
Total | 4,967 | 4,376 | ' |
Amounts in AOCI expected to be recognized as components of net periodic benefit cost over the next fiscal year | ' | ' | ' |
Amortization of net actuarial (gain)/loss | 250 | ' | ' |
Amortization of net prior service cost/(credit) | 660 | ' | ' |
Accumulated Other Comprehensive Income [Roll Forward] | ' | ' | ' |
Beginning balance | 4,376 | 5,171 | ' |
Other Comprehensive (Income) Loss, Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax | -660 | -660 | ' |
Amortization of prior service cost | 28,709 | 26,663 | ' |
Amortization of net gain (loss) | 250 | -260 | ' |
Asset loss/(gain) | 1,501 | 125 | ' |
Currency impact | 0 | 0 | ' |
Ending balance | $4,967 | $4,376 | ' |
Employee_Benefit_Plans_Benefit
Employee Benefit Plans (Benefit Plan Obligations Compared to Plan Assets) (Details) (USD $) | Dec. 28, 2013 | Dec. 29, 2012 |
In Thousands, unless otherwise specified | ||
Pension Benefits [Member] | ' | ' |
Plans with Accumulated Benefit Obligations in Excess of Plan Assets | ' | ' |
Projected benefit obligation | $82,254 | $277,187 |
Accumulated benefit obligation | 81,117 | 271,204 |
Fair value of plan assets | 68,430 | 233,182 |
Plans with Benefit Obligations in Excess of Plan Assets | ' | ' |
Projected benefit obligation | 99,671 | 283,063 |
Accumulated benefit obligation | 93,307 | 275,162 |
Fair value of plan assets | 83,379 | 238,672 |
Supplemental Employee Retirement Plans, Defined Benefit [Member] | ' | ' |
Plans with Accumulated Benefit Obligations in Excess of Plan Assets | ' | ' |
Projected benefit obligation | 29,498 | 27,372 |
Accumulated benefit obligation | 27,938 | 26,495 |
Fair value of plan assets | 0 | 0 |
Plans with Benefit Obligations in Excess of Plan Assets | ' | ' |
Projected benefit obligation | 29,498 | 27,372 |
Accumulated benefit obligation | 27,938 | 26,495 |
Fair value of plan assets | $0 | $0 |
Employee_Benefit_Plans_Compone
Employee Benefit Plans (Components of Net Period Benefit Cost) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Pension Benefits [Member] | ' | ' | ' |
Employee benefits | ' | ' | ' |
Service cost | $3,368 | $3,729 | $3,056 |
Interest cost | 11,273 | 11,289 | 12,107 |
Expected return on plan assets | -14,672 | -13,799 | -13,677 |
Amortization of prior service cost (credit) | 2,711 | 2,461 | -617 |
Amortization of net loss (gain) | -603 | -609 | 978 |
Net periodic benefit cost | 2,077 | 3,071 | 1,847 |
Settlement | 0 | 0 | 23 |
Net pension cost | 2,077 | 3,071 | 1,870 |
Employer contributions | 9,570 | 14,222 | ' |
Expected contributions during the current fiscal year | 6,477 | ' | ' |
Supplemental Retirement Benefits [Member] | ' | ' | ' |
Employee benefits | ' | ' | ' |
Service cost | 643 | 640 | 636 |
Interest cost | 708 | 892 | 1,201 |
Expected return on plan assets | 0 | 0 | 0 |
Amortization of prior service cost (credit) | 249 | 260 | 498 |
Amortization of net loss (gain) | 660 | 660 | 210 |
Net periodic benefit cost | 2,260 | 2,452 | 2,545 |
Settlement | 0 | 0 | -487 |
Net pension cost | 2,260 | 2,452 | 2,058 |
Employer contributions | $726 | $743 | ' |
Employee_Benefit_Plans_Assumpt
Employee Benefit Plans (Assumptions) (Details) | 12 Months Ended | ||
Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | |
Pension Benefits [Member] | ' | ' | ' |
Weighted-average assumptions used to determine benefit obligations | ' | ' | ' |
Discount rate | 4.54% | 4.13% | ' |
Rate of compensation increase | 3.39% | 3.04% | ' |
Weighted-average assumptions used to determine net periodic benefit cost | ' | ' | ' |
Discount rate | 4.13% | 4.47% | 5.20% |
Expected long-term return on plan assets | 6.27% | 6.55% | 6.79% |
Rate of compensation increase | 3.04% | 3.12% | 3.48% |
Supplemental Retirement Benefits [Member] | ' | ' | ' |
Weighted-average assumptions used to determine benefit obligations | ' | ' | ' |
Discount rate | 3.47% | 2.63% | ' |
Rate of compensation increase | 3.00% | 2.50% | ' |
Weighted-average assumptions used to determine net periodic benefit cost | ' | ' | ' |
Discount rate | 2.63% | 3.42% | 4.34% |
Expected long-term return on plan assets | 0.00% | 0.00% | 0.00% |
Rate of compensation increase | 2.50% | 2.50% | 2.50% |
Employee_Benefit_Plans_Plan_As
Employee Benefit Plans (Plan Assets) (Details) (USD $) | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dec. 29, 2014 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 29, 2014 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 29, 2014 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 29, 2014 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 28, 2013 | Dec. 29, 2012 | |
Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Debt Securities [Member] | Debt Securities [Member] | Debt Securities [Member] | Other Plan Asset Categories [Member] | Other Plan Asset Categories [Member] | Other Plan Asset Categories [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | Pension Benefits [Member] | ||||
Cash [Member] | Cash [Member] | Common Stock [Member] | Common Stock [Member] | Debt Securities [Member] | Debt Securities [Member] | Mutual Funds [Member] | Mutual Funds [Member] | Life Insurance Policies [Member] | Life Insurance Policies [Member] | Other Plan Asset Categories [Member] | Other Plan Asset Categories [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Quoted Prices in Active Markets for Identical Assets Level 1 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Other Observable Inputs Level 2 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | Significant Unobservable Inputs Level 3 [Member] | ||||||||||||||||
Cash [Member] | Cash [Member] | Common Stock [Member] | Common Stock [Member] | Debt Securities [Member] | Debt Securities [Member] | Mutual Funds [Member] | Mutual Funds [Member] | Life Insurance Policies [Member] | Life Insurance Policies [Member] | Other Plan Asset Categories [Member] | Other Plan Asset Categories [Member] | Cash [Member] | Cash [Member] | Common Stock [Member] | Common Stock [Member] | Debt Securities [Member] | Debt Securities [Member] | Mutual Funds [Member] | Mutual Funds [Member] | Life Insurance Policies [Member] | Life Insurance Policies [Member] | Other Plan Asset Categories [Member] | Other Plan Asset Categories [Member] | Cash [Member] | Cash [Member] | Common Stock [Member] | Common Stock [Member] | Debt Securities [Member] | Debt Securities [Member] | Mutual Funds [Member] | Mutual Funds [Member] | Life Insurance Policies [Member] | Life Insurance Policies [Member] | Other Plan Asset Categories [Member] | Other Plan Asset Categories [Member] | |||||||||||||||||||||||||||||||||||
Target Allocations | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Defined Benefit Plan, Actual Plan Asset Allocations | ' | 100.00% | 100.00% | ' | 54.80% | 60.00% | ' | 32.60% | 36.00% | ' | 12.60% | 4.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Target Allocation, Total | 100.00% | ' | ' | 60.10% | ' | ' | 31.20% | ' | ' | 8.70% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair value of plan assets | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $272,659,000 | $238,672,000 | $202,652,000 | $1,004,000 | $1,336,000 | $102,916,000 | $105,125,000 | $66,204,000 | $66,452,000 | $100,762,000 | $64,004,000 | $48,000 | $43,000 | $1,725,000 | $1,712,000 | $227,029,000 | $221,160,000 | $1,004,000 | $1,336,000 | $97,857,000 | $100,864,000 | $62,717,000 | $63,283,000 | $65,152,000 | $55,453,000 | $0 | $0 | $299,000 | $224,000 | $44,204,000 | $16,024,000 | $0 | $0 | $5,059,000 | $4,261,000 | $3,487,000 | $3,169,000 | $35,610,000 | $8,551,000 | $48,000 | $43,000 | $0 | $0 | $1,426,000 | $1,488,000 | $1,419,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1,426,000 | $1,488,000 |
Employee_Benefit_Plans_Change_
Employee Benefit Plans (Change in Level 3 Plan Assets) (Details) (USD $) | 12 Months Ended | |
Dec. 28, 2013 | Dec. 29, 2012 | |
Pension Benefits [Member] | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' |
Employer contributions | $9,570,000 | $14,222,000 |
Change in Level 3 plan assets | ' | ' |
Fair value of plan assets at beginning of year | 238,672,000 | 202,652,000 |
Fair value of plan assets at end of year | 272,659,000 | 238,672,000 |
Pension Benefits [Member] | Significant Unobservable Inputs Level 3 [Member] | ' | ' |
Change in Level 3 plan assets | ' | ' |
Fair value of plan assets at beginning of year | 1,488,000 | 1,419,000 |
Actual return on plan assets, Relating to assets still held at end of year | 0 | 51,000 |
Relating to assets sold during the period, Purchases, sales and settlements | 0 | -78,000 |
Relating to assets sold during the period, Transfers in and/or out of Level 3 | 0 | 96,000 |
Fair value of plan assets at end of year | 1,426,000 | 1,488,000 |
Deferred Compensation, Excluding Share-based Payments and Retirement Benefits [Member] | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' |
Employer contributions | $9,525,000 | ' |
Employee_Benefit_Plans_Estimat
Employee Benefit Plans (Estimated Future Benefit Payments) (Details) (USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 28, 2013 |
Pension Benefits [Member] | ' |
Defined Benefit Plan Disclosure [Line Items] | ' |
Defined Benefit Plans, Estimated Future Employer Contributions in Current Fiscal Year | $6,477 |
Defined Benefit Plan, Estimated Future Benefit Payments [Abstract] | ' |
Expected future benefit payments, 2013 | 6,784 |
Expected future benefit payments, 2014 | 7,461 |
Expected future benefit payments, 2015 | 8,470 |
Expected future benefit payments, 2016 | 8,475 |
Expected future benefit payments, 2017 | 8,914 |
Expected future benefit payments, 2018-2022 | 58,164 |
Supplemental Retirement Benefits [Member] | ' |
Defined Benefit Plan, Estimated Future Benefit Payments [Abstract] | ' |
Expected future benefit payments, 2013 | 805 |
Expected future benefit payments, 2014 | 13,232 |
Expected future benefit payments, 2015 | 743 |
Expected future benefit payments, 2016 | 728 |
Expected future benefit payments, 2017 | 714 |
Expected future benefit payments, 2018-2022 | $10,152 |
Employee_Benefit_Plans_PostRet
Employee Benefit Plans (Post-Retirement Health and Life Insurance Plans) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ' | ' | ' |
Cash Surrender Value of Life Insurance | $26,507 | $25,240 | ' |
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent | -297 | ' | ' |
Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax | -23,146 | -37,454 | -33,171 |
Other Pension Plans, Postretirement or Supplemental Plans, Defined Benefit [Member] | ' | ' | ' |
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ' | ' | ' |
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent | 32 | ' | ' |
Service cost | 84 | 201 | 188 |
Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax | -96 | 105 | ' |
Deferred Compensation, Excluding Share-based Payments and Retirement Benefits [Member] | ' | ' | ' |
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ' | ' | ' |
Defined Contribution Plan, Cost Recognized | $3,322 | $2,930 | $2,048 |
Stock_Plans_and_Stock_Based_Co2
Stock Plans and Stock Based Compensation (Stock Based Compensation Expense) (Details) (USD $) | 12 Months Ended | ||
Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | |
Stock-based compensation | ' | ' | ' |
Stock-based compensation expense | $24,542,000 | $21,855,000 | $21,706,000 |
Provision for income taxes | -8,658,000 | -7,793,000 | -7,784,000 |
Net income attributable to common shareowners | 15,884,000 | 14,062,000 | 13,922,000 |
Capitalized stock-based compensation related costs | 0 | ' | ' |
Cost of sales | ' | ' | ' |
Stock-based compensation | ' | ' | ' |
Stock-based compensation expense | 5,381,000 | 5,470,000 | 5,983,000 |
Selling and administration | ' | ' | ' |
Stock-based compensation | ' | ' | ' |
Stock-based compensation expense | 19,161,000 | 16,385,000 | 15,723,000 |
Performance Shares [Member] | ' | ' | ' |
Stock-based compensation | ' | ' | ' |
Stock-based compensation expense | $2,171,000 | ($28,000) | $188,000 |
Stock_Plans_and_Stock_Based_Co3
Stock Plans and Stock Based Compensation (Stock Options and Restricted Stock Grants) (Details) (USD $) | 12 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 12 Months Ended | |||||||||||
Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | Sep. 28, 2013 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | Sep. 28, 2013 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 28, 2013 | Dec. 28, 2013 | |
Restricted Stock [Member] | Restricted Stock [Member] | Restricted Stock [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Employee Stock Option [Member] | Performance Shares [Member] | Minimum [Member] | Minimum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | |||||
months | months | Restricted Stock [Member] | Employee Stock Option [Member] | Restricted Stock [Member] | Employee Stock Option [Member] | |||||||||||
Stock-Based Compensation | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Max PSU Shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 327,694 | ' | ' | ' | ' | ' |
Vesting period, min | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years | '3 years | ' | '4 years | '4 years |
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '7 years | ' | ' | '10 years |
Maximum shares to be awarded under plan | 9,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18,700,000 | ' | ' |
Stock options, shares equivalent | ' | ' | ' | ' | 2.3 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation weighted-average assumptions | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Expected life (in years) | '4 years 2 months 12 days | '4 years 6 months | '4 years 2 months 12 days | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Expected volatility (as a percent) | 33.00% | 35.00% | 33.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Risk-free interest rate (as a percent) | 0.80% | 0.84% | 2.21% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Expected dividend yield (as a percent) | 0.00% | 0.00% | 0.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted-average grant date fair value (in dollars per share) | $11.17 | $10.94 | $11.32 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock option activity, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Options outstanding, balance at the beginning of the period (in shares) | ' | ' | ' | ' | ' | ' | ' | 5,860,403 | ' | ' | ' | ' | ' | ' | ' | ' |
Options granted (in shares) | ' | ' | ' | ' | ' | ' | ' | 600,249 | ' | ' | ' | ' | ' | ' | ' | ' |
Options exercised (in shares) | ' | ' | ' | ' | ' | ' | ' | -2,557,744 | ' | ' | ' | ' | ' | ' | ' | ' |
Options canceled (in shares) | ' | ' | ' | ' | ' | ' | ' | -134,175 | ' | ' | ' | ' | ' | ' | ' | ' |
Options outstanding, balance at the end of the period (in shares) | ' | ' | ' | ' | ' | ' | ' | 3,768,733 | 5,860,403 | ' | ' | ' | ' | ' | ' | ' |
Options exercisable, balance at the end of the period (in shares) | ' | ' | ' | ' | ' | ' | ' | 2,188,734 | ' | ' | ' | ' | ' | ' | ' | ' |
Stock option activity, weighted-average exercise price | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Options outstanding, balance at the beginning of the period (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | $39.11 | ' | ' | ' | ' | ' | ' | ' | ' |
Options granted (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | $40.63 | ' | ' | ' | ' | ' | ' | ' | ' |
Options exercised (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | $36.68 | ' | ' | ' | ' | ' | ' | ' | ' |
Options canceled (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | $44.73 | ' | ' | ' | ' | ' | ' | ' | ' |
Options outstanding, balance at the end of the period (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | $40.81 | $39.11 | ' | ' | ' | ' | ' | ' | ' |
Options exercisable, balance at the end of the period (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | $42.63 | ' | ' | ' | ' | ' | ' | ' | ' |
Stock option activity, weighted-average remaining contractual life | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Options exercisable, balance at the end of the period (in years) | ' | ' | ' | ' | ' | ' | ' | '2 years 1 month 13 days | ' | ' | ' | ' | ' | ' | ' | ' |
Stock option activity, Aggregate Intrinsic Value | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Options exercisable, balance at the end of the period | $1,709,189 | ' | ' | ' | ' | ' | ' | $26,039,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Unrecognized compensation expense | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of unvested awards related to unrecognized compensation cost (in shares) | ' | ' | ' | ' | ' | ' | ' | 1,564,777 | ' | ' | ' | ' | ' | ' | ' | ' |
Unrecognized compensation cost | ' | ' | ' | ' | 28,313,000 | ' | ' | 10,589,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Estimated weighted-average amortization period for unrecognized compensation cost (in months) | ' | ' | ' | ' | 29.7 | ' | ' | 27.4 | ' | ' | ' | ' | ' | ' | ' | ' |
Stock option activity, additional disclosures | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Intrinsic value of options exercised | ' | ' | ' | ' | ' | ' | ' | 24,737,000 | 5,135,000 | 7,950,000 | ' | ' | ' | ' | ' | ' |
Amount of cash received from exercise of options | ' | ' | ' | ' | ' | ' | ' | 93,789,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Actual tax benefit realized for tax deductions from option exercises | ' | ' | ' | ' | 5,372,000 | ' | ' | 8,983,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Non-vested stock option activity, shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Options non-vested, balance at the beginning of the period (in shares) | ' | ' | ' | ' | ' | ' | ' | 1,989,722 | ' | ' | ' | ' | ' | ' | ' | ' |
Options granted (in shares) | ' | ' | ' | ' | ' | ' | ' | 600,249 | ' | ' | ' | ' | ' | ' | ' | ' |
Options forfeited (in shares) | ' | ' | ' | ' | ' | ' | ' | -41,901 | ' | ' | ' | ' | ' | ' | ' | ' |
Options vested (in shares) | ' | ' | ' | ' | ' | ' | ' | -968,071 | ' | ' | ' | ' | ' | ' | ' | ' |
Options non-vested, balance at the end of the period (in shares) | ' | ' | ' | ' | ' | ' | ' | 1,579,999 | 1,989,722 | ' | ' | ' | ' | ' | ' | ' |
Non-vested stock option acitvity, weighted-average exercise price | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Options non-vested, balance at the beginning of the period (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | $34.91 | ' | ' | ' | ' | ' | ' | ' | ' |
Options granted (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | $40.63 | ' | ' | ' | ' | ' | ' | ' | ' |
Options forfeited (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | $36.98 | ' | ' | ' | ' | ' | ' | ' | ' |
Options vested (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | $32.90 | ' | ' | ' | ' | ' | ' | ' | ' |
Options non-vested, balance at the end of the period (in dollars per share) | ' | ' | ' | ' | ' | ' | ' | $38.26 | $34.91 | ' | ' | ' | ' | ' | ' | ' |
Restricted stock activity, restricted stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Balance at the beginning of the period (in shares) | ' | ' | ' | ' | 934,505 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Granted (in shares) | ' | ' | ' | ' | 571,499 | ' | ' | ' | ' | ' | 163,847 | ' | ' | ' | ' | ' |
Vested (in shares) | ' | ' | ' | ' | -373,548 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Canceled (in shares) | ' | ' | ' | ' | -35,906 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Balance at the end of the period (in shares) | ' | ' | ' | ' | 1,096,550 | 934,505 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Min PSU Shares | ' | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restricted stock activity, weighted-average grant date fair value | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Balance at the beginning of the period (in dollars per share) | ' | ' | ' | ' | $35.83 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Granted (in dollars per share) | ' | ' | ' | ' | $40.60 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Vested (in dollars per share) | ' | ' | ' | ' | $40.41 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Canceled (in dollars per share) | ' | ' | ' | ' | $45.32 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Balance at the end of the period (in dollars per share) | ' | ' | ' | ' | $36.44 | $35.83 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restricted stock activity, additional disclosures | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair value of restricted stock grants that vested | ' | ' | ' | ' | $15,095,000 | $10,385,000 | $10,989,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock_Plans_and_Stock_Based_Co4
Stock Plans and Stock Based Compensation (Stock Options by Range of Exercise Prices) (Details) (USD $) | 12 Months Ended |
Dec. 28, 2013 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' |
Number Outstanding (in shares) | 3,768,733 |
Options Outstanding, Weighted Average Remaining Contractual Life (In years) | '3 years 3 months 29 days |
Options Outstanding, Weighted Average Exercise Price (in dollars per share) | $40.80 |
Options Outstanding, Aggregate Intrinsic Value | $49,835,000 |
Options Exercisable (in shares) | 2,188,734 |
Options Exercisable, Weighted Average Remaining Contractual Life (In years) | '2 years 1 month 13 days |
Options Exercisable, Weighted Average Exercise Price (in dollars per share) | $42.63 |
Options Exercisable, Aggregate Intrinsic Value | 26,039,000 |
Closing stock price | $53.33 |
In-the-money, options exercisable | 1,709,189 |
$20.01 - $30.00 [Member] | ' |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' |
Number Outstanding (in shares) | 370,567 |
Options Outstanding, Weighted Average Remaining Contractual Life (In years) | '2 years 1 month 24 days |
Options Outstanding, Weighted Average Exercise Price (in dollars per share) | $25.62 |
Options Outstanding, Aggregate Intrinsic Value | 10,269,000 |
Options Exercisable (in shares) | 368,762 |
Options Exercisable, Weighted Average Remaining Contractual Life (In years) | '2 years 1 month 21 days |
Options Exercisable, Weighted Average Exercise Price (in dollars per share) | $25.60 |
Options Exercisable, Aggregate Intrinsic Value | 10,224,000 |
$30.01 - $40.00 [Member] | ' |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' |
Number Outstanding (in shares) | 1,674,154 |
Options Outstanding, Weighted Average Remaining Contractual Life (In years) | '4 years 1 month 6 days |
Options Outstanding, Weighted Average Exercise Price (in dollars per share) | $36.82 |
Options Outstanding, Aggregate Intrinsic Value | 27,639,000 |
Options Exercisable (in shares) | 680,617 |
Options Exercisable, Weighted Average Remaining Contractual Life (In years) | '3 years 9 months 4 days |
Options Exercisable, Weighted Average Exercise Price (in dollars per share) | $36.71 |
Options Exercisable, Aggregate Intrinsic Value | 11,312,000 |
$40.01 - $50.00 [Member] | ' |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' |
Number Outstanding (in shares) | 1,225,667 |
Options Outstanding, Weighted Average Remaining Contractual Life (In years) | '3 years 6 months 15 days |
Options Outstanding, Weighted Average Exercise Price (in dollars per share) | $43.64 |
Options Outstanding, Aggregate Intrinsic Value | 11,873,000 |
Options Exercisable (in shares) | 641,010 |
Options Exercisable, Weighted Average Remaining Contractual Life (In years) | '1 year 1 month 21 days |
Options Exercisable, Weighted Average Exercise Price (in dollars per share) | $46.39 |
Options Exercisable, Aggregate Intrinsic Value | 4,449,000 |
$50.01 - $60.00 [Member] | ' |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' |
Number Outstanding (in shares) | 463,105 |
Options Outstanding, Weighted Average Remaining Contractual Life (In years) | '1 year 1 month 10 days |
Options Outstanding, Weighted Average Exercise Price (in dollars per share) | $58.17 |
Options Outstanding, Aggregate Intrinsic Value | 54,000 |
Options Exercisable (in shares) | 463,105 |
Options Exercisable, Weighted Average Remaining Contractual Life (In years) | '1 year 1 month 10 days |
Options Exercisable, Weighted Average Exercise Price (in dollars per share) | $58.17 |
Options Exercisable, Aggregate Intrinsic Value | 54,000 |
$60.01 - $70.00 [Member] | ' |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ' |
Number Outstanding (in shares) | 35,240 |
Options Outstanding, Weighted Average Remaining Contractual Life (In years) | '1 year 3 months 11 days |
Options Outstanding, Weighted Average Exercise Price (in dollars per share) | $62.78 |
Options Outstanding, Aggregate Intrinsic Value | 0 |
Options Exercisable (in shares) | 35,240 |
Options Exercisable, Weighted Average Remaining Contractual Life (In years) | '1 year 3 months 11 days |
Options Exercisable, Weighted Average Exercise Price (in dollars per share) | $62.78 |
Options Exercisable, Aggregate Intrinsic Value | $0 |
Commitments_and_Contingencies_1
Commitments and Contingencies (Details) (USD $) | 12 Months Ended | |||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | Sep. 28, 2013 |
Commitments and Contingencies Disclosure [Abstract] | ' | ' | ' | ' |
Rent expense from operating leases | $16,731 | $18,246 | $18,778 | ' |
Maximum insurance deductibles | 750 | ' | ' | ' |
Loss Contingency, Estimate of Possible Loss | ' | ' | ' | 1,500 |
Future minimum payments under noncancellable operating leases | ' | ' | ' | ' |
2014 | 13,978 | ' | ' | ' |
2015 | 10,688 | ' | ' | ' |
2016 | 8,061 | ' | ' | ' |
2017 | 6,008 | ' | ' | ' |
2018 | 4,544 | ' | ' | ' |
Thereafter | $11,839 | ' | ' | ' |
Business_Segment_and_Geographi2
Business Segment and Geographic Information (Business Segment) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Segment Reporting [Abstract] | ' | ' | ' |
Number of reportable segments | 2 | ' | ' |
Business segment information | ' | ' | ' |
Net sales | $1,165,528 | $1,129,530 | $1,142,647 |
Operating income | 151,401 | 165,765 | 174,306 |
Total assets | 1,644,621 | 1,586,344 | ' |
Long-lived assets | 738,146 | 765,679 | 795,689 |
Depreciation and amortization | 96,636 | 81,275 | 85,230 |
Capital expenditures | 39,154 | 47,534 | 49,143 |
Reconciliation of segment operating income to consolidated operating income | ' | ' | ' |
Operating income | 151,401 | 165,765 | 174,306 |
Net sales for each significant service area | ' | ' | ' |
Net sales | 1,165,528 | 1,129,530 | 1,142,647 |
Unallocated corporate overhead | ' | ' | ' |
Stock-based compensation expense | 24,542 | 21,855 | 21,706 |
Depreciation | 78,830 | 63,207 | 63,435 |
Research models | ' | ' | ' |
Business segment information | ' | ' | ' |
Net sales | 381,561 | 381,790 | 401,660 |
Net sales for each significant service area | ' | ' | ' |
Net sales | 381,561 | 381,790 | 401,660 |
Research model services | ' | ' | ' |
Business segment information | ' | ' | ' |
Net sales | 212,647 | 219,671 | 220,698 |
Net sales for each significant service area | ' | ' | ' |
Net sales | 212,647 | 219,671 | 220,698 |
EMD [Member] | ' | ' | ' |
Business segment information | ' | ' | ' |
Net sales | 112,918 | 93,622 | 83,061 |
Net sales for each significant service area | ' | ' | ' |
Net sales | 112,918 | 93,622 | 83,061 |
Total | ' | ' | ' |
Business segment information | ' | ' | ' |
Operating income | 225,377 | 236,990 | 231,244 |
Reconciliation of segment operating income to consolidated operating income | ' | ' | ' |
Operating income | 225,377 | 236,990 | 231,244 |
Research Models and Services | ' | ' | ' |
Business segment information | ' | ' | ' |
Net sales | 707,126 | 695,083 | 705,419 |
Gross margin | 284,808 | 289,750 | 297,327 |
Operating income | 181,321 | 202,362 | 206,319 |
Total assets | 752,499 | 698,134 | 687,346 |
Long-lived assets | 264,706 | 272,559 | 282,388 |
Depreciation and amortization | 54,822 | 37,541 | 37,240 |
Capital expenditures | 24,384 | 36,856 | 34,257 |
Reconciliation of segment operating income to consolidated operating income | ' | ' | ' |
Operating income | 181,321 | 202,362 | 206,319 |
Net sales for each significant service area | ' | ' | ' |
Net sales | 707,126 | 695,083 | 705,419 |
Preclinical Services | ' | ' | ' |
Business segment information | ' | ' | ' |
Net sales | 458,402 | 434,447 | 437,228 |
Gross margin | 110,093 | 102,331 | 104,915 |
Operating income | 44,056 | 34,628 | 24,925 |
Total assets | 892,122 | 888,210 | 869,881 |
Long-lived assets | 473,440 | 493,120 | 513,302 |
Depreciation and amortization | 41,814 | 43,734 | 47,990 |
Capital expenditures | 14,770 | 10,678 | 14,886 |
Reconciliation of segment operating income to consolidated operating income | ' | ' | ' |
Operating income | 44,056 | 34,628 | 24,925 |
Net sales for each significant service area | ' | ' | ' |
Net sales | 458,402 | 434,447 | 437,228 |
Unallocated corporate overhead | ' | ' | ' |
Business segment information | ' | ' | ' |
Operating income | -73,976 | -71,225 | -56,938 |
Reconciliation of segment operating income to consolidated operating income | ' | ' | ' |
Operating income | -73,976 | -71,225 | -56,938 |
Unallocated corporate overhead | ' | ' | ' |
Stock-based compensation expense | 13,411 | 11,724 | 11,159 |
U.S. retirement plans | 4,877 | 4,831 | 3,802 |
Audit, tax and related expenses | 4,365 | 3,019 | 3,069 |
Salary and bonus | 21,983 | 20,050 | 18,421 |
Global IT | 11,646 | 12,622 | 11,785 |
Employee health, LDP and fringe benefit expense | -3,414 | -4,569 | -2,952 |
Consulting and professional services | 4,301 | 4,434 | 8,432 |
Depreciation | 6,334 | 6,260 | 6,312 |
Transaction (acquisition/disposition) costs | 1,752 | 3,772 | 1,329 |
Contingent consideration write-down | 0 | 0 | -5,598 |
Other general unallocated corporate expenses | 8,721 | 9,082 | 1,179 |
Total unallocated corporate overhead costs | $73,976 | $71,225 | $56,938 |
Business_Segment_and_Geographi3
Business Segment and Geographic Information (Geographic Information) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Sales to unaffiliated clients | $1,165,528 | $1,129,530 | $1,142,647 |
Long-lived assets | 738,146 | 765,679 | 795,689 |
U.S. | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Sales to unaffiliated clients | 551,340 | 534,817 | 545,185 |
Long-lived assets | 447,829 | 476,927 | 497,197 |
Europe | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Sales to unaffiliated clients | 353,688 | 341,550 | 348,455 |
Long-lived assets | 130,855 | 122,351 | 123,634 |
Canada | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Sales to unaffiliated clients | 162,404 | 160,004 | 158,997 |
Long-lived assets | 109,811 | 124,302 | 127,531 |
Japan | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Sales to unaffiliated clients | 59,370 | 77,707 | 75,992 |
Long-lived assets | 30,589 | 39,642 | 45,857 |
Other Non-U.S. | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Sales to unaffiliated clients | 38,726 | 15,452 | 14,018 |
Long-lived assets | $19,062 | $2,457 | $1,470 |
Discontinued_Operations_Detail
Discontinued Operations (Details) (USD $) | 12 Months Ended | |||
In Thousands, unless otherwise specified | Dec. 28, 2013 | Dec. 29, 2012 | Dec. 31, 2011 | Jun. 25, 2011 |
Operating results from discontinued operations | ' | ' | ' | ' |
Net sales | $0 | ' | ' | ' |
Income (loss) from operations of discontinued businesses, net of taxes | -1,265 | -4,252 | -5,545 | ' |
Assets and liabilities of discontinued operations | ' | ' | ' | ' |
Current assets | 750 | 495 | ' | ' |
Long-term assets | 3,151 | 3,328 | ' | ' |
Current liabilities | 1,931 | 1,802 | ' | ' |
Liabilities of Disposal Group, Including Discontinued Operation, Noncurrent | 8,080 | 8,795 | ' | ' |
Discontinued Operation, Provision for Loss (Gain) on Disposal, before Income Tax | 1,316 | 7,158 | ' | ' |
Operating Leases, Future Minimum Payments Due | 12,086 | ' | ' | ' |
Guarantor Obligations, Current Carrying Value | 9,787 | ' | ' | 2,994 |
Phase I Clinical [Member] | ' | ' | ' | ' |
Operating results from discontinued operations | ' | ' | ' | ' |
Net sales | ' | 0 | 2,112 | ' |
Income (loss) from operatoins of discontinued businesses, before income taxes | -2,035 | -6,986 | -8,964 | ' |
Provision (benefit) for income taxes | -770 | -2,734 | -3,419 | ' |
Income (loss) from operations of discontinued businesses, net of taxes | -1,265 | -4,252 | -5,545 | ' |
Assets and liabilities of discontinued operations | ' | ' | ' | ' |
Current assets | 750 | 495 | ' | ' |
Long-term assets | 3,151 | 3,328 | ' | ' |
Total assets | 3,901 | 3,823 | ' | ' |
Current liabilities | 1,931 | 1,802 | ' | ' |
Liabilities of Disposal Group, Including Discontinued Operation, Noncurrent | 8,080 | 8,795 | ' | ' |
Total liabilities | $10,011 | $10,597 | ' | ' |